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Abstract. 
Soybeans have been in the human diet since the first millennium BC. They contain three 
major types of isoflavone, genistein, daidzein and glycitein. All three have been shown to 
have a powerful antioxidant effect and bind to oestrogen receptor beta with high 
specificity. It has been demonstrated that dietary soybeans favourably impact bone health 
in postmenopausal women by lowering the incidence of osteoporosis. The literature 
shows that genistein supplementation reduces marrow stromal cell (MSC) differentiation 
to an adipocytic pathway and may favourably stimulate osteogenesis. More recently 
soybean biomaterials (SB) have been developed which contain significant levels of 
isoflavones and have shown bone regeneration potential in vivo. 
The work undertaken in this thesis aims to study the effects of soy extract on the 
differentiation of MSCs to an osteogenic phenotype and to test in vitro the potential of 
novel soybean based biomaterials to differentiate MSCs. These aims were studied by A) 
identifying and characterising a differentiating primary MSC model, B) developing 
multiple differentiation markers, C) characterising the effect of pure genistein 
supplementation on MSCs, D) observing differentiation after addition of extracted crude 
soy extract, E) identifying the mechanism by which soy extract initiates osteoblast 
differentiation, F) analysing the biomaterials with and without MSCs and G) analysing 
the differentiation of MSCs when grown on biomaterials.   
The results described in this thesis show that both pure genistein and crude soy extract are 
osteogenic. This osteogenic effect can be modulated dose dependently and by addition of 
a competitive inhibitor that specifically interrupts isoflavone binding to oestrogen 
receptors. The assessment of the in vitro effects on cell types, including an osteosarcoma 
cell line and several primary MSC strains, indicates that it is important to choose the cell 
type carefully when undertaking work in differentiation models. This work demonstrates 
that isoflavones can dose dependently modulate MSC differentiation, proliferation and 
cell death. Using the characterised differentiating MSC model the soybean biomaterial 
was shown to be significantly osteogenic. 
To conclude, this thesis demonstrates that soy extracted isoflavones and soy extract 
containing biomaterials induce the differentiation of a characterised MSC model into an 
osteoblast phenotype and that this class of novel biomaterials has a potential use in 
regenerative medicine. Treatments based on the use of soy extract biomaterials or soy 
extract biomaterial derived tissue engineering constructs may lead to enhanced clinical 
outcomes in maxillofacial, orthopaedic and periodontal surgery. 
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Chapter 1 
General Introduction 
1.1 Motivation 
Autograft is the gold standard bone reconstruction material; often bone is removed from 
the patient’s iliac crest, shaped and used to reconstruct defects (Dusseldorp and Mobbs 
2009). However this technique is limited in the availability of donor sites and donor site 
morbidity (Giannoudis et al 2005). Therefore a current focus of biomaterials research is 
adjunctive and replacement materials for the reconstruction of defect and donor sites 
(Brydone et al. 2010). One avenue of biomaterials research is the use of calcium 
phosphate cements to fill defects or join gaps between the graft and wound (Ambard and 
Mueninghoff 2006). An improvement in the efficacy of calcium phosphate cements has 
been observed with the addition of osteogenic agents (Heliotis et al. 2006). The naturally 
occurring isoflavones in Soy are osteogenic and therefore their use in calcium phosphate 
cements is postulated to accelerate the differentiation of native cells to mineralising 
osteoblasts (Santin and Ambrosio 2008). Currently there is no in vitro evidence of 
increasing osteogenic differentiation in primary cells when cultured with soy extracts or 
calcium phosphate cements containing soy extract. Therefore an understanding of bone 
biology is required for the isolation of primary osteogenic cells and analysis of soy 
extract induced osteogenesis. 
1.2 Bone formation. 
There are two non-pathogenic bone formation mechanisms, intramembranous and 
endochondral ossification. Intramembranous bones are often flattened or twisting with 
complex structures; the bones comprising the cranial vault and the scapula are formed in 
this manner (Gray 1918). In intramembranous ossification a signalling point develops 
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between two membranes that attracts mesenchymal cells, these mesenchymal cells 
directly differentiate into osteoblasts that subsequently mineralise the area between the 
two membranes, hence the availability of complex shapes (Alborzi et al. 1996). As well 
as de novo bone synthesis intramembranous ossification also occurs at the growth plate 
when injury occurs to endochondral bones during childhood (Xian et al 2004).  
Endochondral ossification has been studied extensively and requires the formation of a 
collagen template; the chondrocytes that produce the template are under strict regulation 
from a myriad of transcription factors and diffusion gradients. Hypertrophic chondrocytes 
differentiate into osteoblasts that subsequently mineralise the collagen scaffold (Pazzaglia 
et al. 2011). During mineralisation several types of bone are formed.  
1.3 Bone mineral composition. 
The inorganic element of the mineralised bone matrix comprises 58% of the dry weight, 
most of it is calcium phosphate almost all of which is calcium hydroxyapatite, 
Ca10(PO4)6(OH)2. The remainder of the inorganic elements are 7% calcium carbonate, 
1% to 2% of calcium fluoride, magnesium phosphate and sodium chloride; the remaining 
(sodium, potassium and strontium) trace minerals less than 1%. 85% of the body’s total 
phosphate is held in bone, with 15% in cells and less than 1% in the blood (Gray 1918, 
Grabowski 2009). Bone is the most important organ involved in calcium homeostasis, 
0.1% of available calcium is in the blood, about 1% in cells and the remainder in bone. 
Between 0.4% and 1% of total bone calcium is readily exchangeable so that the skeleton 
can support the maintenance of blood pH by deposition or release of as much as 500mg 
of calcium per day (Gray 1918, Grabowski 2009).  
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The organic content of bone is 42% of dry weight, about 10% of it is the 
phosphoproteins, osteocalcin and osteonectin, 2% lipids and glycosaminoglycans, the 
remaining 88% is type I collagen (Loveridge 1999).  
1.4 Bone types 
1.4.1 Cortical bone 
Cortical, lamina or compact bone comprises the majority of the weight of the organ. 
Consisting of organised elements called osteons, cortical bone ensures the excellent 
transmission of forces away from impact points (Yacoub et al. 2002). The osteon is a 
process of the antagonistic relationship between the bone dissolving osteoclast and bone 
creating osteoblast (Javed et al. 2010). The osteons are formed in layers, hence lamina, 
around the outside of the bone. This arrangement serves to increase bone strength and 
forms a platform to which tendons and condoyle attach; inside the cortical layer 
trabecular bone predominates.  
1.4.2 Trabecular bone 
Trabecular, cancellous or spongy bone occurs on the inside of cortical bone towards the 
central medullar cavity; forming a three dimensional lattice structure of very high 
strength to weight ratio (Vanderoost et al. 2011). Because of the relatively large spaces 
between the bone structures osteons are not formed, instead flat planar lamellae occur. 
Due to the high surface area occurring in trabecular bone turnover is much higher than in 
cortical bone (Holland et al. 2011). Therefore cortical bone provides the majority of the 
strength while the trabecular bone provides the metabolic activity. Although trabecular 
bone has a smaller contribution to strength the more elastic trabecular region does 
provide increased overall mechanical flexibility (Goncalves et al. 2011). 
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1.4.3 Bone Marrow.  
The intramedullary canal is the central bone space and is full of bone marrow (Hak and 
Pittman 2010). Marrow is also available in all the channels throughout trabecular and 
cortical bone, including the osteon Haversian and Volkmann channels. Marrow 
composition varies dependant on bone type and age (Gurevitch et al. 2007).  
In long bones yellow marrow is more prevalent and increases with age; the yellow 
marrow is comprised of 95% fat and the remaining 5% is cell excaudate, salts and 
connective tissues. The marrow connective tissue is known as the stroma, mononuclear 
cells attach to the stroma, in yellow marrow these cells are mostly adipocytes (Gray 
1918).  
In the articular ends of the long bones, sternum and ribs red marrow prevails; comprised 
of 75 percent water and the remainder globins, salts, excaudate, and nucleoprotein, the 
red marrow contains a similar amount of connective tissue to the yellow marrow (Gray 
1918). However there are far fewer fat cells in the red marrow and therefore other 
mononucleate cells are relatively more numerous; red marrow stroma is the 
haematopoietic stem cell niche and provides all the cells of the blood (Ehninger and 
Trumpp, 2011). 
1.4.3.1 Bone marrow stroma. 
This is the niche of the haematopoietic stem cell (HSC) which is supported by the 
marrow stroma (Ehninger and Trumpp 2011). There is now a large body of evidence that 
supports the presence of the multipotent Bone Marrow Stromal Cell (BMSC), which is 
capable of differentiation to cells of the stroma, osteoblasts, chondrocytes, and adipocytes 
(Majumdar et al. 2000, Bianco et al. 2011). Another cell type arises in BMSC culture but 
has not been isolated directly from an organism, the multipotent adult progenitor cell 
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(MAPC) is observed in carefully maintained BMSC cultures of between 25 and 30 CPD’s 
and they are capable of differentiating into both HSC and BMSC cells (Verfaillie 2005).  
1.5 Bone maintenance 
Constant bone remodelling occurs throughout life, maintained by a continual breakdown 
and deposition of bone by osteoclasts and osteoblasts respectively (O'Brien 2010). The 
turnover of bone ensures that trace minerals are made available, fatigue factures do not 
occur and that density can change in response to mechanical stimuli (Banfi et al. 2010). 
Bone turnover is about 10% of the total mass every year; therefore whole turnover occurs 
at approximately ten year intervals (Banfi et al. 2010). Bones in astronauts lose density 
because the constant transmission of force is a major factor in bone deposition and 
maintenance (Mano et al. 2010). There are well defined mechanisms by which this 
process operates (Matsuo 2009).  
1.5.1 Bone turnover. 
Bone digestion occurs as the initial step in the formation of an osteon. Multinucleate 
osteoclasts initially digest a channel through the bone in a roughly cylindrical shape, 
lining the cut surface above them are osteoblasts which deposit an extracellular matrix 
which is subsequently mineralised. As the channel becomes thinner, due to the 
production of successive layers of mineralised matrix, some of the osteoblasts become 
entombed in lacunae where they become osteocytes, communication and fluid exchange 
between lacunae occurs via the canaliculi that link lacunae to each other and the central 
channel. Following the osteoblasts down the central Haversian channel are endothelial 
cells stimulating angiogenesis and allowing the free exchange of nutrient and waste. 
Haversian channels and lamellae are linked together with cross cutting Volkmann canals 
that often span more than one osteon (Gray 1918, Loveridge 1999). 
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1.5.2 Bone digestion 
Osteoclasts operate at the interface of bone and cell to dissolve bone. They have a tightly 
sealed skirt at the edge of the cell attached to the strongly alkaline hydroxyapatite 
surface; into this space lysosomal enzymes and carbonic acid are produced in order to 
digest both the protein and mineralised extra cellular matrix.  
The hydroxyapatite dissolving reaction can be described as [Ca3(PO4)2]3Ca(OH)2 +8H
+
 
 10Ca+2 +6HPO4
-2
 +2H2O. The resulting dissolved and degraded material from the 
osteoclast skirt is transported in vesicles away from the digestion area and released 
behind the cell (Riches and Ralston 2010). 
1.5.2.1 Control of bone resorption. 
Bone resorption and deposition is controlled by the interaction of osteoblasts and 
osteoclasts. Osteoblasts express RANK ligand (RANKL) and osteoprotegrin (OPG). OPG 
binds to RANKL and blocks it from interacting with RANK. The binding of RANKL to 
RANK (facilitated by a decreased amount of OPG) stimulates osteoclast precursors to 
fuse, forming new osteoclasts which ultimately dissolve bone. Increased OPG or 
decreased RANKL reduces osteoclast differentiation (Riches and Ralston 2010). 
Osteoclasts also influence the differentiation of osteoblasts (Boyce et al. 2009). 
These mechanisms can be exploited to treat disease. Inhibition of bone resorption by 
osteoclast digestion is possible with the addition of bisphosphonates (Matsuo and Irie 
2008, Su et al. 2011). Decreasing the differentiation of osteoclasts is possible with the 
addition of selective oestrogen mimics, TGFb and RANKL antibodies (Turner et al. 
1988, Trouvin and Goeb 2010, Cicek et al. 2011). A reduction in the number of 
osteoclasts can also be achieved by decreasing PTH thereby increasing bone density by 
reducing osteoblast OPG production (Trivedi et al. 2010).  
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It is known that the osteocytes in lacunae have a signalling role in bone maintenance and 
mechanical stimulation prevents their loss (Fonseca et al. 2011). Increased differentiation 
of osteoblasts has also been shown to occur after mechanical stimulation and independent 
from osteocyte signalling (Maul et al. 2011).  
1.6 Genetic regulation of bone. 
 
 
Fig 1.1, Factors involved in the adhesion and condensation of mesenchymal cells. 
Adapted from Hall and Miyake, 2000. 
The regulation of bone formation and maintenance is complicated by the multiple 
functions required from the organ. For such a complicated system there is an array of 
growth and transcription factors orchestrating gene expression and protein function. The 
regulation of scaffold condensation and subsequent mineralisation is complex; initial 
adhesion of mesenchymal cells and initiation of skeletal development is thought to occur 
by aggregation of cells and enhanced proliferation of the condensate (fig 1.1). The 
condensation of cells is mediated by adhesion proteins, N-CAM (Neural Cell Adhesion 
Molecule), fibronectin, tenascin and syndecan. These are in turn regulated by TGFb and 
FGFb. The shape of the condensate is precisely controlled by syndecan and tenascin 
regulation of fibronectin and exclusion of Hoxa2 from the template. The cells within the 
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template are induced to proliferate by FGFb, while template size is under the control of 
BMPs (Hall and Miyake 2000, Wagner and Karsenty 2001). 
Regulation of proliferation within the differentiating template is mediated by Pax1 and 
Pax9, transcription factors which are regulated by BMPs (fig 1.2). Noggin binds and 
inactivates the BMPs regulating differentiation; therefore the Noggin/BMP relationship 
controls the size of the template and the initiation of differentiation and mineralisation.  
 
 
Fig 1.2, regulation and function of BMPs in bone growth, Shh (sonic hedgehog) and 
Noggin regulate BMP activity in condensates. BMPs regulate patterning transcription 
factors, hox and msx genes. BMP-Cbfa1-SMAD interactions regulate differentiation. 
Adapted from Wagner and Karsenty, (2001). 
BMP regulation of Cbfa1 activity is mediated by SMAD and TGFb (fig 1.3); both Cbfa1 
and SMAD are inactivated by Smurf1. BMP interactions with Cbfa1 and SMAD can 
protect from Smurf1, this interaction is thought to redundantly regulate mineralisation 
and ensure that it is confined within the template (Stein et al. 2004, Paredes et al. 2004).  
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Fig 1.3 The mineralisation of the cartilage template. The BMP/SMAD/Cbfa1 interaction 
mediates differentiation to a mineralised phenotype. Adapted from Stein et al. (2004), 
Paredes et al. (2004) Nishio et al. (2006) and Jensen et al. (2010).  
Although there is upstream regulation of Cbfa1 it is required for osteogenic 
differentiation and is directly involved in all major osteogenic gene function, including 
collagen I (Col IaI), matrix metalloproteinase I (MMPI), bone sialoprotein (BSP), TGFb, 
RANKL, alkaline phosphatase (ALP), Osterix (Osx), osteopontin (OP), osteocalcin (OC); 
Cbfa1 expression is greatest in mature osteoblasts (Stein et al. 2004). 
1.6.1 BMP  
Current approaches to bone engineering involve the use of transcription factors to tip the 
healing process in the favour of the desired outcome; many papers have been published 
regarding the use of BMPs to generate de novo bone. (Heliotis et al. 2006, Brandoff et al. 
2008, Chen et al. 2011) BMPs regulate hox genes and are at peak effectiveness during 
cell proliferation, artificially adding BMPs can tip the balance of transcription factors in 
 10 
 
favour of osteogenesis, potently up regulating mineralisation. BMPs are members of the 
TGFb superfamily, which are all (over 20 identified), involved in morphogenesis, 
embryogenesis, cartilage and skeletal development. At the nuclear level increasing 
extracellular BMP influences Cbfa1 mediation of differentiation increases expression of 
ALP, osteopontin, osteocalcin, bone sialoprotein and collagen α-1 (Leboy 2006). 
1.6.2 Cbfa1  
When binding to promoters in complex with BMPs and vitamin D3 Cbfa1 (Runx2) 
regulates osteoblast and chondrocyte differentiation; causing cells to switch to the 
osteoblastic pathway (Leboy 2006). In mice targeted knockdowns of Cbfa1 result in the 
absence of skeletal mineralisation (Komori et al. 1997).  
Cbfa1 is a human homolog of the drosophila runt gene and is similarly essential to 
development; runx1 is essential for haematopoiesis and runx3 for neurogenesis and 
regulation of gastric epithelial cell growth. There is thought to be some cross over 
between the functions of Cbfa1 (runx2) and runx3, because both regulate chondrocyte 
proliferation and maturation (Cohen 2009, Swiers et al. 2010).  
During development expression of Cbfa1 is mediated by TGFb, several BMPs, vitamin D 
and indirectly by sonic hedgehog (Shh). There are several isotypes of Cbfa1; two main 
promoters give rise to isotypes that are found predominantly in mature osteoblasts and 
hypertrophic chondrocytes (Cbfa1 type II). Type I Cbfa1 is found in less differentiated 
osteoblasts and chondrocytes, alternate splicing and regulation via post translational 
modifications has also been demonstrated (Enomoto et al. 2000, Bronckers et al. 2005). 
Cbfa1 is involved in the differentiation of chondrocytes to hypertrophic chondrocytes, 
knockout mice exhibit delayed or non-existent completion of the chondrocyte template 
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essential for endochondral bone formation. Double knockdowns have no hypertrophic 
chondrocytes at all and no mineralisation (Ito and Miyazono 2003).  
Regulation of osteoblast differentiation by Cbfa1 can be shown to occur by the removal 
of post-translational phosphorylation by protein kinases such as MAPK and ERK. 
Activation of the MAPK/ERK pathways increases the availability of Cbfa1 and so 
increases differentiation. MAPK also mediates interactions between smad and Cbfa1 
(Jonason et al. 2009).  
Cbfa1 is not essential for the differentiation or function of osteoclasts, however in Cbfa1 
knockout mice the regulation of the production of RANKL is abnormal; they produce 
more OPG and less RANKL than wild type mice. The balance of OPG-RANKL is the 
main regulator of osteoclastogenesis (Enomoto et al. 2003). 
Ultimately as with all developmental transcription factors the regulation of expression 
and interaction of proteins is extremely complicated and contains many feedback systems 
that effectively regulate the production of bone. Increased expression of Cbfa1 mRNA 
has been shown repeatedly by many authors during osteogenic differentiation and is 
accepted late marker of differentiation (Gabbay et al. 2006, Crippa et al. 2008, Tsai et al. 
2009, Curran et al. 2009, Bessa et al. 2009, Huang et al. 2010).  
1.6.3 Alkaline phosphatase  
Alkaline phosphatase (ALP) is a common marker of osteogenesis and is upregulated in 
many differentiating cell types from the colon to osteoblasts and osteoclasts (Matsumoto 
et al. 1990, Heinemann et al. 2000). ALP has been used in the clinic as a marker for 
osteoblastic function since 1994 and levels increase commensurate with bone turn over 
and mineralisation (Shankar and Hosking 2006, Tuck et al. 2008).  
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Approximately 50% of circulating ALP is from the bone, without functional ALP 
mineralisation fails (Orimo 2010, Saad and Lipton 2010). ALP hydrolyses 
phosphomonoesters at an alkaline pH, and is the sole method of breaking down inorganic 
pyrophosphates. Inorganic pyrophosphate (PPi) is the most important inhibitor of calcium 
phosphate turnover at the bone/cell interface; ALP removes these inhibiting effects and 
locally increases available phosphate (Whyte 2010).  
ALP is used as an early indicator of increased osteoblast differentiation because levels of 
ALP spike at a point between 10 and 16 days after initiation of differentiating conditions. 
(Hoemann et al. 2009) 
1.7 Isolation of marrow stromal cell osteoprogenitors 
In the 1960s McCulloch and Till identified the haematopoietic stem cell by the clonal 
nature of spleen colonies found in nodules after injection with bone marrow derived cells. 
Later they demonstrated that each colony was produced by a single bone marrow derived 
cell (Till and McCulloch 1961, Siminovitch et al. 1963). Friedenstein et al used an 
extension of this work and with colleagues Chailakhan and Lalykina discovered inducible 
osteoprogenitor cells residing in the spleen (Friedenstein et al. 1970). The spleen is the 
only organ in the body to be entirely comprised of mesenchymal elements, inducible 
osteoprogenitors were thought to retain the potential to become osteoblasts when 
stimulated correctly and therefore are not committed to a cell fate (Owen and 
Friedenstein 1988). 
In 1970 Friedenstein et al. isolated from a bone marrow cell suspension an adherent, 
clonogenic, fibroblast like cell culture which he named the CFU-F, these cells were 
demonstrated to be multi-potential were able to support myelopoiesis and could also 
differentiate into adipocytes, chondrocytes and osteoblasts (Friedenstein et al. 1992). In 
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vivo experiments demonstrated that 60% of clones are able to produce de novo bone 
(Friedenstein et al. 1987). After this demonstration by Friedenstein et al. adherent and 
colony forming fibroblast like cells have been investigated as a potential source of 
autologous cells for clinically relevant applications; as well as investigations into the 
plasticity of adult cell populations (Korda et al. 2010).  
The first method published by Friedenstein et al. (1970) consists of initial harvest of the 
bone marrow, sieve homogenisation and culture adherent cells. For the formation of the 
fibroblast colony forming unit, CFU-F, cells were seeded at a density of 1-5x10
4
 cells per 
25cm
2
, Friedenstein noted the colony forming efficiency at approximately 3-10 cells per 
1x10
4
 cells in the bone marrow. Recent human cell data puts this number between 52.2 ± 
4.1 (children) and 32.3 ± 3.0 (adults) cells per 1x10
5
 mononuclear cells (Kuznetsov et al. 
2009). 
Improvements in the method of Friedenstein have been attempted; a trabecular bone wash 
method was proposed (Grundle and Beresford, 1994). Collagenase digestions of 
trabecular bone and mechanically harvested cortical bone have been attempted (Tuli et 
al., 2003). In culture the mRNA phenotype of collagenase released cells decreases for 
markers of osteoblastic differentiation, Cbfa1 and osterix, and also for the adipogenic 
PPARγ and FABP4 indicating a loss of determined cells in vitro (Sakaguchi et al 2004). 
The loss of expression over culture time without loss of differentiation phenotype 
suggests heterogeneity even in clonally derived cultures, or may indicate a form of 
culture selection is occurring (Wagner and Ho 2007). 
It has also been shown that multipotent stromal cells, also MSC, can be isolated from the 
blood, harvesting from 50 ml of buffy coat using a cell elutriator, total cell numbers of 
monocytes on average were 2.14 ± 0.22 x10
7
 and from this between one thousand and ten 
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thousand PB-MSCs survived harvesting, attached to tissue culture plastic and proliferated 
(Zvaifler et al. 2000, Kuznetsov et al. 2001). 
The simplest method of separation is when a single antibody is used to isolate a cell strain 
from a heterogonous population. Modern fluorescent antibody cell sorting (FACS) 
technology allows for the isolation of selected populations of cells by surface epitope 
characterisation. Unfortunately the whole BMSCs population has defied characterisation 
by these methods, authors have reported screening hundreds of surface epitopes with no 
consensus found, either the patterns change with age of culture or they involve subjective 
judgements of labelling dimness (diGirolamo et al. 1999, Harichandan and Buhring 
2011). 
1.7.1 Culture of BMSC. 
The pluripotency of BMSCs can be maintained in vitro given the correct culture 
conditions, cells are grown at sub-confluent levels ranging from 1-5 x10³ cells per cm², in 
DMEM (αMEM is also common) culture media with various quantities of FCS reported 
as being necessary, from 7-20% (Meuleman et al. 2006, Lange et al. 2007). EGF, PDGH, 
and FGF have been shown to ensure non-differentiation of cells over longer culture 
periods with less emphasis on the concentration of cells per cm² (Maegawa et al. 2007).  
1.7.2 in vitro differentiation 
BMSC cultures differentiate into four major cell types, adventitial reticular cells (stromal 
fibroblasts), adipocytes, chondrocytes and osteoblasts (Bianco et al. 2008, Sarugaser et al. 
2009). There have also been more contentious reports of several other cell types, 
including some involving transdifferentiation across a germ line (Bianco. 2007, Bianco et 
al. 2008).  
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The first loss of multipotency from cultures is the stromal fibroblast. Depending on the 
origin of the tissue the potential for differentiation to adipocytes is lost from BMSC 
cultures; this occurs most often in bone marrow derived cultures and least often in 
adipose derived cultures (Xiao et al. 2010). Adipogenesis is achieved with stimulation by 
insulin, indomethacin and dexamethasone, lipid accumulation occurs and can be observed 
after staining with oil red O (Bianco et al. 1999). The next potential lost from the cell 
cultures is the osteoblast or chondrocyte lineage, most often chondrocytes.  
Chondrocytes are differentiated in pellet culture, increased density in three dimensions is 
a potent stimulator of differentiation; addition of TGF-b is the most effective 
chondrogenic supplement (Vater et al. 2011). Osteoblasts are normally the terminal 
lineage of bone marrow derived MSCs and therefore differentiate from almost all 
populations of marrow stromal cells (Vater et al. 2011). Since osteoblasts differentiate in 
situ the major osteogenic stem cell niche is thought to be in close proximity to the 
majority of osteoblast activity (Bianco 2011). 
1.8 BMSC in vivo.  
Multipotent skeletal progenitor cells have been found in a large number of tissues, organs 
and the peripheral blood of humans (Hilfiker et al. 2011), kidneys (Park et al. 2010), 
umbilical cord blood (Erices et al. 2000), adipose (Zuk et al. 2002), heart and dermis 
(Riekstina et al. 2009). All these tissues are highly vascularised, leading some to consider 
that the MSC niche is the vasculature (Augello et al. 2010). Vasculature pericytes, cells 
associated with capillaries, isolated from the retina of cows have been shown to express 
the specific osteogenic markers osteopontin, osteonectin, and bone sialoprotein and when 
inserted into in vivo diffusion chambers produced de novo bone and cartilage (Canfield et 
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al. 1996). Experiments on vascular smooth muscle cells have produced similar results 
(Yan et al. 2011). 
1.8.1 BMSC transplants 
Injection of cultured non-sex matched BMSCs have shown that engraftment to the host 
occurs predominantly to areas of growth and repair, the literature reports engraftment to 
bone, cartilage, the CNS (astrocytes and neurons), lung, spleen, muscle, and thymus after 
systemic injection (Tolar et al. 2010). Allogeneic BMSCs have been shown to reduce and 
even stop the incidence of graft versus host disease after HSC transplant, indicating 
interaction and modulation of cells within the immune system (Porta et al. 2004). 
Transplantation of carefully selected BMSCs has been shown to restore some function to 
pancreatic islets in NOD/SCID mice (Bell et al. 2011), restore cartilage (Richter 2009) 
and support angiogenesis (Casteilla et al. 2010). BMSC have been shown to enhance 
bone regeneration (Ma et al. 2011). 
1.9 Bone replacements  
The gold standard for bone replacement is autografted bone however there are problems 
associated with its use, including lack of donor tissue, graft site morbidity and resorption 
of graft or underlying bone (Stellingsma et al. 2004, Giannoudis et al 2005, Brandoff et 
al. 2008, Dusseldorp and Mobbs 2009). When looking at alternatives to the autograft the 
surgeon takes into account the biocompatibility of the implant, availability, ease of 
shaping and molding during surgery, the long term stability and radio translucence 
(Brydone et al. 2010).  
There are several materials currently available on the market that meet some of these 
requirements, polymethyl methacrylate (PMMA), bioactive glass, allograft or 
demineralised bone tissue and calcium phosphate cements (Brydone et al. 2010). 
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Additionally some materials are or purport to be integrating, osteoconductive or 
biomimetic, this generation of materials has been designed purposefully with the intent to 
replace or fully integrate the graft with the patient’s own tissue (Lu et al. 2010). 
Bone cements have been in use for several decades; the most commonly used is PMMA 
(Acharya et al. 2011, Lewis 2011). PMMA sets in an exothermic reaction and does not 
integrate with the surrounding tissues. This is both positive and negative; for temporary 
repair of bone tissue in the young or for cosmetic surgery the use of a non-integrating 
polymer can be beneficial (Acharya et al. 2011, Lewis 2011). However for long term 
repair of tissue a regenerative or integrating polymer is of more use and there are 
marketed materials available for the surgeon in this case (Ambard and Mueninghoff 
2006). PMMA has a reputation as being more difficult to keep clean and as there is no 
integration with the host tissue and therefore no blood supply it is difficult to remove an 
infection once it has compromised the cement (Winkler 2009).  
For some time hydroxyapatite has been used as a bone filler in the shape of blocks or 
packed in as granules, HA has some disadvantages, it is not remodelled fully if made too 
thick for example, however it does have the advantage that it can be soaked in growth 
factors that can promote the production of new bone (Heliotis et al. 2006, Beekmans et al. 
2008).  
Calcium phosphate cements are well known and commercially available, discovered in 
the 1980’s they are extensively researched with several thousand papers published and 
were a focus of research in the “bone and joint decade” (Woolf 2000, Dreinhofer et al. 
2004). Calcium phosphate cements are entering a second generation of development as 
bioactive, fast setting, drug eluting scaffolds for tissue regeneration and delivery of a 
desired pharmaceutical (Chow 2009).  
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Due to extensive research into calcium phosphate cements over the last 25 years it is well 
known that setting times can be manipulated easily by adjusting the powder sizes, the 
concentration of accelerant, total volume of liquid phase and the addition of nucleation 
foci or crystallisation inhibitors (Chow 2009). It is also known that porosity is malleable 
and that lower porosity equates to stronger materials and increased persistence in the 
defect, however reducing the porosity inhibits remodelling of the cement (Takagi et al. 
1998, Chow 2009). 
The major benefits of calcium phosphate cements are that they are injectable, can be drug 
eluting throughout the matrix of the cement, it has good compressive strength, low setting 
times at body temperature, it is moulded into the defect and therefore provides a perfect 
fit, it exhibits porosity which can be used to increase in growth of new tissue. It can be 
utilised instead of packing with HA because of these qualities (Takagi et al. 1998, Low et 
al. 2010).  
In most available calcium phosphate cements there are two end point setting products; 
brushite and apatite. Apatite cements in vivo continually increase mechanical strength 
compared with surrounding tissue after the setting period. Brushite cements decrease 
their mechanical strength after the setting time (Moseke and Gbureck, 2010).   
Cements on the market are made with two components, all use tetra calcium phosphate 
(TTCP) as the main dissolving component, the faster setting cement systems with high 
early strength were developed using the more soluble DCPD (brushite) instead of DCPA 
(monetite) as the second nucleating cement component. Some experimental cements use 
nanocrystaline hydroxyapatite as the nucleating agent, in an attempt to form calcium 
deficient hydroxyapatite (CDHA) as an end product (Johnsson and Nancollas 1992, 
Barralet et al. 2004, Burguera et al. 2006).  
 19 
 
Cements have been developed with addition of agents for enhanced osteogenesis, 
infection control, and reduction in resorption (Brandoff et al. 2008, Panzavolta et al. 
2010, Neut et al. 2010). The addition of selective oestrogen receptor modulators has been 
demonstrated, but the effect on primary cell culture is unknown (Perut et al. 2011). 
1.10 Soy phytoestrogens. 
Glucose conjugated isoflavones (fig 1.4a), glycosides, and malonates (fig 1.4c) are the 
prevalent phytoestrogens in the soybean, Glycine max and are the storage form within the 
plant (Barnes 2010). In Asian food the use of soy, historically and today, is mostly as a 
fermented product, soy sauce, miso, soy paste, and tempeh are all produced in this 
manner. Fermentation of soy results in an increased concentration of the aglycones and 
decreased conjugates (Barnes 1998). Using boiling water to make soy milk hydrolyses 
the malonates to glycosides and toasting dry soy decarboxylates malonates to produce 
acetylates (fig 1.4b) (Friedman and Brandon 2001). Therefore isoflavones and their 
conjugates are different in different foods depending on processing. 
After ingestion of isoflavones the aglycones are readily absorbed by the human gut and 
glycosides are quickly broken down by cells expressing lactase (Day et al. 2000). The 
remaining conjugates are metabolised and modified by the bacteria in the large intestine, 
metabolites are dependent on gut microflora (Chien et al. 2006, Nielsen and Williamson 
2007, Barnes 2010).  
Once in the blood isoflavone aglycones are active in the human body as mimics of 
oestrogen, and are therefore phytoestrogens (Lindner 1976). High dietary intake of 
phytoestrogens has been linked with a reduction in breast cancer risk, an increase in bone 
density and reduction in the incidence of fractures (Usui 2006, Castelo-Branco and 
Cancelo Hidalgo 2011). Some studies show an 8-14% increase in bone density, soy 
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consumption has been linked to the inhibition of bone loss in menopausal and post-
menopausal women (Lagari and Levis 2010). Phytoestrogens have been shown to bind to 
and activate oestrogen receptors α and β, ERα ERβ (Pilsakova et al. 2010).  
 
Isoflavone R1 R2 
genistein OH H 
daidzein H H 
glycitein H OCH3 
 
       
 
       
Fig 1.4, Drawing of a generic isoflavone and the three main isoflavonoid aglycones, 
modifications to carbon 7 occur in the soy plant and after heat treatment of aglycones. 
Modifications can include A) glycosides, B) acetyl glycosides, C) malonyl glycosides. 
For comparison the human hormones D) 17β-estradiol, E) estrone, D) progesterone are 
also represented. Molecules are orientated as found in vivo at ERβ (Pike et al. 1999). 
Genistein and daidzein bind ERβ with greater efficiency than ERα, once bound they are 
reported as activating transcription of an overlapping but different set of responsive genes 
than oestrogen, dependant on the model used (Katzenellenbogen et al. 2000, Kushner et 
al. 2000, Akbas et al. 2004, Schreihofer 2005, Tang et al. 2008, Rando et al. 2009, 
Hartman et al. 2009, Ni et al. 2010). The selectivity in ER ligand binding has led to the 
term selective oestrogen receptor modulator, SERM. (Pilsakova et al. 2010)  
A B C 
D E F 
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Genistein has agonist activity for both ERα and ERβ, but has an affinity between 7-30 
times greater for ERβ, dependant on the conditions of the study (Morito et al. 2001). 
Similarly daidzein has affinities of 420nM and 100nM for α and β respectively, although 
the isoflavones never reach saturation levels in vivo (Krishnan et al. 2000, Morito et al. 
2001). The SERMs ER ligand has been shown to modulate the expression of different 
genes compared with oestrogen (Akbas et al. 2004).  
In developing human bone both ER types are expressed, in adult bone ERα is 
predominantly expressed in compact bone and ERβ is expressed at higher levels in 
trabecular bone (Robinson et al. 1997). ERα deficiency in men causes non fusion of the 
growing bone epiphyses, and therefore continuous longitudinal growth of the long bones 
and low BMD (Smith et al. 2010). ERβ -/- female mice have a masculine bone phenotype 
which is not different from the male wild type (Smith et al. 2010).  
Oestrogen receptors were first reported as nuclear transcription factors that are ligand 
activated with specificity dependent on ligand (Nilsson and Gustafsson 2011). ERs have 
also been found outside the nucleus, bound to membranes and acting as transcription 
factors without ligand binding (Giguere 2002, Mendelsohn and Karas 2010).  
While ERα is most highly conserved ERβ has multiple isoforms, including variants that 
have; extended N termini, an 18 amino acid insert in the ligand binding domain or 
carboxyl terminal variants unable to form ligands or modulate transcription (Foryst-
Ludwig and Kintscher 2010). In mice double knockouts survive to adulthood, suggesting 
that there may be other ERs (McCauley et al. 2002). There is evidence for oestrogen 
related receptors that may offer redundancy in the system (Giguere 2002).   
The activity of the dimerised transcription factor once bound to a ligand varies dependant 
on the conformational change induced in the receptor. The variation in conformational 
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change between the two receptor types can be most fully seen when comparing the action 
of a ligand forming agent such as the SERM tamoxifen. When bound to ERα tamoxifen 
shows oestrogen agonist activity, however upon binding ERβ tamoxifen is an antagonist, 
differences in the N terminal region of the receptors are thought to explain the agonist or 
antagonist effect on the ERE (Chang et al. 2008, Alexi et al. 2009).  
The ERs have been shown to bind the promoter of some genes thereby modulating their 
activation (Leclercq et al. 2006). Activated ERs can also bind other transcription factors 
influencing the transcription of genes that they cannot directly mediate. Indirect activity 
of ERα in the absence of a ligand binding factor and therefore transcription factor activity 
has been demonstrated subsequent to activation of membrane receptors for IGF-I, EGF 
and TGF (Kushner et al. 2000, Bondar et al. 2009). Most of these authors suggest the 
mechanism of activation is due to a phosphorylation of the N terminal of the ER, 
suggesting that variation occurs in receptor isotypes and perhaps between cell types 
(McCauley et al. 2003, Ho 2004).  
Oestrogens have an indirect effect on osteoclasts by increasing the osteoblast production 
of OPG and thereby reducing osteoclast activation by the RANK ligand, oestrogen may 
also directly effect osteoclast differentiation, maturation and activity by modulating 
cytokine production (Martin-Millan et al. 2010). 
Evidence for indirect regulation of genes binding other transcription factors has been 
substantiated, for instance AP-1, Sp1 and some c-AMP responding elements are all 
managed in similar activated ER to protein binding processes (Safe and Kim 2008). AP-1 
is up-regulated by ERα ligand but down-regulated by the active ERβ with possible 
methods including sequestering of cofactors that combine with fos and jun (Jakacka et al. 
2001, Zhao et al. 2010). AP-1 regulation may explain the reported proliferation effects of 
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isoflavone doping, and go some way to explain the selective effect of isoflavones on 
tissue and cell types (Schreihofer 2005). 
1.11 Measurements of isoflavone concentrations in vivo: 
After studying Japanese men that consume a soy rich diet Adlercreutz et al. report a mean 
concentration of total, free plus un-conjugated, genistein at 276nM with approximately 
4% (9.64 nM) available to activate ERs; Setchell and Cassidy describe the free genistein 
levels to be between 1 and 1.5% temporally relative to consumption of soybeans (Setchell 
and Cassidy 1999, Adlercreutz 2002).  
Further studies by Adlercreutz observed the free genistein levels in plasma to be between 
20 and 40nM for 2 to 8 hours after consumption, no residual genistein is found after 24 
hours (Adlercreutz et al. 2004). Comparing these levels of free genistein with those found 
to activate ERα and β it is apparent that activation of ERβ is easily possible with 
physiological levels of genistein, however the concentration of genistein for ERα 
activation is sub-optimal (Rickard et al. 2003). Modulation of ER expression is apparent 
in some studies at these concentrations (Berner et al. 2010).  
In a long term fully randomised study undertaken by Squadrito et al. in 2007 
supplementing 55mg of daily dietary genistein compared to HRT and placebo, in all 90 
postmenopausal women took part and their responses were investigated at 6 and 12 
months (Squadrito et al. 2003, Atteritano et al. 2007). The group that received the 
isoflavone supplement were measured as having 1.5μM serum genistein at 6 months and 
1.7μM at 12 months, using the Aldercreutz report as a guide they are likely to have about 
20nM free genistein, sufficient to activate ERβ.  
At six months the genistein group demonstrated significantly increased serum levels of 
ALP and osteocalcin and at 12 months the OPG/RANKL ratio was reduced to a greater 
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extent in the isoflavone group than the HRT group. Measurements of BMD showed 
increases of 3-4% after 12 months in both the HRT and genistein groups relative to minor 
losses in the placebo group. Key to this study is the length of time the participants were 
followed, the number of participants, and the concentration of free genistein (Squadrito et 
al. 2003, Atteritano et al. 2007). In this study free genistein was available in sufficient 
quantities to activate ERβ. However not all studies provide measurements of the 
bioavailability of the administered genistein, therefore the level of free genistein is likely 
the reason for the reported variability in the effects of genistein supplementation. 
It is apparent from the study of isoflavones in the human diet that systemic concentrations 
are almost always lower than full saturation of ERs. Therefore pharmaceutical doses of 
isoflavones in cements should be considered for maximum effect in order to influence the 
local environment. 
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1.12 Hypothesis. 
The overall hypothesis of this study is that the addition of soy extracts to a calcium 
phosphate cement increases the osteogenic differentiation of primary human cells.  
This overall hypothesis can also be separated into several sections; that pure isoflavone 
and soy extracts will increase osteogenesis of a confluent cell model; the increase in 
osteogenesis will be observable in culture medium, osteogenic medium, and components 
of osteogenic medium; the addition of a competitive ER inhibitor will reduce the 
observed effect demonstrating that phytoestrogens are responsible for the osteogenesis.  
 
1.13 The aim of the work.  
These hypotheses will be pursued by observing the effect of a wide range of 
concentrations of genistein on an osteosarcoma cell line, developing the methodology for 
analysis of proliferation and differentiation. Once a model is established primary human 
cells will be isolated and characterised prior to addition of soy extract to the primary 
model. The soy extract will be incorporated into osteogenic cements and the results 
related to the observations with pure isoflavone and soy extract.  
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CHAPTER 2 
MATERIALS AND METHODS. 
2.1. Materials. 
2.1.1. Equipment for extraction of BMSCs. 
Product Source 
Surgical Nail clippers Swann-Morton® Ltd, Sheffield, UK 
Scalpels  
Needles. All gauges  NHS direct. UK 
syringes 
 
2.1.2 Extraction consumables 
Product Source 
Ficoll Paque plus – 1073g/ml Sigma-Aldrich Company Ltd., Dorset, UK 
 
2.1.3 Cell culture plastic 
Product Source 
Cellstar® 25cm
2
, 75cm
2
, 175cm
2
 Filter Cap 
Tissue Culture Flasks  
Greiner Bio-One Ltd, Stonehouse, Glos, 
UK  
30 ml sterile universal plastic tubes  
BD Falcon® 1ml, 5ml, 10ml, 25 ml 
Serological Pipettes  
Becton Dickinson Labware, NJ, USA. 
Supplied by Marathon Laboratory Supplies 
Ltd, London, UK  BD Falcon® Blue Max™ 50ml 
Polypropylene Conical Tubes  
BD Falcon® Blue Max™ Jr. 15ml 
Polystyrene Conical Tubes  
BD Falcon® Integrid™ Petri Dishes  
BD Falcon® Multiwell™ 96-well culture 
plates 
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Product Source 
Nunc™ CryoTube™ 1.8ml Vials  Fisher Scientific UK, UK 
Non and plugged glass Pasteur pipettes  
 
2.1.4 Cell culture consumables. 
Product Source 
Hanks’ Balanced Salts Solution (HBSS) 
without CaCl2 and MgCl2 
Gibco™ Invitrogen Life Technologies Ltd, 
Paisley, Scotland, UK 
0.05% Trypsin-EDTA 
Dimethyl Sulphoxide (DMSO) Hybri-
Max® 
Sigma-Aldrich Company Ltd., Dorset, UK 
 
2.1.5 Wash buffers 
Product Source 
Penicillin/Streptomycin solution, stock 
activity of 5000U/ml & 5000µg/ml 
Gibco™ Invitrogen Life Technologies 
Ltd, Paisley, Scotland, UK 
clindamycin 5000U/ml Sigma-Aldrich Company Ltd., Dorset, UK 
 
2.1.6 Isolation and Culturing Medium  
Product Source 
Dulbecco's Modified Eagle's Media (D-
MEM) + 1000mg/l Glucose + 
GlutaMAX™ + Pyruvate 
Gibco™ Invitrogen Life Technologies Ltd, 
Paisley, Scotland, UK 
10% Foetal Calf Serum, New Zealand (heat 
inactivated at 56°C for 35 minutes) 
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2.1.7 Osteogenic medium 
Product Source 
Dulbecco's Modified Eagle's Media (D-
MEM) + 1000mg/l Glucose + 
GlutaMAX™ + Pyruvate 
Gibco™ Invitrogen Life Technologies Ltd, 
Paisley, Scotland, UK 
10% Foetal Calf Serum, New Zealand (heat 
inactivated at 56°C for 35 minutes) 
10nM Dexamethasone Sigma-Aldrich Company Ltd., Dorset, UK 
50µg/ml ascorbate-2-phosphate 
10mM β-glycerophosphate 
 
2.1.8 Adipogenic medium 
Product Source 
Dulbecco's Modified Eagle's Media (D-
MEM) + 4000mg/l Glucose + 
GlutaMAX™ + Pyruvate 
Gibco™ Invitrogen Life Technologies Ltd, 
Paisley, Scotland, UK 
10% Foetal Calf Serum, New Zealand (heat 
inactivated at 56°C for 35 minutes) 
1µM dexamethasone Sigma-Aldrich Company Ltd., Dorset, UK 
10 µg/ml insulin 
60µM indomethacin 
500µM isobutyl-methylxanthine 
 
2.1.9 Chondrogenic medium 
Product Source 
Dulbecco's Modified Eagle's Media (D-
MEM), 4000mg/l Glucose, GlutaMAX™  
Pyruvate 
Gibco™ Invitrogen Life Technologies Ltd, 
Paisley, Scotland, UK 
10% Foetal Calf Serum, New Zealand (heat 
inactivated at 56°C for 35 minutes) 
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Product Source 
100nM dexamethasone Sigma-Aldrich Company Ltd., Dorset, UK 
 50µg/ml ascorbate-2-phosphate 
40 μg/ml L-proline 
100 μg/ml pyruvate 
10 ng/ml transforming growth factor 
(TGF)-β3 
50 mg/ml ITS+ Premix Becton Dickinson 
 
2.1.10 Experimental media 
2.1.10.1 Growth medium 
Product Source 
Dulbecco's Modified Eagle's Media (D-
MEM) + 1000mg/l Glucose + 
GlutaMAX™ + Pyruvate 
Gibco™ Invitrogen Life Technologies Ltd, 
Paisley, Scotland, UK 
Foetal Calf Serum, New Zealand (heat 
inactivated at 56°C for 35 minutes) 
50µg/ml ascorbate-2-phosphate Sigma-Aldrich Company Ltd., Dorset, UK 
 
2.1.10.2 β-glycerophosphate medium 
Product Source 
Dulbecco's Modified Eagle's Media (D-
MEM) + 1000mg/l Glucose + 
GlutaMAX™ + Pyruvate 
Gibco™ Invitrogen Life Technologies Ltd, 
Paisley, Scotland, UK 
10% Foetal Calf Serum, New Zealand (heat 
inactivated at 56°C for 35 minutes) 
50µg/ml ascorbate-2-phosphate Sigma-Aldrich Company Ltd., Dorset, UK 
10mM β-glycerophosphate 
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2.1.10.3 Dex medium 
Product Source 
Dulbecco's Modified Eagle's Media (D-
MEM) + 1000mg/l Glucose + 
GlutaMAX™ + Pyruvate 
Gibco™ Invitrogen Life Technologies Ltd, 
Paisley, Scotland, UK 
10% Foetal Calf Serum, New Zealand (heat 
inactivated at 56°C for 35 minutes) 
10nM Dexamethasone Sigma-Aldrich Company Ltd., Dorset, UK 
50µg/ml ascorbate-2-phosphate 
 
2.1.10.4 Osteogenic medium 
Product Source 
Dulbecco's Modified Eagle's Media (D-
MEM) + 1000mg/l Glucose + 
GlutaMAX™ + Pyruvate 
Gibco™ Invitrogen Life Technologies Ltd, 
Paisley, Scotland, UK 
10% Foetal Calf Serum, New Zealand (heat 
inactivated at 56°C for 35 minutes) 
10nM Dexamethasone Sigma-Aldrich Company Ltd., Dorset, UK 
50µg/ml ascorbate-2-phosphate 
10mM β-glycerophosphate 
 
2.1.11. Staining solutions. 
2.1.11.1 Alizarin red stain, for calcium anions  
Product Source 
40mM Alizarin Red S (ARS), CI: 58005  Sigma-Aldrich Company Ltd., Dorset, UK 
10% Acetic acid 
10% ammonium hydroxide 
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2.1.11.2 Von Kossa stain. 
Product Source 
5% sodium thiosulfate Sigma-Aldrich Company Ltd., Dorset, UK 
1% Silver Nitrate 
0.1% nuclear fast red 
ammonium sulphate 
 
2.1.11.3 Oil Red O, lipid stain. 
Product  Source 
4% Oil Red O Sigma-Aldrich Company Ltd., Dorset, UK 
2-Propanol (isopropanol)  
 
2.1.11.4 Cartilage stain, for the assessment of proteoglycans. 
Product  Source 
0.5%, w/v Alcian Blue (C.I. 74240) pH 2.5 
in 3% acetic acid 
Sigma-Aldrich Company Ltd., Dorset, UK 
Weigert's Iron Hematoxylin 
 
2.1.11.5 Collagen staining 
Product source 
0.1% Sirius red F3B (C.I. 35782) Sigma-Aldrich Company Ltd., Dorset, UK 
Saturated aqueous solution of picric acid 
HCl acid 
 
2.1.11.6 HPI stain for membrane integrity 
Product Source 
Dulbecco's Modified Eagle's Media (D-
MEM) + 1000mg/l Glucose + 
GlutaMAX™ + Pyruvate 
Gibco™ Invitrogen Life Technologies Ltd, 
Paisley, Scotland, UK 
Propidium iodide (1mg/ml) Sigma-Aldrich Company Ltd., Dorset, UK 
Hoechst (5mg/ml) 
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2.1.12 Cell lysate buffer 
Product  Source 
0.1% Triton X-100 Sigma-Aldrich Company Ltd., Dorset, UK 
10 mM Tris-HCl pH 7.8 
0.5mM MgCl2 
 
2.1.13 Solutions for determination of ALP activity  
Product Source 
p-Nitrophenol phosphate (p-NPP) Sigma-Aldrich Company Ltd., Dorset, UK 
0.1M NaOH 
shrimp ALP, (EC: 3.1.3.1) 
p-NP 
 
2.1.14 Total protein determination by Bradford reagent 
Product Source 
Bradford reagent Sigma-Aldrich Company Ltd., Dorset, UK 
BSA 
 
2.1.15 LDH cytotoxicity testing 
Product Source 
Promega's CytoTox 96 non-radioactive 
cytotoxicity LDH assay 
Promega UK Ltd. Southampton, UK 
PBS Sigma-Aldrich Company Ltd., Dorset, UK 
 
2.1.16 Immunohistology 
Product  Source 
10% neutral-buffered formol saline Genta Medical, York, UK 
Menzel-Glaser® Microscope Slides Surgipath Europe Ltd., Peterborough, UK 
Microscope Glass Cover Slips Chance Propper Ltd, Smethwick, Warley, 
UK 
ImmEdge Hydrophobic Barrier Pen Vector Laboratories, Ltd., Peterborough, 
UK 
Vectabond™ Reagent  
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Product Source 
Acetone/methanol 50:50 Sigma-Aldrich Company Ltd., Dorset, UK 
Haematoxylin (Gill’s, Harris’) BDH, VWR International Ltd., Poole, UK  
Eosin Y   
 
2.1.17 Immunohistology antibodies. 
Product  Source 
1º Monoclonal Mouse Anti-human STRO-1 R&D Systems, Abingdon Science Park, 
UK 
1º Monoclonal Mouse Anti-human SSEA-4 Abcam plc. Cambridge UK 
2° Sheep Anti-Mouse IgG (Whole 
Molecule) FITC Conjugate 
Sigma-Aldrich Company Ltd., Dorset, UK 
Normal sheep serum (for the 2° FITC Anti-
Mouse IgG non-specific staining 
elimination) 
 
2.1.18 Antibody diluent 
Component Source 
1% BSA (blocking & stabilizer) Sigma-Aldrich Company Ltd., Dorset, UK 
0.5% Triton X-100 (penetration enhancer) 
0.05% sodium azide (preservative) 
0.1% cold fish skin gelatine (blocking) 
0.01M PBS, pH 7.2-7.4  
 
2.1.19 Cryostat sectioning 
Product Source 
O.C.T.® Compound, embedding medium 
for frozen tissue specimens  
Tissue-Tek, Europe 
Vectabond™ Reagent  Vector Laboratories, Ltd., Peterborough, 
UK 
Menzel-Glaser® Microscope Slides Surgipath Europe Ltd., Peterborough, UK 
Liquid Nitrogen BOC gases, Guildford, UK 
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2.2 Methods. 
For all studies a LEEC incubator operating at 37ºC and 5% CO2 was used to maintain 
constant culture conditions. In order to maintain sterility of the culture environment all 
cell manipulations were undertaken using GLP and aseptic technique in a class II 
microbiological hood. 
2.2.1 BMSC Extraction protocol. 
After ethical approval and consent was received (Brighton and mid sussex REC 
06/Q1907/81) routinely discarded tissue was collected from the operating theatres at the 
Queen Victoria Hospital, East Grinstead. After removal of any attached soft tissue, the 
samples were washed for 15 minutes in Hanks Buffered Salt Solution (HBSS) with 
penicillin, streptomycin and clindamycin added at 5000Uml
-1
/5000µgml
-1
/5000Umg
-1
 
respectively. Subsequently the marrow channel was flushed with DMEM with added 
penicillin, streptomycin and clindamycin, at the same concentrations as in the Hanks 
using a 10ml syringe and a 19G needle, the marrow channel flushings were collected 
aseptically and left to sediment. The bone was opened using surgical nail clippers and the 
marrow channel was scraped clean of bone fragments. Both the flushings and trabecular 
bone fragments were pooled and minced with a scalpel. The cell suspension was diluted 
to a known volume then homogenised by pushing through decreasing graduations of 
needle diameter, starting with 16G and working down to 20G.  
After homogenisation the solution was layered over the top of the same volume of Ficoll-
Paque PLUS (1.073g/ml) in a 50ml falcon tube. The resulting tubes were spun in a 20°C 
cooled centrifuge at 400g for 30-40 minutes with the brake off. The Ficoll-Paque PLUS 
gradient produces a buff coloured layer at the interface known as the buffy coat. This 
layer consists of the mono-nuclear cells including the bone marrow stromal cells 
(BMSCs) and stem cells. The buffy coat was carefully removed from the Ficoll-Paque 
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PLUS and the cells were washed in HBSS and counted in a haemocytometer. BMSCs 
occur at a frequency of between 1 and 50 cells in every 100 thousand mononuclear cells 
(Jaiswal et al. 1997, Kuznetsov et al. 2009). Therefore the mononuclear cells were plated 
into tissue culture plastic flasks with an area of 75cm
2
 at a seeding density of 5x10
3
/cm
2
 
with isolation medium and left to attach for 18 hours. Any BMSCs will attach to the 
tissue culture plastic in this time; the remaining cells are discarded in the first medium 
change. Due to the rarity of BMSC in the initial culture the cells grew in clonal colonies 
and appeared to have a fibroblast like phenotype. At the periphery of the colony a few 
cells had the appearance of osteoblasts, square and with noticeable actin bundles in the 
cytoplasm. After between several days to weeks, the colonies in the flasks achieved 80% 
confluence and were passaged. All subsequent flasks were seeded at 3x10
3
 cells per cm
2
 
and harvested at 80% confluent. 
2.2.2 Cell maintenance 
Medium was completely exchanged every 2-3 days; the old medium was removed and 
replaced with fresh warm medium until the cells grew to the correct confluence for 
passaging. Cells were seeded at 3-5x10
3
 cells per cm
2
 and harvested at 80-90% confluent. 
2.2.3 Cell Passaging. 
Before the cells reach the point at which confluence retards cell growth (for BMSCs this 
is approximately 80-90%) the cells require passaging. The medium was removed from 
the monolayer which was then washed in HBSS to remove remaining serum. After 
washing, the cell layer was covered in a small amount of trypsin solution (for a 75cm
2
 
flask about 1ml of solution is sufficient) and then placed into the 37°C incubator until the 
cells ball up and begin to detach from the tissue culture plastic. This takes about 5 
minutes. The tissue culture flask was tapped gently to aid removal of the cells from the 
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surface. The trypsin was then “inactivated” with the addition of a known volume of 
growth medium; being careful to rinse all the cells from the plastic and into suspension. 
A sample was taken from the suspension and counted on a haemocytometer. Cells were 
then used experimentally or a sample seeded into a new flask at a known cell number. 
Alternatively, where cell numbers were higher samples of cells were frozen and stored 
above liquid N2. 
2.2.4 Cell freezing 
BMSCs are frozen in much the same way as any other human primary cells. The freezing 
medium is prepared by adding 10% DMSO to growth medium, in this case DMEM with 
10% FCS, stored at 4ºC prior to use. The cells are passaged and counted on a 
haemocytometer. After counting the cells are centrifuged to a pellet and re-suspended in 
the cold freezing medium at 3x10
6
 cells per ml and pipetted into a freezing vial. The 
freezing vial is placed into a controlled rate freezing vessel that regulates the drop in 
temperature to 1°C per minute down to -80ºC when put into a -80°C freezer overnight. 
After overnight freezing the vial is removed the following morning and stored above 
liquid nitrogen. Prolonged storage in a -80°C freezer decreases viability. 
2.2.5 Cell thawing 
Cells were removed from liquid nitrogen storage and thawed in the hand, once the 
medium inside the vial was liquid, but still cold, the cell suspension was removed and 
placed into a sterile 30ml universal. 4°C DMEM was added to the freezing vial and any 
remaining cells were washed into the universal. The volume was made up to 10ml and 
the universal centrifuged at 400g for 5 minutes. The supernatant is removed and the cells 
re-suspended in 4°C DMEM with 10% FCS then centrifuged and re-suspended in warm 
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DMEM with 10% FCS. After a viable cell count on a haemocytometer, the cells were 
seeded into cell culture flasks at the desired concentration per cm
2
. 
2.2.6 Quantification of cell number by haemocytometer. 
Cells were removed from the homogeneous suspension using a sterile glass pipette, and 
placed into the chamber of a prepared haemocytometer. Live cells in the four outside 
corner squares of the chamber grid were counted and the number divided by four. 
Because of the known volume of the liquid over the chamber grid (1x10
-4
 ml) this cell 
number (n) represents the number of cells x10
4
 per ml of liquid in the original sample of 
cell suspension. For example, a count of 300 cells divided by 4, is 75 (n=75), so 
75x10
4
/ml in 10 ml. Therefore 7.5x10
5
ml
-1
 and 7.5x10
6
 cells total. 
2.2.7 Growth curves.  
The number of population doublings (PDs) achieved by the cells was determined as 
described by the equation.  
Log(x/y) 
Log2 
Where x is the total number of cells harvested and y the total number of cells seeded. PDs 
are combined at each passage and these cumulative PDs (CPDs) can plotted against the 
time in culture. 
2.2.8 Cambrex BMSC maintenance protocols. 
Cambrex primary human mesenchymal stem cells (BMSCs) were purchased from 
Poietics (POPT-2501). Cambrex cells are positive for CD105, CD166, CD29, and CD44 
and negative for CD14, CD34 and CD45. After maintenance in commercial culture 
medium (POPT-3001) pluripotency was demonstrated by differentiation into 
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chondrocytes, adipocytes and osteoblasts in the media described at 2.1.1.7, 2.1.1.8 and 
2.1.1.9.  
2.2.9 Characterisation of putative BMSCs 
2.2.9.1 Immunohistochemistry 
1x10
4
 cells were transferred to a glass slide using a cytospin centrifuge and fixed in 
formal saline or 50/50 acetone and methanol (2.1.1.16). After fixation the cells were 
rinsed in PBS and placed into a humidified chamber for 30 minutes incubation at 20°C 
with the normal serum from the species used for secondary antibody (2º) preparation 
(Sheep/Goat) at a concentration of 1:30 diluted in PBS (2.1.1.17). The use of this serum 
prevented non-specific binding of the secondary antibody. A wax pen was used to mark 
out the area to which the antibody was to be added. To stain the cells the primary 
antibody (1º) was diluted to the predetermined optimal concentration in antibody diluent 
and added to the sample. After overnight incubation with the primary antibody at 4°C the 
slide was washed once in Tween PBS (1/4000) for one minute followed by three washes 
in PBS for 5 minutes each. The secondary antibody was added at predetermined optimum 
dilution to minimise cross reactivity and determine best use of stock and incubated at 
room temperature for 1 hour. After staining was complete the slide was washed once in 
Tween PBS (1/4000) for one minute and could be mounted in DPX for long term storage. 
Visualisation of the fluorescein tagged antibody was undertaken on a fluorescent 
microscope. Antibodies were diluted in antibody diluent.  
2.2.9.2 Single cell cloning. 
A limiting dilution of BMSC suspension was plated at 0.3 cells per well in a 96 well 
plate, after 4 hours any cells that had not attached or wells containing duplicate cells were 
discarded and the medium was changed. Cells were cultured in growth medium and when 
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the well reached approximately 75-80% confluence they were trypsinised, counted, and 
the total cell suspension was split into 4 and grown in either growth, osteogenic, 
chondrogenic or adipogenic media with medium changes every three days. SSCs to be 
differentiated in chondrogenic medium cultures were plated in a small volume in the 
centre of the tissue culture plastic and allowed to attach in a small area before addition of 
the medium. These cultures were maintained for 21-30 days or until visual analysis 
indicated that cells were differentiated. 
2.2.9.3 Differentiation 
2.2.9.3.1 Attached monolayer culture differentiation. 
Homogeneous single cell clones or enriched heterogeneous cell populations were 
differentiated by passaging into and maintaining the cells in the appropriate 
differentiation medium. Cells were monitored for changes in their morphology, indicating 
a changing phenotype. After 21-30 days in differentiation media the different monolayers 
were stained for either adipocyte, chondrocyte or osteoblast differentiation. 
2.2.9.3.2 Pellet culture for the differentiation of chondrocytes. 
1ml of a cell suspension of 2x10
5
ml
-1
 was pipetted into a 15ml polypropylene falcon tube 
in chondrocyte differentiation media. The tube was centrifuged at 500g for 5 minutes and 
placed in the incubator where it remained for 21-30 days. Medium changes occurred at 3-
4 day intervals. 
2.2.9.3.3 Qualitative assessment of mineralisation by Von Kossa. 
5% sodium thiosulfate and 1% Silver Nitrate aqueous solutions were prepared for the 
Von Kossa stain. 0.1% nuclear fast red counter stain was also prepared with 0.1g nuclear 
fast red and 5g ammonium sulphate per 100ml dh20. The mineralised monolayers were 
immersed in the 1% silver nitrate solution and placed on the window sill in direct 
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sunlight for half an hour or, if dark, next to a 60-100W bulb for about an hour. When a 
darkening of the monolayer was observed the flask was washed in several changes of 
distilled water followed by a 5 minute wash with 5% thiosulfate solution to remove any 
un-reacted silver. After several washings in distilled water the counter stain was applied 
for about 5 minutes or until the staining was notable.  
Using this stain any calcium deposits show as black or brown-black, cell nuclei as red 
and cytoplasm as pink. 
2.2.9.3.4 Qualitative assessment of adipocytes by Oil red O staining. 
Adipocytes were stained using 4% w/v oil red O dissolved in isopropyl alcohol to make a 
stock stain. The working stain solution was made by mixing the stock stain 40/60 with 
dH20, mixing for 2 minutes and leaving to settle for 10 minutes before filtering the stain 
through a Whatman's number 1 filter and using immediately. Cell monolayers were very 
gently fixed in formal saline for 10 minutes and washed in PBS to remove debris. After 
fixing the monolayer was overlaid with the working stain solution for 5 to 10 minutes on 
the bench. Lipid vacuoles in the cell are visible as red globules. Burst cells were avoided 
as they spread stained lipid over the cells and obscured the field.  
 
2.2.9.3.5 Qualitative assessment of Chondrocyte differentiation.  
2.2.9.3.5.1 Preparation of chondrocyte pellets for cryostat sectioning.  
Chondrocyte pellets were removed from culture and placed in foil boats with an 
appropriate volume of OCT for their size. The foil was then placed into the vapour phase 
immediately above a quantity of liquid nitrogen. After 10-15 minutes the frozen OCT had 
become hard and opaque. The now frozen samples were stored at -80ºC until ready to cut. 
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2.2.9.3.5.2 Cryostat sectioning and staining of pellet cultures 
After warming the frozen tissue block to -20ºC it was mounted and sectioned at a 
thickness of 10-15µm onto Vectabond treated glass slides and left to dry for 24 hours at 
room temperature. After fixation in 10% formal saline the slides were stained. 
2.2.9.3.5.3 Assessment of chondrocyte differentiation by cartilage staining. 
Formal saline fixed samples were stained in Weigert's Iron Hematoxylin for 10 minutes 
followed running tap water for 10 minutes to de-stain. An 0.5% w/v alcian blue solution 
(pH 2.5) was added and left to stain for 25 minutes followed by a dip destain in 1% acetic 
acid. The 3% acetic acid solution (pH2.5), Alcian blue stains both sulphated and 
carboxylated acid mucopolysaccharides and sulphated and carboxylated sialomucins 
(glycoproteins). Using this stain nuclei are black, while cartilage (glycosaminoglycans) is 
blue-green. 
2.2.10. Quantitative analysis of experimental cultures. 
2.2.10.1 Quantification of mineralization, osteoblast differentiation staining. 
Using a modification of the method described by Gregory et al. (2004) an Alizarin Red 
quantitative stain directly determines the amount of mineralization that has occurred in 
cells grown in osteogenic medium. Cell monolayers were fixed in formal saline and 
stored in PBS. Before staining the monolayer was washed twice with excess distilled 
water (dH20) and blotted dry. 200µl of 40mM Alizarin Red S (ARS) at pH 4.1 was 
applied per well of a 96 well plate which was then incubated at room temperature for 20 
minutes. Unincorporated dye was aspirated, the plate washed four times with dH20 for 
five minutes per wash, then finally aspirated and blotted dry. At this point the protocol 
could be continued or if time is short the stained cell monolayers could be frozen at -
20ºC.  
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The dye quantification was achieved by incubating the stained monolayer with 200µl of 
10% acetic acid for 30 minutes at room temperature, or until the monolayer became 
loosely attached to the plate. The plate was scraped and the suspension was transferred to 
an epindorff tube. The tubes were then heated to 85ºC for 10 minutes and transferred to 
ice for five. After heating the slurry was centrifuged at 15,000g for 30 minutes and the 
supernatant was removed to a new tube. 100µl of 10% ammonium hydroxide was added 
to the supernatant to neutralise the acid and the pH was checked to ensure it was between 
pH 4.1 and 4.5. Supernatants were read at 405nm and quantified using a standard curve 
of ARS at the same pH. 
2.2.10.2 Analysis of osteoblast differentiation by alkaline phosphatase (ALP). 
The alkaline phosphatase (ALP) assay is based on the procedure used by H. Declercq et 
al. (2004) and measures the hydrolysis of p-Nitrophenol phosphate (p-NPP) to p-
Nitrophenol (p-NP) catalysed by the ALP enzyme, the quantity of enzyme present is 
directly measureable by the speed of p-NP production. Shrimp ALP of known activity 
was used as a positive control. 
The differentiated osteoblast monolayer was lysed with 0.1% Triton X-100 in dH2O at 
37ºC. After lysis has been observed the lysate was removed in a total volume of 250µl 
using buffer. The buffer comprised of; 10 mM Tris-HCl pH 7.8, 0.5mM MgCl2 and 0.1% 
Triton X-100. The lysate solution was then stored at -80ºC until testing. 
To test ALP activity 50µl of ALP substrate containing p-NPP from Sigma (N7653) was 
added to 50µl of cell lysate solution in an optical 96 well plate and the time noted. The 
plate was incubated at 37ºC until the colour developed. Absorbance measurements were 
checked at 405nm to ensure levels of at least 0.2, at an absorbance of 0.2 slightly visible 
yellowing can be observed with the eye. To stop the reaction 50µl of 0.1M NaOH was 
added. The time was noted and final measurements were taken at 405nm. As a positive 
 43 
 
control shrimp ALP (sigma, P9088) was used at physiological levels of between 7 and 13 
U/L, to produce a 45 minute end point absorbance of approximately 0.2. A standard curve 
was produced from serial dilution of p-NP (sigma, N7660) in 0.1M NaOH. Only linear 
data from the standard curve was used to determine the levels of ALP in the lysates. The 
final ALP activity was measured in µM of p-NP per minute per mg protein, enough 
enzyme to produce the product at 1µM/minute = 1 Unit, after adjustments for total 
protein levels to minimise fluctuations due to cell number or metabolism, ALP is 
expressed as Umg
-1
 protein. 
2.2.10.3 Determination of total protein content by Bradford reagent. 
Protein levels in the lysate from the ALP assay were quantified using Bradford reagent. 
5µl of lysate was added to 195µl of x1 Bradford reagent. The absorbance measurements 
were made at 595nm within 10 minutes. The standard curve was calculated on a diluted 
BSA 2mg/ml stock solution and only linear data was used to determine protein content. 
2.2.10.4 Quantification of collagen by Sirius red staining. 
Cell culture lysate was centrifuged at 500g for 5 minutes and 50µl of supernatant was 
plated into a 96 well plate, covered, and allowed to sit in a humidified 37ºC incubator for 
24 hours. After 24 hours had elapsed, the plate was uncovered and placed into a non-
humidified drying oven at 37ºC for a further 24 hours or until dry. After drying, the plates 
were washed repeatedly in 100µl of dH2O and tapped dry. 0.1% Sirius red stain in 
saturated Picric acid (dissolved in dH2O) was applied at 100µl per well and developed on 
the bench for 1 hour. After 1 hour the residual stain was removed from the wells and 
discarded. The stained collagen was washed with three further 100µl quantities of 0.1M 
HCl. After tapping the plates dry, 100µl of 1M NaOH was added to the wells and left 
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with mild shaking for fifteen minutes. Collagen production was measured on a plate 
reader at 540nm. 
2.2.10.5 Quantification of cell proliferation and death.  
2.2.10.5.1. LDH determination. 
2.2.10.5.1.1 LDH Standard curve  
To plot a standard curve, the optimum cell number and the maximum sensitivity of 
Promega's CytoTox 96 non-radioactive cytotoxicity LDH assay were determined. Cell 
dilutions of 50 to 1x10
6
 cells per 100µl were prepared in PBS and added to wells of a 96 
well plate. The cells were ruptured by two freeze thaw cycles. 50µl of supernatant was 
removed from each well and transferred to a fresh plate. The samples were incubated in 
the dark at room temperature for 30 minutes with an equal volume of substrate mixture 
provided in the CytoTox 96 non-radioactive cytotoxicity assay. After incubation, 50µl of 
the stop solution was added to each well and the change in colour was measured 
spectrophotometrically at 490nm. Only linear data from the standard curve was used to 
determine the cell number in the lysates  
2.2.10.5.1.2 Quantification of cell number by LDH assay 
Further experimental samples tested for LDH activity were lysed using the lysis 
procedure in the ALP assay. The monolayer was lysed with 0.1% Triton X-100 in dH2O 
at 37ºC. After lysis had been observed the cell lysate was removed in a total volume of 
250µl of buffer containing 10 mM Tris-HCl pH 7.8, 0.5mM MgCl2 and 0.1% Triton X-
100. 50µl of these lysates were each added to a well of a 96 well plate and incubated in 
the dark at room temperature for 30 minutes with an equal volume of substrate mixture 
provided in the CytoTox 96 non-radioactive cytotoxicity assay. After incubation 50µl of 
the stop solution was added to each well and the change in colour was measured 
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spectrophotometrically at 490nm. Comparisons were made with the control samples and 
cell numbers were quantified using the previously defined standard curve. 
2.2.10.5.1.3 Relative quantification of cell death by LDH release. 
LDH is a highly conserved mitochondrial enzyme involved in the Krebs cycle. LDH can 
be used as a measurement of cell number but is also released from a cell when it dies. 
Therefore measurement of supernatant LDH can quantify cell death relative to monolayer 
LDH and produce a value that is relative to both cell death and proliferation. This 
quantification of the culture is free as the supernatant would otherwise be discarded and 
allows inference of the proliferation and cell death that occurs between measurements of 
the cell number in the monolayer.  
LDH was used in this study as a relative measurement of cell death occurring between 
harvesting points. The LDH available in the monolayer combined with the LDH activity 
of the supernatant, harvested at the same time, was used as the measure of total LDH. The 
supernatant LDH was expressed as a percentage of total LDH. Therefore cultures in 
which cells have died heavily and have small numbers of cells remaining in the 
monolayer relative to large amounts of LDH activity in the supernatant will have a value 
approaching 100%. The method used was as described here. 
Media supernatants were harvested from cultures prior to lysis of monolayers. 
Supernatant LDH was measured by addition of 50µl to a well of a 96 well plate and 
incubation in the dark at room temperature for 30 minutes with an equal volume of 
substrate mixture provided in the CytoTox 96 non-radioactive cytotoxicity assay. After 
incubation 50µl of stop solution was added to each well and the change in colour was 
measured spectrophotometrically at 490nm. 
The total LDH output of the culture was combined from measurements of the lysis LDH 
and the supernatant LDH, the supernatant LDH was expressed relative to total LDH. 
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2.2.10.5.2 Measurement of proliferation by Brd-U incorporation 
Brd-U incorporation was undertaken using a BrdU Cell Proliferation Assay Kit (QIA58-
1000TEST) from calbiochem. The manufacturer’s instructions were followed. 10,000x 
BrdU stock was diluted 1:2000 into tissue culture media. 20µl of this stock was added to 
the monolayer of BMSCs attached to each well of a 96 well plate. The plate was returned 
to the incubator with the BrdU for 18 hours to label all the actively dividing cells. This 
was followed by several washes in PBS and fixing in formal saline for 30 minutes at 
room temperature. The quantification of BrdU incorporation was performed using an 
ELISA as provided in the Calbiochem kit. The primary anti-BrdU antibody was diluted 
1x1000 in antibody diluent and 100µl was added directly to the washed monolayers for 1 
hour. After repeated washings, 100µl of the peroxidase goat anti-mouse IgG HRP 
conjugate was added to the cells for 30 minutes. The plate was washed in wash buffer x3 
and then once in dH2O before 100µl of the substrate solution was added to the plate and 
incubated for 15 minutes in the dark. After incubation, 100µl of the stop solution was 
added and the plate dual read in a spectrophotometer at 450-540nm within 30 minutes of 
addition of stop solution.  
2.2.10.5.3 Quantification of proliferation by the uptake of radio labelled thymine. 
2x10
4
 cells were pulse labelled with 2mCi of [
3
H]-thymine for 18 hours in medium, after 
this period the remaining radio label was removed and the cells harvested on membranes. 
Cells were lysed using a lysis buffer supplied by Perkin and Elmer and the cell lysate was 
passed through a membrane mat. The mat was dried and heat sealed into a plastic 
package with just enough scintillate to cover the mat. Reading of the incorporated 
thymine was undertaken in a microbeta trilux from Perkin and Elmer. 
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2.2.10.5.4 Live and dead staining with Hoechst Propidium Iodide. 
Hoechst Propidium Iodide (HPI) stain was prepared by adding 5mg/ml Hoechst and 
1mg/ml Propidium Iodide to growth medium. To use the stain the medium was removed 
from the cultured cells and replaced with the staining solution, staining was visualised 
using an inverted fluorescent microscope with UV and Texas red blocks for respective 
visualisation of Hoechst and Propidium Iodide. Live cells stain blue (H), dead cells 
stained red (PI) and late apoptotic cells stained both blue and red. 6-8 representative 
micrographs of the stained cells were taken combined with phase contrast photographs of 
the same.  
2.2.10.6 Quantification of levels of intracellular Adenine triphosphate  
ATP was quantified as a measurement of cell activity by using the PerkinElmer ATPlite 
kit, the protocol followed was as per the manufactures recommendations. Cells were 
grown in PerkinElmer CulturPlate's, opaque tissue culture treated plastic plates. To each 
100µl volume of medium 50µl of lysis solution was added and the plate shaken at 
700rpm for 5 minutes. After shaking, 50µl of substrate solution was added to the cell 
lysate and shaken for a further 5 minutes at 700 rpm. The plate was then dark adapted for 
10 minutes and the luminescence was measured in a microbeta trilux from Perkin and 
Elmer.  
2.2.10.7. Molecular biological techniques for the determination of mRNA quantities.  
2.2.10.7.1. Total RNA extraction from monolayers. 
RNA was extracted using the Rneasy mini kit from Qiagen, following the manufacturers 
recommended methods. First the monolayer of cells was washed several times in excess 
hanks, followed by the addition of a lysis buffer (buffer RLT) at 350µl per 5x10
6
 cells. 
After lysis was observed, the lysate was homogenised by repeated pipetting through a 
200µl eppendorff tip. An equal volume of RNase/DNase free 70% ethanol was added and 
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the solution was homogenised. 700µl of the homogenised lysate was added to each silica 
spin column provided in the kit and centrifuged (8,000G for 15-30 seconds). Each 
column was washed with 700µl wash buffer (RW1) and centrifuged. This was followed 
by two washes in 500µl of buffer 2 (RPE). The column was centrifuged for 5 minutes at 
full speed to remove all remaining buffers and to dry the column. Elution from the 
column into a clean tube was achieved with 30-50µl of RNase free dH2O and 
centrifugation at 8,000G for 2 minutes. For extremely high levels of RNA (greater than 
30µg) a repeat elution using the same volume of RNase free dH2O was used. 
2.2.10.7.2. Quantification of total RNA. 
1µl of the extracted total RNA was quantified using a RNA Quantit kit from Invitrogen 
and a Qubit fluorimeter following the manufacturer’s protocols. 1µl of isolated RNA was 
added to 199µl of RNA quantification buffer containing the fluorescent marker Quant-iT 
RNA Br at room temperature and analysed against the standards provided in the kit to 
find the concentration in ng/ml. 
2.2.10.7.3. Production of cDNA from total RNA. 
1ng of RNA was used in a reverse trascriptase (RT) PCR reaction to create cDNA. The 
following was added per reaction tube;  
Component  Quantity 
1ng of total RNA x µl 
50ng of random hexamers 1µl 
10mM dNTP mixture 1µl 
dH2O to a total volume of 10µl x µl 
This mixture was homogenised and incubated at 65ºC for 5 minutes and then placed 
directly on ice for at least 1 minute. 9µl of master mix was added to the primer template 
mix and incubated for 2 minutes. Per run the master mix consisted of; 
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Component  Quantity 
10x Buffer 2µl 
25mM MgCl2 4µl 
0.1M DTT 2 µl 
ribonuclease inhibitor 1µl 
To the 19µl volume per reaction a 1µl volume or 50U of reverse transcriptase 
SuperScript II was added and incubated for 10 minutes at 25ºC, followed by 42ºC for 50 
minutes and a termination step of 70ºC for 15 minutes and placed on ice immediately. 
cDNA is much more stable than RNA and was either frozen at -80ºC for long term 
storage or used immediately. Prior to qPCR the RNA strand was removed from the 
RNA:DNA hybrid by incubation with 1µl RNase H at 37ºC for 20 minutes before 
continuing to the qPCR protocol. 
2.2.10.7.4. qPCR primer design. 
The gene of interest was found on the NCBI gene website. Searching for cbfa-1 results in 
the display of the Homo sapiens gene runt-related transcription factor 2 (RUNX2). The 
geneID, 860, was taken and this information was used in an online primer design 
program (www.RTPrimerDB.org). Such programs are much quicker than designing 
primers by hand, eliminate human error, provide comparisons with multiple miss-priming 
databases and contain interon spanning primers which eliminate genomic products. The 
primers were compared with the available literature for efficacy. RUNX2(CBFA1) 
primers were F- CACCTCTGACTTCTGCCTC, R- GACTGGCGGGGTGTAAGTAA 
producing a 178bp product. While GAPDH was F-GAGTCCACTGGCGTCTTCA and 
R-GGGGTGCTAAGCAGTTGGT and a product of 190bp 
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2.2.10.7.5 Experimental design for qPCR 
qPCR is a test for the relative abundance of mRNA species, it is a significant 
improvement over standard PCR techniques because it is quantitative in real time. SYBR 
green detection of double stranded DNA product from qPCR is the most commonly used 
as well as the cheapest and easiest method of detection. Because SYBR green is a non-
specific detection technique it is particularly important that the design of primers does not 
produce product from gDNA. Although, since cDNA was made, this technique is only 
semi-quantitative accurate measurements of gene expression are possible for most 
applications. For low copy number mRNA transcripts the most efficient method of 
quantification is to compare the number of transcripts of the gene of interest with the 
number of copies of a housekeeping gene that has a more static level of expression. 
GADPH is a commonly used housekeeping gene that was chosen as the relative standard 
in these experiments. For the qPCR reaction a master mix was made using the volume of 
25µl per well and making enough to provide for an extra well. The master mix contained; 
Component Volume (µl) 
x10 buffer 2.5 
10mM dNTP’s 1.25 x 4 (5) 
X1000 SYBR 0.25 
Primers 1 x 4 (4) 
dH2O x 
Taq 1 
cDNA 1ng x 
Total 25 
 
The mix was divided into the wells of a qPCR plate (25µl/well) and run through the RT-
PCR machine programmed as follows; 
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Repetitions Temperature (°C) Time (seconds) 
1 95  180 
40 95 10 
60 30 
Followed by a melt curve analysis of double stranded products from 50ºC to 95ºC after 
40 cycles had elapsed. 
2.2.10.7.6. Analysis of qPCR results. 
The melt curve for each PCR was examined, the melt curve should be a steady declining 
line from the coldest, and therefore most double stranded products, to 95ºC, where all the 
products are melted. Towards the end of the melt, at approximately 80ºC depending on 
the length of product, the most abundant product in the PCR should melt all at once 
producing a step in the graph. When this melt graph was plotted in the accepted inverse 
way there appeared to be a large spike at this temperature. Double peaks or no peak at all 
indicated a problem with the reaction and the result was discarded. Any peaks in the no 
cDNA control and the result was discarded. Next the threshold was set; the threshold was 
the major factor that impacted on the Ct, i.e. the point at which the exponential PCR 
reaction crossed the threshold. The threshold was set by the controls at the linear part of 
the data by adjusting the line, using the data plotted on a log scale. This allowed easy 
evaluation of the time at which the fluorescence measured above background. The same 
threshold was used for all the samples in the experiment.  
2.2.10.7.7. The ΔΔCt analysis method. 
This method utilises the difference in levels of reference mRNA and experimental mRNA 
to determine the relative change in expression of the experimental mRNA. The reference 
mRNA acts as a loading control to eliminate any variation within each sample. In the 
experimental design we compared treated cells with untreated cells and without a stable 
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point of reference in the qPCR any differences could have been due to template loading 
in the reaction mixture. Therefore for one sample the difference between the reference 
and the experimental is the ΔCt. The ΔΔCt is the difference between the experimental 
samples after the adjustment for the reference genes has been taken into account. 
2.2.11. Extraction and characterisation of isoflavones from soy. 
2.2.11.1 The extraction of isoflavones from soy flour. 
500g of Soy flour was de-fatted with 500ml of hexane overnight. Soy isoflavones were 
extracted from defatted soy flour by shaking at 30°C in an ethanol/water, 20/80 solvent 
mix overnight. The supernatant was removed, centrifuged and then layered over a column 
packed with 3 cm glass wool and 1 cm silica gel. After vacuum rotary evaporation of the 
ethanol at 30°C the remaining extract was freeze dried to produce a stable isoflavone 
concentrate. The efficacy of the extraction process was determined by HPLC analysis 
using internal forononetin standards and bookend standard runs as described at 2.2.11.2.  
2.2.11.2 The determination of the soy extract composition by HPLC. 
The freeze dried crude soy extract from 2.2.11.1 was dissolved in 80/20 DMSO/dH2O 
and its composition determined by HPLC in the following manner. 
The HPLC setup consisted of a 25ºC, 21.2 minute program running at 1ml/minute and 
consisting of a solvent gradient composed of A and B (A/B) where A is Acetonitrile and 
0.1% glacial acetic acid, B is ultra pure water and 0.1% glacial acetic acid. At the start of 
the run 10µl of sample was injected into solvents in the following ratio (A/B) 10/90 for 0 
minutes, followed by 15/85 for 0.1 minutes, 20/80 for 4 minutes, 40/60 for 9 minutes and 
60/40 for 4.1 minutes and finally 100/0 for 4 minutes. After the sample has run off the 
column at 21.2 minutes a 10 minute period was allocated for the column to return to 
10/90 solvent ratios in preparation for the next sample run. Samples were run through a 
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262nm UV spectrophotometer and the area under the peak integrated and used to 
determine relative composition with the standards. Bookend standards included genistein, 
daidzein and formononetin, an internal formononetin spike was included with every 
unknown.  
Using this reverse-phase HPLC setup it is expected that the first to elute will be the 
glucosides of isoflavones in the order, puerarin, daidzein, glycitin, and genistein. 
Followed by the malonylglucosides, acetlyglucosides and the aglycones in the same 
running order. Metylated aglycones, of daidzein (formononetin) and genistein (biochanin 
A), are retained for longest. 
2.2.12. Production of Biomaterials. 
2.2.12.1 Production of calcium phosphate cement containing soy extract. 
The components for the cement are described in 2.2.12.3. The 10% gelatine solution was 
warmed until molten in a 50ºC water bath. 3.636g of the CaP cement was weighed, which 
corresponds to 2ml of the liquid phase. 1ml of the soy solution and 1ml of the gelatine 
solution were mixed and frothed at 50ºC for 1 minute. The cement and the liquid phase 
were then combined and mixed gently. The cement was placed into a 5ml syringe and 
then injected into a mould, for the purposes of the cell studies this was the well of a 96 
well plate. After 2 hours incubation in the dark at 37ºC the cement was immersed in 
saline solution at 37ºC for 12 days. The saline was changed every 2 days until the 
cements were fully set at day 12. 
2.2.12.2 Production of calcium phosphate cement containing gelatine. 
The components for the cement are described in 2.2.12.3. The 20% gelatine solution was 
warmed until molten in a 50ºC water bath. 3.636g of the CaP cement was weighed, which 
corresponds to 2ml of the liquid phase. 2ml of the gelatine solution was mixed and 
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frothed at 50ºC for 1 minute. The cement and the liquid phase were then combined and 
mixed gently. The cement was placed into a 5ml syringe and then injected into a mould, 
for the purposes of the cell studies this was the well of a 96 well plate. After 2 hours 
incubation in the dark at 37ºC the cement was immersed in saline solution at 37ºC for 12 
days. The saline was changed every 2 days until the cements were fully set at day 12. 
2.2.12.3 Components required for production of the gelatine and soy cements. 
Cement components 
10% gelatine in dH2O 250mM Na2HPO4 (accelerant) 
20% gelatine. in dH2O Calcium phosphate cement; 98% α-
TCP(5.4µm) and 2% hydroxyapatite w/w.  40% soy extract in accelerant 
 
2.2.13 Experimental method for the application of isoflavones to cell cultures. 
2.2.13.1 Initial seeding densities and media. 
After passaging the experimental cells were seeded at confluent density in growth 
medium as per the table at 2.2.13.4 and left overnight at 37ºC and 5% CO2 to form 
confluent monolayers in 96 well tissue culture grade plates. After attachment the medium 
was removed and replaced with experimental medium containing genistein or soy extract 
and then incubated in a humidified incubator at 37ºC and 5% CO2. The experimental 
medium consisted of low glucose (1g/l) D-MEM (invitrogen 21885-108) for BMSCs and 
α-MEM (invitrogen A10490-01) for MG63s, with the addition of 10% selected heat 
inactivated FCS and 50µg/ml ascorbate-2-phosphate, as in the tables at 2.1.1.10. To this 
medium was added either 10mM β-glycerophosphate (β-gly) (sigma G6501), or 1x10-8M 
dexamethasone (dex) (sigma D4902), or osteogenic medium containing both β-gly and 
dex (osteo).  
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2.2.13.2 Experimental setup for analysis of the effect of pure genistein. 
For the addition of pure genistein to the cells a stock solution of 300mM Genistein 
(Sigma G6776) was prepared in DMSO (Sigma D4540), this stock solution was diluted to 
the required concentrations in the experimental media. After dilutions the DMSO vehicle 
was at most 1µl/10ml of media, this concentration was added to media applied to the 
controls. Medium was removed and replaced every 3 days. After the required incubation 
time the medium was removed from the monolayer and stored at -80ºC. The monolayers 
were washed in PBS and the remaining cells assayed as described in the results section 
using the methods described at 2.2.10.  
2.2.13.3 Experimental setup for the culture of soy extract with CBMSCs. 
For the application of crude soy isoflavone extract produced as per the instructions at 
2.2.11.1 the amount of genistein in the extract was characterised by HPLC as per the 
instructions at 2.2.11.2 and the quantity of soy extract that contains 300mM of genistein 
was determined and dissolved in DMSO, this stock solution was prepared freshly each 
time, diluted as required in experimental medium and used immediately. DMSO vehicle 
was applied to the controls at a concentration of 1µl/10ml. In a duplicate experiment 
fulvestrant was added to the media at 100nM in addition to soy extract or vehicle. 
Medium was removed and replaced every 3 days. The quantity of genistein in the extract 
is described by the table at 2.2.13.5. After the required incubation time the medium was 
removed from the monolayer and stored at -80ºC. The monolayers were washed in PBS 
and the remaining cells assayed as described in the text using the methods at 2.2.10. 
2.2.13.4 Experimental seeding densities for production of a confluent monolayer. 
Cell type Cell number (cm
-2
) 
MG63 passage 120-123 1x10
5
 
Passage three BMSCs, purchased from Cambrex™ 2x104 
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2.2.13.5 Quantity of Genistein in the soy extract. 
Genistein concentration (µM)  Soy extract (mg/ml) 
0.94 8.44 
1.88 16.89 
3.75 33.78 
7.5 67.57 
15 135.14 
30 270.27 
300 540.54 
 
2.2.14 Experimental method for the application of BMSCs to cement biomaterials. 
4.5x10
4
 CBMSCs were seeded in growth medium to the surface of the cements and left 
overnight at 37ºC and 5% CO2 to attach; methods for cement production are at 2.2.12. 
After attachment the medium was exchanged with fresh growth medium and then 
incubated at 37ºC and 5% CO2. Medium was exchanged every 2 days for 24 days, wells 
were harvested on days 0, 12 and 24. Analysis of results was achieved by use of the 
methods described at 2.2.10.  
2.2.15. Preparation and visualisation of biomaterials by SEM.  
Medium was removed from the cements and they were washed twice in PBS prior to 
fixing in 1% glutaraldehyde in PBS for 3 hours followed by 5 washes in dH2O. Cements 
were subsequently freeze dried under vacuum overnight at -80°C prior to sputter coating 
in a thin layer of palladium and visualisation in a JEOL JSM-6310 scanning electron 
microscope.  
CHAPTER 3. 
THE DEVELOPMENT AND CHARACTERISATION OF A 
CONFLUENT DIFFERENTIATING IN VITRO MODEL FOR 
THE ANALYSIS OF OSTEOGENESIS DURING CULTURE 
WITH GENISTEIN. 
3.1 Introduction 
Immortal cell lines are often used for large scale screening and testing of compounds 
(Godl et al 2003). They are an effective compromise between gauging the accurate 
effects of compounds, achieving adequate cell numbers and reproducing the same test 
conditions over long periods of time (Rubinstein et al 1990). Cell lines originating in 
human osteosarcomas have been tested with many oestrogenic compounds (Dubin et al. 
2001, Kian et al. 2004, Stossi et al. 2004).  
There is discussion in the literature regarding osteosarcoma cell lines and the level of ER 
expression. U2OS cell lines are often used to study the effect of activating oestrogen 
receptors because they are not constitutively expressed, allowing levels of expression to 
be controlled. (Kallio et al 2008, Djiogue et al 2010). SAOS2 cells have been reported to 
have an abnormal receptor expression profile with regards to sex-steroid response 
elements, whereas MG63s have been shown to behave in a more native manner and are 
the cells of choice for this study (Chen et al. 2006, Saraiva et al. 2008).  
The MG63 cell line expression of oestrogen receptors is normally weighted in a ratio of 
ERβ to ERα for adult trabecular bone. Activation of the ERα ligand in MG63s increases 
57 
 
proliferation (Morris et al 2006, Kameda et al 2010). Genistein, a SERM, binds ERα with 
low efficiency, and signalling by the differentiating ERβ ligand predominates. Because 
ERs are expressed in a tissue specific manner and the effect of genistein is dependent on 
cell line derivation and ER expression binding of genistein to ERs effects the expression 
of genes containing ERE regions in their promoters. For example, studies undertaken in 
human MCF-7 breast carcinoma and G-292 osteosarcoma cell lines cells show that 
genistein and daidzein are greater than 100 fold more effective at stimulating ERβ than 
ERα. MCF-7 cells have a 208 fold excess of ERα over β where as G-292 cells have a 1.3 
fold excess of β over α. Clearly there is a large variation in immortalised cell lines and 
their expression and possible responses to SERMs (Chrzan 2007). 
MG63s exhibit a relatively normal early osteoblast expression phenotype, they are 
capable of differentiation and although they proliferate more quickly than primary human 
osteoblasts, and have a less inducible ALP expression, they are an ideal cell line model to 
study the effects of SERMs such as genistein (Nakamura et al 1988, Farley et al 1989, 
Fournier and Price 1991, Dang 1994, Clover 1994). 
MG63s have been used to study the effects of genistein previously. In 2006 Morris et al 
reported the effects at 48 hours finding an increase in collagen and mineralisation, 
markers of osteogenesis (Morris et al. 2006). In this chapter this study will be expanded 
to include a confluent MG63 model and analysis of 4 and 6 days genistein treatment. 
Chen et al (2003) used a mouse cell line, MC3T3-E1, to demonstrate the up-regulation of 
ALP to a maximum expression at 6 days with and without genistein. Consequently we 
used the incubation time of 6 days to monitor the effects of genistein on differentiation 
markers in human MG63s.  
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In the literature, genistein is often used as an osteogenic supplement to osteogenic 
medium. To clarify the contribution of genistein to the differentiation that occurs in 
osteogenic medium and to increase understanding of genistein induced differentiation 
several different media formulations were tested; growth medium (GM) alone, GM 
containing β-glycerophosphate (Beta), GM containing dexamethasone (dex) and 
osteogenic medium containing both dexamethasone and β-glycerophosphate (Osteo). 
From this study such information should allow a comparison of the use of genistein as an 
osteogenic agent alone and in combination. 
3.2 Hypothesis  
Addition of genistein to a confluent cell line model accelerates osteogenic differentiation 
when compared with confluent cells in growth medium, osteogenic medium and 
osteogenic medium components.  
3.2.1 Aims. 
To determine an optimum concentration range of genistein in both growth medium and 
osteogenic medium for the efficacious differentiation of osteoblasts in a confluent 
differentiating immortal cell model, identifying relevant methods for the continued study 
of in vitro effects in more relevant cell types.  
3.3 Methods. 
3.3.1 Experimental procedure. 
MG63s at passage 120-123 were seeded at 1x105 cells cm-2 in growth medium (alpha-
MEM, 10% heat inactivated FCS and 50µg/ml ascorbate 2-polyphosphate) and incubated 
overnight to form confluent monolayers in 96 well plates. After attachment the medium 
was removed and replaced with experimental media formulations comprising growth 
medium (GM), GM + β-glycerophosphate (beta), GM+ dexamethasone (dex) or 
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osteogenic medium (osteo) as described at 2.1.10. Genistein was added at concentrations 
0-300 µM to each of these media types and the culture continued for 2, 4, and 6 days with 
media changes every three days where appropriate. Full methodology is at 2.2.13 
After the required incubation time the used media were removed and stored at -80ºC for 
later analysis. The monolayers were washed in PBS and the remaining cells assayed as 
described at 2.2.10. 
3.3.2 Statistics 
Statistical analysis was performed in Minitab 15. The analysis of data was achieved using 
a one-way analysis of variance (ANOVA) with multiple comparison tests; Tukey’s 
family error rate was used to determine the significance between groups without a 
defined control. i.e. Comparisons of a single concentration of genistein across time 
points. Dunnett’s family error rate was used to compare groups with a defined control i.e. 
genistein compared with vehicle. The confidence level was set at 95 and P values of 
<0.05 were considered significant.   
3.4 Results 
3.4.1 The effect of genistein on cell number as derived by analysis of lactate 
dehydrogenase (LDH) content.  
A standard curve was prepared by lysis of known MG63 cell numbers and quantification 
of the LDH they contained. Experimental monolayers were lysed and the LDH activity 
was converted into cell numbers, the cell number was plotted against the concentration of 
genistein for each media. Full methods can be found at 2.2.10.5.1. 
 
Microscopic evaluation of the monolayers was undertaken prior to LDH assessment, 
LDH derived cell numbers were commensurate with observations.  
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3.4.1.1 The LDH derived cell number found after MG63s were cultured in 
formulations of growth media containing genistein for 2, 4 and 6 days. 
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Fig 3.1 Total MG63 cell number available in the monolayer after culture in growth media 
and genistein, derived from LDH activity and assessed on Days 2, 4 and 6. 3x104 cells 
were seeded per well on Day 0. N=2, error bars are SD, * indicates statistically 
significant compared with control (p<0.05).  
 
 
The vehicle control MG63s, cultured in growth medium (Fig 3.1), did not proliferate over 
the 6 day experiment.  
The addition of genistein to growth medium had no significant effect until Day 6 when 
the cell number increased significantly from earlier time points. This significant increase 
in cell number on Day 6 was observed in genistein concentrations from 1.88µM to 30µM 
but no increase was seen at the highest genistein concentration, 300µM. 
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3.4.1.2 The LDH derived cell number after MG63s were cultured in formulations of 
beta-glycerophosphate media containing genistein for 2, 4 and 6 days. 
 
 
0.0E+00
2.0E+04
4.0E+04
6.0E+04
8.0E+04
1.0E+05
1.2E+05
0 1.88 3.75 7.5 15 30 300
Ce
ll 
N
um
be
r
Genistein (µM)
Beta Day 0
Beta Day 2
Beta Day 4
Beta Day 6
* 
* 
* 
* * * 
 
Fig 3.2 Total MG63 cell number available in the monolayer after culture in beta media 
and genistein, derived from LDH activity and assessed on Days 2, 4 and 6. 3x104 cells 
were seeded per well on Day 0. N=2, error bars are SD, * indicates statistically 
significant compared with control (p<0.05).  
 
 
Control MG63s cultured in beta medium (Fig 3.2) with vehicle did not significantly 
change from seeded cell number at any time over the experiment. 
In genistein supplemented media MG63s did not significantly differ from the control or 
seeded cell number until Day 6. At Day 6 all treatment cultures were significant when 
compared with the control.  
  
62 
 
3.4.1.3 The LDH derived cell number after MG63s were cultured in formulations of 
dexamethasone media containing genistein for 2, 4 and 6 days. 
 
0.0E+00
2.0E+04
4.0E+04
6.0E+04
8.0E+04
1.0E+05
1.2E+05
0 1.88 3.75 7.5 15 30 300
Ce
ll 
nu
m
be
r
Genistein concentration (µM)
Dex Day 0
Dex Day 2
Dex Day 4
Dex Day 6
* 
 
Fig 3.3 Total MG63 cell number available in the monolayer after culture in dex media 
and genistein, derived from LDH activity and assessed on Days 2, 4 and 6. 3x104 cells 
were seeded per well on Day 0. N=2, error bars are SD, * indicates statistically 
significant compared with control (p<0.05).  
 
 
In dex medium control cultures (Fig 3.3) the cell number remained statistically the same 
until Day 6 when cell number was significantly larger than at the previous time points. 
In genistein treated cultures a trend of increasing cell number was observable at Day 4, an 
earlier time point than when genistein was supplemented to growth media (fig 3.1) and 
beta-glycerophosphate media (Fig 3.2). At Day 6 cell number was significantly higher 
than previous time points for all treatments; 0-300µM. In genistein treatments cell 
numbers were equivalent to growth and beta media (P>0.05).  
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3.4.1.4 The LDH derived cell number after MG63s were cultured in formulations of 
osteogenic media containing genistein for 2, 4 and 6 days. 
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Fig 3.4 Total MG63 cell number available in the monolayer after culture in osteogenic 
media and genistein, derived from LDH activity and assessed on Days 2, 4 and 6. 3x104 
cells were seeded per well on Day 0. N=2, error bars are SD, statistical significance is 
represented by * (p<0.05).  
 
 
 
 
Control cultures in osteogenic media (fig 3.4) do not significantly increase in cell number 
until Day 6 of the experiment.  
In genistein treated cultures a trend of increasing cell number was observed at Day 4, 
earlier than GM (fig 3.1) and beta media (fig 3.2) and in keeping with the dex media (fig 
3.3). At Day 6 a significant increase in cell number, compared with controls, was 
apparent (P<0.05). 
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3.4.1.5 Summary of cell number found after treatment of MG63s with genistein. 
After treatment of cells with genistein added to media without dex, i.e. GM and beta 
media, (fig 3.1 - 3.2) cell number increased compared with controls when measured at 
Day 6. In media with added dex, i.e. dex and osteogenic media, (fig 3.3 – 3.4) cell 
number was observed to increase at Day 4 and Day 6. There was little difference between 
concentrations of genistein, however in growth media cells treated with 300µM did not 
behave the same as in the other media types; they proliferated significantly more than the 
controls. 
 
3.4.2 Relative cell death measured by release of supernatant LDH. 
LDH is a highly conserved mitochondrial enzyme involved in the Krebs cycle. LDH 
activity can be used as a measurement of cell number (3.2.1) but is also released from the 
cell when it dies. Therefore measurement of supernatant LDH can quantify cell death 
relative to monolayer LDH and produce a value that is relative to both cell death and 
proliferation. This quantification of the culture is free, as the supernatant would otherwise 
be discarded, and allows an inference of the proliferation and cell death that occurs 
between measurements of the cell number in the monolayer.  
LDH was used in this study as a relative measurement of cell death occurring between 
harvesting points. The LDH available in the monolayer combined with the LDH activity 
of the supernatant, harvested at the same time, was used as the measure of total LDH. The 
supernatant LDH was expressed as a percentage of total LDH and presented against 
genistein concentration. Therefore treatment wells in which cells have died heavily and 
have small numbers of cells remaining in the monolayer relative to large amounts of 
LDH activity in the supernatant will have a value approaching 100%. The methods used 
can be found in full at 2.2.13  
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3.4.2.1 Relative LDH release after culture in growth media with genistein.  
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Fig 3.5 Relative LDH released from MG63 cultures after treatment in growth media 
supplemented with genistein for 2, 4 and 6 days. The data is expressed as the percentage 
of LDH in the supernatant compared with the total LDH found in both the monolayer and 
the supernatant. N=3, error bars indicate SD, bars marked with * are significant (P<0.05) 
compared with the control. 
 
Growth medium vehicle controls (Fig 3.5) increased the LDH found in the supernatant 
across all time points. Since the cell number remained the same throughout (fig 3.1) this 
indicates proliferation and cell death occurred equally at all time points but that cell death 
increased over the experimental time period. 
In the genistein treatments at Days 2 and 4 there was a dose response to increasing 
genistein supplementation with a larger percentage of cell death at low levels of 
genistein, 1.88 – 15µM are significant at both time points. At Day 6 the percentage of 
LDH in the supernatant was reduced, corresponding with a large increase in the cell 
number (fig 3.1). 300µM genistein has similar LDH release to the controls at Day 2 while 
at Days 4 and 6 LDH release was lower than controls, and the opposite effect observed at 
lower concentrations of genistein.   
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3.4.2.2 Relative LDH release after culture in beta media with genistein. 
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Fig 3.6 Relative LDH released from MG63 cultures after treatment in beta media 
supplemented with genistein for 2, 4 and 6 days. The data is expressed as the percentage 
of LDH in the supernatant compared with the total LDH found in both the monolayer and 
the supernatant. N=3, error bars indicate SD, bars marked with * are significant (P<0.05) 
compared with the control. 
 
In beta medium controls (Fig 3.6) there was an increase in the amount of cell death over 
time. At Day 6 the percentage of total LDH found in the supernatant was nearly 60%. 
There was no change in the cell number over the experiment (Fig 3.2) indicating there 
was faster proliferation than in growth medium. 
In genistein treated cells from concentrations 1.88 – 30µM at Day 2 relative supernatant 
LDH was 50% of the total, higher than the control.  
Day 4 LDH was the same as controls in all the concentrations. At Day 6 there was a 
reduction in relative LDH release with commensurate increase in cell number (fig 3.2) 
found at all treatments 1.88µM to 30µM are significantly lower than the control.  
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3.4.2.3 Relative LDH release after culture in dex media with genistein. 
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Fig 3.7 Relative LDH released from MG63 cultures after treatment in dex media 
supplemented with genistein for 2, 4 and 6 days. The data is expressed as the percentage 
of LDH in the supernatant compared with the total LDH found in both the monolayer and 
the supernatant. N=3, error bars indicate SD, bars marked with * are significant (P<0.05) 
compared with the control. 
 
 
In Dex medium controls (Fig 3.7) LDH release was lower than the growth (fig 3.5) and 
beta media (fig 3.6), cell number increased at Day 6 (Fig 3.3) reducing the relative LDH. 
After treatment with genistein in dex media at Day 2 LDH release was similar from 
1.88µM to 15µM and reduced with increasing concentration. At Day 4 the same dose 
response was repeated, as cell number increased (fig 3.3) relative LDH release decreased. 
By Day 6 cell number increased significantly (fig 3.4) and relative LDH release reduced 
commensurately, the dose response persists at Day 6.  
  
68 
 
3.4.2.4 Relative LDH release after culture in Osteo media with genistein. 
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Fig 3.8 Relative LDH released from MG63 cultures after treatment in osteogenic media 
supplemented with genistein for 2, 4 and 6 days. The data is expressed as the percentage 
of LDH in the supernatant compared with the total LDH found in both the monolayer and 
the supernatant. N=3, error bars indicate SD, bars marked with * are significant (P<0.05) 
compared with the control. 
 
In osteogenic media (Fig 3.8) control cultures were very similar to dex media, cell 
number increased at Day 6, reducing the relative LDH release. 
After 2 Days treatment with genistein in osteogenic media relative LDH release was 
higher than controls for all concentrations, lowest at 300µM. By Day 4 there was a larger 
cell number in the monolayers (fig 3.4) and relative LDH release drops commensurately. 
At Day 6 cell number is much larger and relative LDH release is low, almost inverse of 
the Day 2 effect, 1.88 – 30µM is lower than the control and 300µM is not significantly 
different.  
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3.4.2.5 Summary of the relative LDH release after culture with genistein. 
Cell death occurs in all the supplemented media types and in all the controls. In the media 
without Dex added, i.e. GM and beta (3.4.2.1 and 3.4.2.2), the relative release of LDH 
was similar until proliferation increased and consequently relative LDH was suppressed. 
In cultures where no increase in cell number occured; i.e. the growth medium control, 
growth medium with 300µM and the beta medium control, the relative LDH release does 
increase, but not significantly from Day 4 to 6. In the beta media relative LDH release is 
similar within concentrations at Days 2 and 4, decreasing at Day 6 due to an increase in 
cell number. Therefore the amount of LDH released from non-dex cultures is relatively 
similar across time points.  
In dex containing media, i.e. dex and osteogenic, proliferation occurs more quickly. 
Observations show an increase at Day 4 (fig 3.3-3.4) so there was a greater decrease in 
relative LDH release. In 300µM concentrations of genistein LDH release does not change 
significantly over time, but the cell number does increase, suggesting a greater amount of 
cell death. 
 
3.4.3 Measurements of ALP activity after treatment with genistein. 
Alkaline phosphatase (ALP) is a well known and characterised marker of osteogenic 
differentiation, monitoring activity of ALP has been shown to be a determinant of cell 
fate (Zipori 2006). ALP is an enzyme that is predominately found in matrix vesicles 
during mineralisation of extracellular collagen. Units of ALP activity are measured in the 
quantity of enzyme that can change 1µmol of PNPP to PNP in 1 minute. Since the 
activity of ALP is relative to the cell number total, protein levels are used to adjust the 
activity. Therefore ALP units are Umg-1 protein.  
Levels of ALP were measured using the methods described in 2.2.11 and 2.2.12
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3.4.3.1 ALP activity after culture with genistein in growth media. 
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Fig 3.9. ALP activity in MG63 monolayers cultured in growth media supplemented with 
genistein for 2, 4 and 6 days. ALP is expressed as U mg-1 protein, where 1 unit is the 
amount of enzyme that converts 1µmol of substrate to product per minute adjusted for 
total protein. N=3, error bars indicate SD. * indicates significance when compared with 
controls P<0.05.  
 
 
In growth medium controls (fig 3.9) there was a reduction in activation of ALP over time, 
by Day 6 activity was almost non-detectable.  
All of the genistein treatments and time frames studied produced significantly greater 
activation than the controls. Relatively ALP activity was similar at all concentrations of 
genistein and time points. 
 
  
71 
 
3.4.3.2 ALP activity after culture with genistein in beta media. 
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Fig 3.10 ALP activity in MG63 monolayers cultured in beta media supplemented with 
genistein for 2, 4 and 6 days. ALP is expressed as U mg-1 protein, where 1 unit is the 
amount of enzyme that converts 1µmol of substrate to product per minute adjusted for 
total protein. N=3, error bars indicate SD. all genistein treatments are significant when 
compared with controls P<0.05.  
 
 
After culturing in beta media ALP activity in controls (fig 3.10) declined from Day 2 to 
almost undetectable at Day 6. 
All genistein containing experiments were significantly greater from controls. However 
overall there was little significant difference between the genistein treatments over all the 
time points tested. 
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3.4.3.3 ALP activity after culture with genistein in dex media  
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Fig 3.11 ALP activity in MG63 monolayers cultured in dex media supplemented with 
genistein for 2, 4 and 6 days. ALP is expressed as U mg-1 protein, where 1 unit is the 
amount of enzyme that converts 1µmol of substrate to product per minute adjusted for 
total protein. N=3, error bars indicate SD. all genistein treatments are significant when 
compared with controls P<0.05.   
 
When MG63s were cultured in dex medium (fig 3.11) activity reduced with time until 
nearly undetectable at Day 6. 
After culture with all concentrations of genistein, ALP activity at Day 2 was more than 
double the control. At Day 4 ALP was nearly uniformly 1.5 Umg-1, with only 30µM 
genistein higher at 2 Umg-1. On Day 6 a dose response was discernable, decreasing ALP 
with increasing genistein. Activation increases from Day 4 to Day 6  
At concentrations of genistein from 1.88 – 7.5µM there was a stepwise activity increase 
over time, at concentrations from 15µM to 300µM the peak activation was at Day 4.
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3.4.3.4 ALP activity after culture with genistein in osteogenic media. 
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Fig 3.12 ALP activity in MG63 monolayers cultured in osteo media supplemented with 
genistein for 2, 4 and 6 days. ALP is expressed as U mg-1 protein, where 1 unit is the 
amount of enzyme that converts 1µmol of substrate to product per minute adjusted for 
total protein. N=3, error bars indicate SD. all genistein treatments are significant when 
compared with controls P<0.05. 
The activity of ALP in fully osteogenic medium controls (fig 3.12) started low and 
reduced until Day 6. With the addition of genistein to osteogenic media ALP activity 
increases over time in a similar manner to the dex media; however peak activities are 
greater in osteogenic media. 1.88µM and 3.75µM of genistein activate most strongly and 
with the greatest increase between time points. 300µM does not increase as strongly as 
the other concentrations and activity reduces from Day 4 to Day 6. 
3.4.3.5 Summary of the activation of ALP with the addition of genistein. 
In all control media tested ALP activity decreases over the course of the experiment. In 
media without added dex ALP activation occurs to the same degree at all genistein 
concentrations and time points. In media with added dex; i.e. dex and osteo media, 
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activation is greater at lower concentrations of genistein and increases at each time point, 
at high concentrations of genistein ALP activity peaks at Day 4. 
3.4.4 Measurements of total collagen production after treatment with genistein. 
Collagen is an important precursor for mineralisation, production of collagen is one of the 
earliest markers activated during differentiation to osteoblastic cells. Collagen was 
measured using the method described in 2.2.10.4. 
3.4.4.1 Collagen production after culture with genistein in growth media. 
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Fig 3.13 The quantity of collagen observed after MG63 monolayers were cultured in 
growth media supplemented with genistein for 2, 4 and 6 days. N=8, error bars indicate 
SD. All treatments are significantly less than controls, * indicates significant increase 
over previous time point. P<0.05.  
 
Growth media controls (Fig 3.13) deposit more collagen than in the genistein 
supplemented wells an increase in the controls was observed between Days 2 and 4 and 
there was no change in deposition after Day 4. 
In growth media supplemented with genistein there was a slight upward trend over time 
in culture, significant at day 4 in most cultures.   
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3.4.4.2 Collagen production after culture in beta media with genistein. 
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Fig 3.14 The quantity of collagen observed after MG63 monolayers were cultured in beta 
media supplemented with genistein for 2, 4 and 6 days. N=8 error bars indicate SD. All 
treatments are significantly less than controls, * indicates significant increase over 
previous time point P<0.05. 
 
 
In beta media controls (fig 3.14) there was an increase in collagen deposition over time in 
culture.  
After genistein treatment there was an increase in collagen at all the concentrations and at 
all the days tested, although levels remained below the deposition in the controls. 
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3.4.4.3 Collagen production after culture with genistein in dexamethasone media. 
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Fig 3.15 The quantity of collagen observed after MG63 monolayers were cultured in dex 
media supplemented with genistein for 2, 4 and 6 days. N=8 error bars indicate SD. † 
denotes significant decrease when compared to controls, * indicate significant increase 
compared with control. § indicates significant increase over previous time point. P<0.05. 
 
 
In dex media controls (fig 3.15) collagen deposition increased from Day 2 to 4 and 
remained the same from Day 4 to 6.  
After treatment with genistein supplemented media at Day 2 there was a similar level of 
collagen at all the concentrations of genistein except 300µM which was higher than the 
other concentrations. At day 2 no treatments were higher than the controls. 
After treatment with all genistein concentrations collagen increased from Day 2 to Day 4. 
At Day 6 a further increase occurred at ≥15µM while at ≤7.5µM there was no increase 
from Day 4. 
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3.4.4.4 Collagen production after culture with genistein in osteogenic media. 
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Fig 3.16 The quantity of collagen observed after MG63 monolayers were cultured in 
osteogenic media supplemented with genistein for 2, 4 and 6 days. N=8 error bars 
indicate SD. † denotes significant decrease when compared to controls, * indicate 
significant increase compared to control. § indicates significant increase over previous 
time point. P<0.05. 
 
In osteogenic media controls collagen accumulation increased from Day 4 to 6. In 
genistein treatments on Day 2 there was an increase in collagen commensurate with an 
increase in genistein concentration, significant at 30µM and 300µM. At Day 4 total 
collagen was similar from 1.88µM-15µM, while at 30µM and 300µM there was a large 
increase in collagen.  
After 6 days culture in osteogenic media supplemented with genistein all concentrations 
induced a significant increase in collagen when compared with controls. 
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3.4.4.5 Summary of collagen production after culture in media containing genistein. 
 
After genistein treatment in media without dex (GM, beta) collagen deposition in all the 
experiments was lower than found in the controls. Although lower, similar stepwise 
collagen accumulation did occur at all concentrations of genistein over the course of the 
experiment. 
In media that contained dex (dex, osteo) some of the genistein concentrations did induce 
collagen deposition above controls, most often collagen increased with time in culture. 
30µM and 300µM genistein induced the greatest increase in collagen. 
Therefore it would appear there is a synergistic effect of genistein and dex that effects 
differentiation to a greater degree than either acting alone. 
 
 
 
 
3.4.5 Alizarin Red staining for quantification of mineralisation. 
Alizarin red forms a salt with calcium ions and is therefore more selective than a Von 
Kossa stain which stains phosphates. The Alizarin red stain has been described as a 
quantitative method by Gregory et al. (2004) and an adaptation of their method was used 
here.  
The method for alizarin red staining and quantitative determination of the mineralized 
ECM can be found at 2.2.10.1 
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3.4.5.1 Alizarin red staining after culture with genistein in growth media. 
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Fig 3.17 The quantity of Alizarin red staining observed after MG63 monolayers were 
cultured in growth media supplemented with genistein for 2, 4 and 6 days. N = 3 error 
bars indicate SD. * = significance compared with controls P<0.05. 
 
Extra cellular matrix calcium staining in growth medium control cultures increases 
slightly between Day 2 and 4 and then remained similar over the rest of the experimental 
period (fig 3.17). 
In the genistein treatments at Day 2 mineralisation was less than the control and not 
different from each other. At Day 4 mineralisation was the same as the control in all the 
concentrations of genistein. On Day 6 mineralisation was greater than the control 
between 1.88µM and 7.5µM, while 300µM was lower than control values, a reduction 
from Day 4. 
In cultures containing concentrations of genistein between 1.88µM and 15µM there was 
an increase in mineralisation over the experimental time period.   
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3.4.5.2 Alizarin red staining after culture with genistein in beta media. 
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Fig 3.18 The quantity of Alizarin red staining observed after MG63 monolayers were 
cultured in beta media supplemented with genistein for 2, 4 and 6 days. N = 3 error bars 
indicate SD. * = significance compared with controls P<0.05.  
 
 
When mineralisation was observed in MG63s cultured in beta medium (Fig 3.18) there is 
no change in alizarin red staining of the control over time.  
In the genistein treatments Day 2 was lower than controls and not different when 
compared with each other. At Day 4 mineralisation was higher between 1.88µM and 
15µM. At Day 6 mineralisation was higher than controls at 1.88µM to 15µM and lower 
at 300µM. 
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3.4.5.3 Alizarin red staining after culture with genistein in dex media. 
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Fig 3.19 The quantity of Alizarin red staining observed after MG63 monolayers were 
cultured in dexamethasone media supplemented with genistein for 2, 4 and 6 days. N=3, 
error bars indicate SD. * = significance compared with controls P<0.05. 
 
Dex medium alone (Fig 3.19) induced no change in the mineralisation of MG63s over the 
time course of the experiment. Similarly in genistein treated MG63s at Day 2 there was 
no difference between the concentrations of genistein tested or with the control.  
At Day 4 in all genistein concentrations mineralisation occurred above controls, 
significantly at 1.88 µM to 7.5µM, but not different from each other. On Day 6 
mineralisation increased again between 1.88 and 30µM, while 300µM was reduced when 
compared with controls.  
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3.4.5.4 Alizarin red staining after culture with genistein in osteogenic media. 
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Fig 3.20 The quantity of Alizarin red staining observed after MG63 monolayers were 
cultured in osteogenic media supplemented with genistein for 2, 4 and 6 days. N=3, error 
bars indicate SD. * = significance compared with controls P<0.05. 
 
 
In osteogenic medium the controls accumulate mineralisation over the course of the 
experiment. After treatment with genistein at Day 2 mineralisation was higher at low 
genistein ≤15µM. At Day 4 mineralisation was the same as Day 2 for concentrations of 
genistein from 1.88 to 15µM, at 30 and 300µM there was an increase in mineralisation 
from Day 2. On Day 6 there was equal mineralisation for all genistein concentrations. 
 
3.4.5.5 Summary of the effect of genistein on alizarin red staining. 
Generally at genistein concentrations between 1.88µM and 15µM mineralisation above 
control levels accumulated over the course of the experiment. In osteogenic media 
mineralisation occurred to a detectable degree over the studied time period, however 
addition of genistein accelerated the observed effects.   
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3.5 Results summary. 
3.5.1 Cell death. 
LDH data is complicated by growth and cell death in the intervening period between the 
start of the experiment and the assay. Because the data is a net figure comparing 
monolayer and supernatant availability it can be more informative than a cell count, 
monolayer number may be unchanged but a large supernatant availability of LDH 
suggests cell death occurred that was masked by proliferation. 
Therefore genistein at the tested concentrations has an effect on cell proliferation and 
death. Cell death in the vehicle controls increased over the course of the experiment in all 
the media formulations. In the growth and β-glycerophosphate media with genistein 
treatments relative LDH release increased from Day 2 to Day 4 and decreased from Day 
4 to Day 6, suggesting an even amount of cell death masked by proliferation between 
Days 4 and 6. After culturing in dex and osteogenic media observations show a shorter 
delay prior to proliferation. 
3.5.2 ALP activity 
ALP activity in this chapter has been shown to be relatively low for controls, in keeping 
with MG63 ALP expression reported in the literature (Masters, 1998). MG63s can be 
induced to increase ALP by genistein. The data presented here for growth media and beta 
media shows genistein mediated increase of ALP compared with controls at Day 2, 
activity remains constant at all the time points and concentrations tested. Dex and 
osteogenic media containing genistein induces activation increases at each time point. 
Genistein at 1.88 and 3.75µM are the most potent activators studied in these media. 
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3.5.3 Collagen synthesis. 
While trends of increasing deposition over time are observable in non-dex containing 
media (GM and beta) collagen synthesis was significantly lower than controls. In dex 
containing media (dex and osteo) observations of genistein treatments show a significant 
collagen increase at high concentrations of genistein (30µM and 300µM), and at all 
concentrations by Day 6 when compared with the controls.  
3.5.4 Mineralisation. 
In control MG63 cultures alizarin red staining of mineralisation was similar across the 
time period studied, in osteogenic media an accumulation of mineralisation occurred.  
For genistein treatments mineralisation accumulated over time. Genistein at 1.88µM to 
15µM mineralisation increased at each time point, concentrations of genistein 1.88µM to 
7.5µM mineralised most strongly. At 300µM genistein mineralisation was below control 
or reduced over time in culture. 
3.6 Discussion 
As discussed in the introduction immortalised cell lines are used in much of the literature 
that seeks to elucidate the effects of genistein on the differentiation of osteoblasts. Morris 
et al. (2006) have previously used MG63s to test the osteogenic effects of genistein.  
To summarise their findings they suggested application of genistein for two days at 
concentrations from 2.5–30 µmol dm-3 induced MG63s to present phosphatidylserine on 
the outside of the cell membrane, binding calcium and increasing osteogenesis by 
nucleation, ALP activity was not changed and collagen synthesis was increased in non-
osteogenic media and reduced in osteogenic media.  
This mechanism of mineralisation is not regarded as the normal means by which 
mineralisation occurs. Reports suggest that although phosphatidylserine can bind Ca2+ 
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directly the normal mechanism of osteogenesis is calcium dependant phosphatidylserine-
annexin binding in mineralising matrix vesicles introduces calcium channels through the 
membrane allowing control of Ca2+ influx (Tait et al. 1992, Wuthier et al. 1992, Kirsch et 
al. 1997 & 2000). In fact the lipid component of matrix vesicles has been studied and it is 
reported by Boyan and Schwartz that phosphatidylserine is 4.8 times more concentrated 
in the matrix vesicle than on the plasma membrane (Boyan et al. 2009, Golub 2009).  
Other matrix vesicle components and collagen have been shown to combine with 
amorphous calcium phosphate and regulate its formation into a precisely controlled 
crystalline hydroxyapatite structure (Gajjeraman et al. 2007). It is certain that cell 
mediated calcification in matrix vesicles is tightly regulated by highly conserved 
processes, for example, it is known the loss of the matrix vesicle protein ALP in vivo 
results in loss of mineralisation and neonatal death (Fedde 1999).  
The mechanism for phosphatidylserine reversal from cytoplasmic membrane lipid to 
external presentation is caspase mediated and regarded as one of the first signs of 
apoptosis (Martin et al 1996). Phosphatidylserine may directly cause phagocytosis or may 
work indirectly by binding other signalling agents (Ravichandran et al. 2007). A review 
of the role of phosphatidylserine receptors in apoptosis by Hart et al (2004) summarises 
the view that serum opsonins such as antibodies and complement components can bind to 
apoptotic cells, presenting phosphatidylserine, and mediate phagocytosis by “traditional” 
phagocytic mechanisms without the need for specific phosphatidylserine responsive 
phagocyte receptors.  
Therefore phosphatidylserine is involved in mineralisation but not necessarily in 
apoptosis, however the precise mechanisms for both mineralisation and apoptosis are 
contentious, many theories are under investigation. Two strains of phosphatidylserine 
receptor deficient mice have been developed, neither study reported bone defects. PSR-/- 
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is a lethal neonatal mutation effecting the development of some tissues; 
phosphatidylserine and its receptors may mediate tissue specific functions (Kunisaki 
2004, Li 2003). 
Several tissue specific phosphatidylserine receptors have been discovered that can 
regulate cell engulfment in the brain, spleen, lymph, liver and kidney, so far no bone 
specific PSR have been found (Park 2007, Miyanishi 2007, Ichimura 2008). So although 
phosphatidylserine might mediate cell engulfment in some tissues, it is enriched in 
mineralising matrix vesicles and has a function regulating Ca2+ concentration  
Morris et al observe that phosphatidylserine presentation occurs at 2.5µM while nuclear 
condensation is detectable with TEM at >10µM genistein, but offer no assay to quantify 
the degree of DNA fragmentation at lower concentrations. Although it seems available 
they did not include data showing MG63s positive for phosphatidylserine but negative for 
propidium iodide; using a membrane integrity study over time would provide definitive 
proof for either necrosis or apoptosis. This is necessary because pathogenic 
mineralisation of extracellular collagen can occur during PCD and does not require ALP 
or annexins (Kirsch 2003). 
Measurements of ALP in Morris et al were noted to be effected by high protein levels 
caused by collagen deposition as cell number decreased. They reported that the activity of 
ALP remained the same even though cell number was falling with increasing genistein. 
An increase in protein caused a relative decrease in ALP IUmg-¹ of protein. Therefore 
while the paper by Morris et al. 2006 demonstrates phosphatidylserine presentation on the 
external membrane surface it may be present due to apoptosis or release of mineralising 
matrix vesicles from cell membranes they do not present any other evidence of genistein 
mediated osteogenesis.  
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There are several differences between the model employed by Morris et al and the one 
presented here. Firstly the model in the paper utilises proliferating cells which have been 
cultured prior to the experiment in osteogenic media containing; EMEM, +10% FCS, 
250µM ascorbic acid and 10mM β-glycerophsophate (Sandrini 2005). The data presented 
in this chapter uses MG63s that have been maintained in culture in non-osteogenic media, 
αMEM +10% FCS. For the experimental media, 50µM ascorbate-2-phosphate was added 
as well as either or both 10mM β-glycerophosphate and 10nM dexamethasone. 
Dexamethasone is a potent osteogenic agent that acts on differentiation pathways separate 
from the action of genistein (Terkeltaub 2008, Tait 1992). This formulation of osteogenic 
media is used more widely in the current literature (Decaris and Leach 2010, Brey 2011). 
A differentiating cell model, rather than a differentiated model may behave in a 
completely different manner to inducers of osteogenesis (Slootweg et al. 1996). 
In this chapter it was undertaken to elaborate these findings by using a confluent culture 
system. This system was selected to try to limit the effect of genistein on proliferation 
and cell death. The Day 2 collagen data presented here is consistent with that presented in 
the paper. When we compare the paper with the ALP measurements shown in this chapter 
all results presented here are significantly higher than controls and display a greater 
increase in activity at Day 2. This more pronounced effect is either; due to the difference 
in reporting the units of ALP, lower protein production, or because the change to a 
confluent differentiating system changed the influence of ER-genistein ligands on 
differentiating cells, rather than a pre-differentiated model.  
In 2005 Kim et al demonstrated that 10-9M genistein increased MG63 proliferation in 
non-confluent conditions by 153.1% and at 10-6M inhibited proliferation vs controls 
(61% of control) after 5 days. This proliferative effect was reduced to control values with 
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the addition of a competitive inhibitor, the pure anti-oestrogen ICI 182,780 (trademarked 
as Fulvestrant and Faslodex) that due to its pure anti-oestrogenic nature had no effect on 
its own. This data was used to prove that in MG63s genistein binds to the oestrogen 
receptor and that the concentrations of genistein tested here should inhibit the 
proliferation of MG63s. Depending on the time in culture the data presented here either 
agrees or disagrees with Kim et al., at time points earlier than 5 days we observe 
increased proliferation most often. However after 5 days, relative to controls, cell number 
is reduced in our culture system. 
Whilst there is little other available record of MG63s treated with genistein other cell 
lines have been exploited to test the effects of genistein. KS483, a differentiating mouse 
cell line that can form both osteoblasts and adipocytes was cultured with daidzein by 
Dang et al. (2004). Their findings show an increase in ALP activity at low doses (1-
20µM), as well as concurrent nodule formation and inhibition of adipocyte formation. At 
high concentrations this situation was reversed (30-75µM), ALP and mineralisation was 
inhibited and the differentiation of adipocytes increased.  
Schmidt et al (2007), investigated genistein as a topoisomerase inhibitor in several 
malignant human glioma lines at concentrations between 5-100µM. EC50 was between 
25-80 µM associated with cell cycle arrest at G2/M, decreasing proliferation combined 
with an increase in LDH release, no differentiation was detected. Higher concentrations 
resulted in apoptosis independent of caspase induction, although this effect was tissue 
type specific and is affected by expression of ERs. Cells without topoisomerase are 
resistant to this genistein effect (López-Lazaro 2007).  
Kang (2001) report that in the immortalised rat hepatic stellate cell line HSC-T6 
proliferation and collagen type I synthesis was inhibited by 38.1% after 48 hour 
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incubation of with 35µM genistein. It was demonstrated by Heugarten et al. (1999) that 
estradiol can suppress the expression of collagen I by modulating the expression of c-fos 
and regulation of the transcription factor AP-1 via the MAP kinase cascade. The MAP 
kinase cascade has been previously shown to be rapidly activated by oestrogen (1nM-
1pM) in the rat osteoblast cell line ROS 17/2.8 (Endoh et al. 1997). 
Uchiyama & Yamaguchi (2007) treated sub-confluent mouse MC3T3-E1 osteoblasts with 
10µM genistein in β-glycerophosphate medium and found increased proliferation, protein 
synthesis and ALP but not collagen or mineralisation at 1, 2 and 3 days. The same 
authors report (2008) that treatment of MC3T3-E1 with oestrogen caused no increase of 
ALP at day 3, but 106M genistein did up-regulate ALP. Cbfa-1 was reported to be up-
regulated by oestrogen but not genistein. 
In agreement with Uchiyama’s (2007) mouse cell line but not Kang’s (2001) rat the 
collagen levels in growth media in this study are similar across all the tested 
concentrations of genistein and mineralisation levels are static Day 2 and 4 as well, 
however on Day 6 mineralisation did increase compared to controls.  
Much work has investigated the mechanism of action of oestrogens on human osteoblast 
like cell lines, U2OS cells have often been transiently transfected with oestrogen 
receptors to further understand the mechanisms involved in the differentiation of 
osteoblasts. Salvatori et al (2009) described the effects of both oestrogen (10nM) and 
genistein (1µM) on such a model. Their findings indicate that oestrogens cause the 
cessation of cell growth at G1/G0 and induce apoptosis; they also observed increased 
differentiation in arrested cells.  
Much of the variation in responses to genistein in the literature can be explained by the 
use of many different cell lines. Genistein is certainly reported as toxic in the range of 
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concentrations tested in this chapter, however in this range there is also increased 
differentiation and even selection of differentiated phenotypes. These different effects are 
at least partly due to the effects phytoestrogens exert as SERMs. Therefore different 
tissue types and organisms will be affected relative to their expression of ERs and the 
affinity of the species ER for genistein. 
Osteosarcoma and immortalised cell lines have, by definition, an unusual cell death 
mechanism, since genistein in this concentration range has a toxic effect a primary 
differentiating cell should used to investigate effects. It is preferable to use a human cell 
strain since Rat and Mouse cell lines have different responses to genistein (Kang et al. 
2001, Uchiyama et al. 2007). A primary human BMSC strain has a distribution of 
oestrogen receptors that is more relevant to an in vivo situation and is more likely to 
undergo cell death in a normal manner. Therefore in the next few chapters the use of a 
differentiating primary human cell type is explored to provide a more realistic model. 
3.7 Conclusions: 
The hypothesis that genistein accelerates the osteogenic differentiation of a MG63 culture 
was proved to be correct. The range of genistein concentration utilised in these 
experiments was found to have relevant effects on the confluent cell model.  
The confluent MG63 osteosarcoma cell line described here was useful to describe the 
action of genistein on markers of differentiation alone, and in combination with 
components of osteogenic medium after short culture periods. 
The use of the MG63 cell line was not thought to offer the most precise tool for the 
extrapolation of genistein effects from in vitro to in vivo. Therefore a primary cell model 
was investigated for further study.  
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CHAPTER 4 
AN IN VITRO EVALUATION OF THE OSTEOGENIC EFFECT OF 
GENISTEIN ON A CONFLUENT DIFFERENTIATING BMSC MODEL. 
4.1 Introduction 
Bone marrow stromal cell (BMSC) cultures, as described in the introduction contain 
osteogenic progenitors. Since genistein has been shown to up regulate markers of 
osteogenesis in MG63s understanding the in vitro effect on primary isolates of BMSCs 
would provide further evidence of the likely in vivo effect. Therefore in this chapter the 
application of genistein to primary human multipotent BMSCs was investigated as a 
confluent differentiating model. This primary differentiating model is more likely to be 
relevant to real osteogenesis than an osteosarcoma model. 
Since the initial report by Friedenstein describing what became known as the BMSC 
population the development of techniques to isolate and characterise BMSCs has been 
well studied with no consensus (Friedenstein et al 1970, Caplan 1991). Authors have 
refined the Friedenstein method to select proportions of the whole bone marrow 
population by density gradient, collagen treatment, sieving and phenotypically by surface 
epitope sorting using magnetic bead or fluorescence-activated techniques (Castro-
Malaspina et al 1980, Sakaguchi et al 2004, Leong et al. 2004, Bianco et al. 2008, Yu et 
al. 2010). All of these techniques isolate populations of cells that are distinct at isolation 
but, at least in vitro, share the stem cell property of pluripotency.  
There is no consensus for the isolation of BMSCs because no single marker has been 
discovered that is constitutively expressed; they are phenotypically plastic and share 
features with many other cell types including endothelial, epithelial and muscle cells, 
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their isolation has been reported from every vascularised tissue type and their function in 
vivo is unknown (Tárnok et al. 2010). In the last 40 years of research there has been no 
significant gain in a definitive technique to select the BMSC population from the in vivo 
environment, making extrapolation of in vitro effects to an in vivo setting difficult. 
Because of the overall lack of consensus non-comparable data can be the result, both 
between the array of culturing methods and from culture to organism. 
Therefore after each isolation the selected population must be fully characterised for its 
individual capabilities of multi-potentiality and reproduction. Currently in the literature 
many authors use antibody screening to concurrently select for and characterise their cell 
population and to this end many antibody panels have been developed that select 
interesting sub-populations (Pountos, et al. 2007). A promising marker of a subset of 
bone marrow stromal cells is MCAM (CD146), a marker of classically described 
adventitial reticular cells from the stroma (Cattoretti et al. 1993). MCAM is a cell 
adhesion molecule also expressed by pericytes residing in the microvasculature, it has 
been postulated that pericytes could be in vivo BMSCs although they are spontaneously 
myogenic in vitro and are not osteogenic in vivo (Shi and Gronthos 2003, Dellavalle et al. 
2007, Feng et al. 2010). 
The international society for cellular therapy (ISCT) has proposed minimal markers for 
the selection of BMSCs. According to the ISCT the BMSC should be; plastic adherent, 
positive for surface epitopes CD73, CD90 and CD105 and negative for CD34, CD45, 
HLA-DR, CD11b or CD14, CD19 or CD79α and also capable of differentiation to 
osteoblasts, chondrocytes and adipocytes (Horwitz et al. 2005, Dominici et al. 2006).  
Although a basic level of characterisation in the literature is welcome there are some 
problems with the ISCT definition; it does not recommend the classic method of initial 
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seeding at clonal density. Perhaps most importantly it does not uniquely recognise the 
BMSC population; Sabatini et al (2005) reported that bronchial fibroblasts are 
indistinguishable from BMSCs by the above criteria.  
The ISCT definition does not require analysis of the culture to determine if any cells 
within it have the self renewal and differentiation capacity of a stem cell. Single cell 
cloning to analyse the number of self renewing cells that are tri-potent is a fundamental of 
the Friedenstein method. Also not recommended is the final pillar in the Friedenstein 
method, proof of in vivo bone formation ability from a cloned single cell, a demonstration 
of true stem cell behaviour.  
The ISCT only recommends an initial characterisation of the cell population resulting 
from the selection criteria but that “…each cell preparation does not need to be re-
evaluated.” BMSCs lose differentiation capacity over time in culture, in order to provide 
appropriate controls re-evaluation of the capacity for pluripotency should be an essential 
step at every passage prior to experimental use. Since initial CFU-F formation ability at 
isolation varies between authors and with donor age and sex, culture propensity for CFU-
F and single cell cloning determination is a vital characterisation step (Kuznetsov et al. 
2009). The CFU-F formation capacity has been shown to directly relate to the number of 
cells in the culture that have in vivo stem cell capacity (Friedenstein et al. 1974). The lack 
of even a mention of CFU-F characterisation and differentiation capacity before 
experimental use makes the ISCT criteria misleading and potentially useless (Kuznetsov 
et al. 2009). 
With regards to the ISCT ruling it’s worth noting that in the literature it has been reported 
that cultures of some BMSC isolates from adipose tissue are CD34 positive (Yoshimura 
et al. 2006). Endothelial cells (positive for CD34 and CD31) cultured with BMSC media 
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and seeding densities become positive for the ISCT criteria (da Silva Meirelles et al. 
2009).  
There is evidence available that suggests isolation of plastic adherent cells in selective 
conditions may represent a homogenous culture. The use of some batches of FBS in 
isolation media can produce cell isolates that after culture selection alone individually 
display similar expression of 48 known BMSC markers (Lennon et al 1996, Pittenger et 
al 1999). Therefore heavy reliance on the use of selection by marker panel does not 
guaranty adequate characterisation or even selection of the correct cell type; depending 
on the tissue cells were isolated from, the seeding densities and media composition 
(Dominici et al. 2006, Meirelles et al. 2006, Kuznetsov et al. 2009). 
It has been controversially reported that dedifferentiation and transdifferentiation can be 
induced to occur in BMSC populations when they are cultured in specialised 
environments, although the potential of single BMSCs to differentiate into tissues other 
than those of skeletal origin has not been formally proven in vivo (Krabbe et al. 2005, 
Martin et al. 2009, Roobrouck et al. 2011). 
There are also different reports of culture limits for BMSC growth without 
differentiation, most authors point to about 20 population doublings before bulk cultures 
loose capacity for differentiation (Kozhevnikova et al. 2008). However, the Verfaille 
group reports that a subpopulation of BMSCs, which they call multipotential adult 
progenitor cells (MAPCs), can be cultured almost indefinitely, certainly to above 120 
population doublings (Serafini and Verfaillie 2006). It is the definition of the term stem 
cell that it has a large capacity for self renewal with maintenance of potential, therefore it 
is expected that CPDs should be large or that current culture conditions initiate 
differentiation. 
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This culture induced plasticity of human BMSCs has made it difficult to extrapolate the 
in vitro behaviour to an in vivo niche, in vivo function is also elusive; in other stem cell 
literature there is consensus for characterisation. The gold standard proofs of stem cell 
function are based on work on haematopoietic stem cells (HSC). For this proof HSC 
scientists utilise a single ex vivo HSC to serially reconstitute multi-lineage 
haematopoiesis in irradiated mice (Kim et al. 2010). This assay establishes several 
important things; there are no in vitro steps, in vivo assessment is critical, 
multipotentiality is based on data from the single cell level and serial self renewal 
indicates that there are identical daughter cells with identical properties propagating over 
extremely large numbers of population doublings (Kim et al. 2010). 
This definition might not hold true for skeletal stem cells because even at the very outset 
of non haematopoietic stem cell research McCulloch and Till, using single cell clones, 
found de novo bone speck formation in the spleen (Becker et al. 1963). Indicating that 
unlike HSCs, BMSCs do not home to their original niche and that to repopulate a skeletal 
defect BMSCs are required in greater numbers than HSCs. This difference may well be 
due to the longevity of the tissue type, bone has a low turnover relative to 
haematopoiesis. Ideally an in vivo experiment replicating the precision of the HSC 
experiments would be required for definitive stem cell proofs. 
Therefore, in conflict with the ISCT and directly because of the limitations of antibody 
screening any work concerning primary BMSCs should, until the in vivo niche is 
extrapolated, include characterisation methods that undertake to prove in vitro self 
renewal with concurrent maintenance of pluripotency, CFU-F determination or single cell 
cloning is still the gold standard method to determine this (Kuznetsov et al. 2009, 
Sarugaser et al 2009). Cloning allows determination of the number of cells within the 
culture that have self renewal potential and removes the possibility that the culture 
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contains multiple lineages that provide the illusion of multipotentiality (Friedenstein et al. 
1974, Kuznetsov and Robey 1996). Because the number of pluripotent self renewing cells 
in the culture is low it is likely that the population of cells, although initially homogenous 
for the selection criteria, is heterogeneous in age and functionality (Sarugaser et al 2009). 
Once single cell clones (SCCs) have been shown to be pluripotent and capable of in vitro 
self renewal the culture has been shown to contain a proportion of in vitro stem cells. 
However, the last step to fully characterise the potential of the isolated population, and to 
overcome the issue of in vitro plasticity, is by an in vivo experiment. In order to achieve 
this full characterisation of the population the multipotent SCCs can be placed into in 
vivo chamber models; those cells that mediate the production of de novo bone are true 
skeletal stem cells. Only about 10% of those human in vitro cells capable of self renewal 
and pluripotency are true in vivo stem cells (Bianco et al. 2006). It is this small 
population of skeletal stem cells in the BMSC culture that is commonly referred to as the 
“mesenchymal stem cell”, although there is still no proof of its in vivo function or 
differentiation to all mesenchymal tissues. Although some of the culture may have stem 
cell functionality the whole culture is heterogeneous for potential and should not be 
described as a population of stem cells.  
Most publications in the literature do not use the final proof of in vivo de novo bone 
formation due to implications of cost, ethics and time. Perhaps a more important issue is 
that subsequently there will be changes in the population and further sub culturing would 
require a repeat in vivo experiment. Changes in the cultured cells can occur no matter 
how extensively characterised, re-affirming phenotype takes time and uses cells that 
could be spent experimentally. However, the extensive characterisation of the population 
is extremely important for the reproducibility of data between cultures and for analysis of 
data compared to robust controls.  
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In this chapter the STRO-1 and SSEA-4 antibodies were used for further characterisation 
of the isolate. The STRO-1 antibody is the classical BMSC antibody that has been used 
extensively as either a characterisation or isolation marker of BMSC populations; 
however as with the other BMSC markers it cannot be used alone as it is expressed by a 
variety of cell types that includes BMSCs (Simmons and Torok-Storb 1991, Salem and 
Thiemermann 2010). STRO-1 positive sorting by FACS increases the number of 
clonogenic cells in the culture; since at isolation cultures were seeded at clonal density it 
is likely that this selection criteria also concurrently increased STRO-1 positivity in the 
culture (Sacchetti et al. 2007). 
Much of the available isolation and characterisation literature based on the production of 
an antibody marker panel for BMSCs does not include the final in vivo testing of clones 
characterisation. However of the recent papers that do undertake in vivo testing the most 
complete is the paper by Gang et al (2007) concerning the use of SSEA-4 as a marker of 
BMSCs. Therefore SSEA-4 was also utilised here as a marker of BMSCs, in combination 
with STRO-1, initial seeding at clonal density, adherence to tissue culture plastic, single 
cell cloning and pluripotent differentiation.  
After the described characterisation the primary human BMSCs were used 
experimentally to determine the effect of genistein on osteogenic differentiation markers, 
as described. 
4.2 Hypothesis 
Primary bone marrow stromal cells isolated from discarded human tissue differentiate to 
an osteogenic phenotype in an accelerated manner after the addition of genistein. The 
osteogenic effect of genistein is observable in growth medium, osteogenic medium, and 
in medium containing osteogenic components. 
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4.2.1 Aims 
Isolation of BMSC cultures by limiting dilution and adherence at clonal densities to 
tissue culture plastic. Characterisation of the primary cell strains for cell surface epitopes, 
in vitro proliferation potential, differentiation capacity and morphology was undertaken 
to achieve a characterised and confluent in vitro model. These BMSC cultures were 
observed for production of ALP, collagen, mineralisation and Cbfa-1 before and during 
osteogenic differentiation to produce a differentiation profile. Concurrent to analysis of 
differentiation phenotype genistein was applied to BMSC cultures in order to confirm the 
induction of the osteogenesis observed in MG63’s and to study the effect on proliferation, 
cell death, ALP, collagen, mineralisation. The effect of genistein on BMSCs was 
compared to MG63 observations and the literature. 
4.3 Methods 
Isolation and culture of BMSCs is described in full at 2.2.1 – 2.2.7. Methods for the 
characterisation of BMSCs are described at 2.2.9. In brief, mononuclear cells were 
isolated from the buffy coat and cultured at a seeding density of 5x10
3
 cells cm
-2
, since 
BMSCs occur at a frequency of approximately 1-50 every 1x10
5
 cells this seeding density 
results in colony formation. Colonies were allowed to combine and were characterised for 
expression of STRO-1, SSEA-4, quantity of single cell clones and differentiation 
capabilities prior to culturing in media containing genistein.  
4.3.1 Experimental procedure  
The experimental methods for determination of effects of genistein are described in full at 
2.2.13. In brief; the BMSCs were seeded at confluent density. The medium was removed 
and replaced with media containing genistein, harvesting subsequently occurred at Days 
2, 4 and 6. Analysis methods are described in full at 2.2.10. 
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4.3.2 Statistical analysis. 
Statistical analysis was performed in Minitab 15. The analysis of data was achieved using 
a one-way analysis of variance (ANOVA) with multiple comparison tests; Tukey’s 
family error rate was used to determine the significance between groups without a 
defined control. i.e. Comparisons of a single concentration of genistein across time 
points. Dunnett’s family error rate was used to compare groups with a defined control i.e. 
concentrations of genistein compared with vehicle. The confidence level was set at 95 
and P values of <0.05 were considered significant.   
 
4.4 Results 
4.4.1 Characterisation of BMSC cultures. 
Plastic adherent mononuclear bone marrow cells were isolated at clonal density and 
characterised for growth (Fig 4.1), staining for STRO-1 and SSEA-4 antibodies (Fig 4.2), 
and cultured in media that induced differentiation of osteoblasts (fig 4.3), adipocytes (fig 
4.4) and chondrocytes (fig 4.5).  
 
4.4.2 BMSC Growth curves in isolation and culturing medium. 
 
Fig 4.1 The cumulative population doublings of BMSCs in isolation and culturing 
medium from isolation until the cell number no longer increased. 
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4.4.3 Antibody staining for the characterisation of surface epitope phenotype. 
 
 
Fig 4.2 Photomicrographs of BMSCs after cytospin preparations were stained. 
Photographs show staining with antibodies for A) STRO-1 (x20), B) SSEA-4 (x40) and 
negative control staining for C) STRO-1 and D) SSEA-4. 
 
 
 
BMSC cultures were stained for SSEA-4 and STRO-1 using methods described at 
2.2.9.1. BMSC isolated by adherence to tissue culture plastic at clonal densities were 
positive to SSEA-4 and STRO-1 antibodies. Indicating that selection by classic methods 
also selects cells that stain for recognised antigen production and have been shown to 
demonstrate pluripotent differentiation. 
 
C D 
A B 
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4.4.4 Characterisation of the multipotentiality of isolated populations.  
The pluripotency of bulk cultures was demonstrated by sub-culturing the isolates in 
differentiation medium for 21-30 days or until morphology and culture observations 
indicated BMSCs had differentiated, as shown in figures 4.3 to 4.5, Alizarin red staining 
showing accumulation of mineralisation during osteoblast differentiation (fig 4.3), Oil 
Red O staining of cells with lipid vacuoles after adipocyte differentiation (fig 4.4) and 
Alcian blue staining of glycosaminoglycans in the collagen of pellet cultured cells during 
chondrocyte differentiation (fig 4.5). 
 
 
 
4.4.4.1 Characterisation of the BMSC culture for osteogenic potential 
 
Fig. 4.3 BMSC differentiated monolayers cultured in osteogenic media stained with 
Alizarin red to determine mineralisation of the extra cellular matrix. A) Single 
mineralised nodule (x20) B) whole culture mineralisation (x10). 
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4.4.4.2. Characterisation of the BMSC culture for adipogenic potential 
  
Fig 4.4 BMSC differentiated monolayers cultured in adipogenic media stained with Oil 
red O to show lipid accumulation (x20). 
 
 
 
 
 
 
4.4.4.3 Characterisation of the BMSC culture for chondrogenic potential. 
  
Fig 4.5, BMSC differentiated pellets cultured in chondrogenic media stained with Alcian 
blue for glycosaminoglycans in the collagen matrix A) the stained pellet, B) close up, C) 
a section of the pellet (x20). 
A 
B 
C 
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4.4.5. The differentiation potential of BMSCs with time in culture and the analysis 
of the culture potential for multipotent single cells. 
 
Table 1 lists the differentiation potential of isolated cell cultures. The colony forming 
efficiency of the cultures was, on average 30.33 cells per 1x10
5
 seeded mononuclear 
cells. After between 1 and 9 passages there was a loss in the differentiation potential of 
the cultures. Often the loss in potential corresponded with reduced proliferation compared 
to the normal doubling rate of the culture. 
 
 
After the BMSCs were characterised for surface epitope production and differentiation 
potential the method for single cell cloning (2.2.9.2) was utilised to determine the self 
renewal properties of individuals within the culture, which allowed an inference of 
culture stem cell capacity. Table 2 outlines the expected and found numbers of self 
renewing cells within the plated cells. For a culture of cells 1056 wells were seeded with 
352 cells at a density of 0.3 cells per well, any wells with more than one attached cell 
after 4 hours were discarded.  
 
 
On average, compared to the literature, there was a normal distribution of colony 
formation from the isolated monocytes, where as a high percentage (5.3%) of single cell 
clones were capable of multiple lineage differentiation and more than 30 population 
doublings (Akintoye et al 2006, Kuznetsov et al 2009, Sarugaser et al 2009).  
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Differentiation to multiple cells types at passage  
Cell Strain CFU-F 1 2 3 4 5 6 7 8 9 10 
B381 44 3 3 3 3 3 3 3 3 3 2 
B382 20 3 3 3 2 2 2 1 1 - - 
B383 32 3 3 3 3 3 3 2 2 2 1 
B386 36 3 3 3 3 3 3 3 3 2 2 
B388 37 3 3 3 3 3 2 2 2 1 1 
B389 12 2 2 1 1 - - - - - - 
B390 19 3 3 2 2 1 1 - - - - 
B392 38 3 3 3 3 3 1 1 - - - 
B393 52 3 3 3 3 3 3 3 3 3 3 
B404 41 3 3 2 2 2 1 1 - - - 
B409 32 3 3 3 3 3 3 3 2 2 2 
B423 51 3 3 3 2 2 2 2 2 1 1 
B428 22 3 3 3 3 1 1 - - - - 
B438 39 3 3 3 3 3 3 2 2 2 2 
B442 17 3 3 3 2 2 2 1 1 - - 
Table 4.1. Showing the capability of isolated cells to form colonies at isolation, /10
5
 cells 
seeded, and differentiate into multiple cell lineages at each passage, loss of potential 
follows differentiation of the cell population tested. Only B389 was not capable of 
differentiation to osteoblasts, chondrocytes and adipocytes. All other isolates were 
capable of differentiation to all three lineages until at least passage 2. 
 
 
Cell 
strain 
Wells seeded 
at 0.3 cells per 
well 
Expected 
colonies 
Returned 
colonies 
Clones 
surviving 
at least 10 
CPDs 
Tripotent 
clones 
% of 
original 
seeding 
density 
B386ss 1056 352 60 48 21 5.97 
B409ss 1056 352 39 31 15 4.26 
B438ss 1056 352 55 47 20 5.68 
Table 4.2. Table showing the single cell clones capable of in vitro self renewal and 
potential for multiple differentiations from three primary cell populations, the mean 
capacity of the populations seeded for stem cells was 5.3% ± 0.91 SDs. The probability 
that each returned colony originated from a single seeded cell was 95.54%.  
 106 
 
4.4.6 Temporal characterisation of differentiation markers 
Once established, multipotent BMSC cultures were cultured in osteogenic medium, 
differentiation was monitored by analysis of several osteogenic markers; collagen, ALP, 
Cbfa1, mineralisation, cell proliferation and death. A profile of the expression found in 
differentiating BMSC cultures can be found at Fig 4.6. 
 
 
Fig 4.6 The activity profile of some of the common markers used to identify the 
osteoblastic differentiation of BMSC. Primary BMSC were seeded into flasks at normal 
seeding and harvesting densities and cultured in osteogenic media for 35 days. Samples 
of the cultures were tested according to the relevant methods and data expressed as a 
percentage of the maximum value.   
 
 
4.4.7. Summary of BMSC cultures. 
The cultures described and utilised in this chapter were isolated from bone marrow by 
density gradient and adherence to tissue culture plastic at clonal densities, they are 
positive for known BMSC antigens. Single cell clones (SCCs) within the culture are 
capable of in vitro self renewal and differentiation to osteoblast, chondrocytes and 
adipocytes. 
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4.4.8 Osteogenic effect of genistein after culture with primary human BMSCs in 
several medium types for 2, 4 and 6 days. 
 
4.4.8.1. Genistein effect on total cell number in the monolayer 
LDH from the lysed monolayer was plotted against a graph of the LDH found in known 
cell numbers. The data presented is expressed as the cell number found in the monolayer. 
The method is described at 2.2.10.5.1 
 
4.4.8.1.1 Cell number after culture with genistein in growth media.  
 
Fig 4.7, BMSC number derived from the content of LDH extracted from the monolayer 
after 0, 2, 4 and 6 days culture in growth medium and growth media with genistein. N=2, 
error bars indicate SD. * is significant from control P<0.05. 
 
In growth media controls (fig 4.7) cell number increased slightly over the course of the 
experiment. Genistein treatment media at 1.88µM induced a trend of increased 
proliferation compared with cells seeded at T0 over the course of the experiment. 
Concentrations greater than 7.5µM induced a reduction in cell number, significant at 30 
and 300µM.
* * *       * * * 
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4.4.8.1.2 Cell number after culture with genistein in beta media. 
 
 
 
Fig 4.8, BMSC number derived from the content of LDH extracted from the monolayer 
after 0, 2, 4 and 6 days culture in beta medium and beta media with genistein. N=2, error 
bars indicate SD. * significant from control P<0.05. 
 
 
 
Beta medium induced a slight increase in cell number in the controls (fig 4.8) over the 
course of the experiment. 1.88µM and 3.75µM genistein supplemented beta media 
induced a trend of increasing cell number at each time point. Cell death was apparent at 
≥7.5µM concentrations; cell death occurred significantly and at early time points after 
addition of genistein concentrations 30 and 300µM. 
* * *       * * * 
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4.4.8.1.3 Cell number after culture with genistein in dex media. 
 
 
 
Fig 4.9, BMSC Cell number derived from the content of LDH extracted from the 
monolayer after 0, 2, 4 and 6 days culture in Dex medium and Dex media with genistein. 
N=2, error bars indicate SD. * is significant from control P<0.05. 
 
 
In dex medium controls a significant increase in cell number can be observed at Day 2 of 
the experiment (fig 4.9). A dose response is apparent when genistein is added to dex 
media, lower concentrations initiate the greatest increase in cell number at Day 2. 
However the increase in cell number is not sustained over the period of the experiment. 
The toxic effect of genistein apparent in growth media and beta media is delayed to 30 
and 300µM of genistein in dex media. 
* * *       * * * 
* 
* 
* 
* 
* * * 
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4.4.8.1.1 Cell number after culture with genistein in osteogenic media. 
 
 
 
Fig 4.10, BMSC Cell number derived from the content of LDH extracted from the 
monolayer after 0, 2, 4 and 6 days culture in osteogenic medium and osteogenic media 
with genistein. N=2, error bars indicate SD. * significant from control P<0.05. 
 
 
In osteogenic medium controls (fig 4.10) cell number increased significantly at Day 2, 
dropping again to T0 values at Day 6. After addition of genistein to osteogenic media 
proliferation occurred at 1.88 – 15 µM, higher concentrations were toxic. The increase in 
cell number was not sustained over the experimental time period.  
An increased effect on proliferation compared with the other media was observed in 
osteogenic media formulations. 
* *       * * * 
* 
* 
* 
*             *             *         * 
* 
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4.4.8.2 The effect of genistein on LDH release compared with total LDH 
Because measurements of the supernatant LDH are “free” and comparisons with the 
monolayer are readily available LDH was used in this study as a measurement of cell 
death over time in culture. The amount of LDH available in the monolayer at the end of 
the experiment was combined with the supernatant LDH and this was used as a measure 
of 100%. The LDH available in the supernatant was directly compared with the total 
available LDH. The methods used were as described by the manufacturer and can be 
found in full at 2.2.10.5.1 
 
4.4.8.2.1 LDH release after culture with genistein in growth media. 
 
Fig 4.11, LDH content of the supernatant as compared to total LDH after BMSCs were 
cultured for 2,4 and 6 days in growth medium and growth media with added genistein. 
N=2, error bars indicate SD. * significant from control P<0.05. 
 
Growth medium controls (fig 4.11) did not induce a change in LDH release over the 
experimental time period. After genistein treatment LDH release occurred at similar 
levels in all time points and from concentrations of gen from 0 to 15µM. At gen 
concentrations 30 and 300µM LDH release increased over the control values. 
*   *  * 
*  * * 
* * 
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4.4.8.2.2 LDH release after culture with genistein in beta media. 
 
 
 
Fig 4.12, LDH content of the supernatant as compared to total LDH after BMSCs were 
cultured for 2,4 and 6 days in beta medium and beta media with added genistein. N=2, 
error bars indicate SD. * significant from control P<0.05. 
 
 
In beta medium controls (fig 4.12) cell death remained similar throughout the experiment. 
Genistein treatment induced release of LDH into the supernatant at similar levels in 
concentrations of gen from 0 - 15µM across all time points. At gen concentrations 30 and 
300µM LDH release increased over the control values. 
 
*  * * 
*  * * 
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4.4.8.2.3 LDH release after culture with genistein in dex media. 
 
 
 
Fig 4.13, LDH content of the supernatant as compared to total LDH after BMSCs were 
cultured for 2,4 and 6 days in dex medium and dex media with genistein. N=2, error bars 
indicate SD. * significant from control P<0.05. 
 
 
 
In dex medium control cultures (fig 4.13) lower cell death was observed at Day 2 than in 
growth (fig 4.11) or beta media (fig 4.12), at Days 4 and 6 the LDH release was similar to 
previous observations.  
At Day 2 addition of gen at concentrations between 1.88 and 7.5µM, caused a reduction 
in LDH release and an increase at 30-300µM when compared with controls. At Day 4 and 
6 LDH release matched controls until 30 and 300 µM where an increase was observed. 
* 
*  *  * 
* 
* 
*   * 
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4.4.8.2.2 LDH release after culture with genistein in osteogenic media. 
 
 
 
Fig 4.14, LDH content of the supernatant as compared to total LDH after BMSCs were 
cultured for 2,4 and 6 days in osteogenic medium and osteogenic media with genistein. 
N=2, error bars indicate SD. * significant from control P<0.05. 
 
 
 
Osteogenic medium controls (fig 4.14) induced an increase in cell death over time in 
culture in a similar manner to observations of dex medium. In gen supplemented 
osteogenic media the protective effect from 1.88-15µM was sustained until Day 4 and at 
Day 6 LDH release matched controls. LDH release at 30µM and 300µM was much 
higher than controls at all time points and increased stepwise over concentrations and 
time points. 
* 
* 
* 
* 
* * 
*  *  * 
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4.4.8.3 ALP activity after addition of genistein to BMSC cultures.  
 
ALP is a well known and characterised marker of osteogenic differentiation, monitoring 
activity of ALP has been shown to be a determinant of cell fate (Zipori 2006). Levels of 
ALP were measured using the method described in 2.2.10.2 and 2.2.10.3 
 
4.4.8.3.1 ALP activity after culture with genistein in growth media. 
 
Fig 4.15 ALP Umg
-1
 protein found in growth media cultured BMSC monolayers after 2, 
4 and 6 days treatment with Genistein. N=3, error bars indicate SD, * significant from 
control P<0.05 
 
In growth medium controls (fig.4.15) there is no significant increase in ALP activity by 
Day 6. In the gen treated cells there is little detectable activity at Day 2 rising to above 
control levels at Day 4. By Day 6 there is a significant increase in ALP activity. ALP at 
30 and 300µM genistein was reduced compared to ≤15µM genistein. 
* 
* 
* 
* 
* 
* 
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4.4.8.3.2 ALP activity after culture with genistein in beta media. 
 
 
 
Fig 4.16 ALP Umg
-1
 protein found in beta media cultured BMSC monolayers after 2, 4 
and 6 Days treatment with Genistein. N=3, error bars indicate SD, * significant from 
control P<0.05 
 
 
Beta medium controls (fig 4.16) have low observable ALP activity similar with growth 
medium controls. In the gen treatment cells there is no significant increase in activity at 
all the concentrations tested until Day 6.  
On Day 6 there is a significant increase in activity of ALP above controls. There is no 
significant difference in activation between concentrations 1.88µm to 7.5µm. 30 and 
300µM concentrations are significant compared to controls but lower than 1.88-7.5µM. 
* * 
* * 
* 
* 
* 
* 
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4.4.8.3.2 ALP activity after culture with genistein in dex media. 
 
 
Fig 4.17 ALP Umg
-1
 protein found in dex media cultured BMSC monolayers after 2, 4 
and 6 days treatment with genistein. N=3, error bars indicate SD, * significant from 
control P<0.05 
 
 
In dex medium (fig 4.17) activation of ALP was similar to the growth and beta control 
media formulations, no significant differences were detected. After Gen treatment in dex 
media there is a general trend of rising activity from controls to 300µm, increasing from 
Day 2 to Day 4. At Day 6 activation tends towards an increase with increasing 
concentration. When compared to the growth (fig 4.15) and beta (fig 4.16) media 
formulations application of gen in dex medium causes earlier ALP upregulation. 
* 
* 
* 
* 
* 
* * 
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4.4.8.3.3 ALP activity after culture with genistein in osteogenic media. 
 
 
 
 
Fig 4.18 ALP Umg
-1
 protein found in osteogenic media cultured BMSC monolayers after 
2, 4 and 6 days treatment with genistein. N=3, error bars indicate SD, * significant from 
control P<0.05 
 
 
 
 
In osteogenic medium controls (fig 4.18) there is no significance increase in ALP activity 
over the time in culture.  
After adding gen to osteogenic media formulations an increase in ALP activity is 
observed at Day 2. At Day 4 treatment with gen induces a significant increase in ALP 
activity at concentrations of gen from 1.88µM to 15µM, inversely proportional to 
concentration. By Day 6 there is a significant increase in ALP activity above controls, 
activation is higher gen concentrations from 1.88-7.5µM when compared with 
concentrations ≥15µM. 
 
* * 
* 
* * 
* 
* 
* 
* 
* 
* * 
 119 
 
4.4.8.3.4 Summary of the effect of Genistein on ALP activity. 
Comparing medium types it is apparent that those media containing dex and genistein 
have increased activity of ALP over time (figs 4.15 to 4.18), there is no difference in ALP 
activity in the vehicle controls. Genistein combined with dex increases ALP activity 
earlier when compared with media that do not contain dex. 
4.4.8.4 Total collagen observed after the addition of genistein. 
Collagen was measured using the method described in 2.2.10.4 
4.4.8.4.1 The collagen observed after culture with genistein in growth media. 
 
Fig 4.19 Staining of collagen in growth media cultured BMSC monolayers after 2, 4 and 
6 days treatment with genistein. N=8, error bars indicate SD, * is significant from control, 
† denotes significant increase from Day 2 to Day 6. P<0.05 
 
Collagen production in growth media control cultures (fig 4.19) does not significantly 
change over time. Significant difference from the controls only occurs with 30µM 
genistein at Day 6, after treatment with ≤30µM deposition increases from Day 2 to Day 
6.
† † † † 
† 
* 
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4.4.8.4.2 Quantity of collagen observed after culture with genistein in ß-
glycerophosphate media. 
 
 
 
Fig 4.20 Staining of collagen in beta media cultured BMSC monolayers after 2, 4 and 6 
days treatment with genistein. N=8, error bars indicate SD, † denotes significant increase 
from Day 2 to Day 6. P<0.05 
 
 
In beta medium controls (fig 4.20) there is a significant difference in collagen deposition 
over time, from Day 2 to Day 6. Collagen in the genistein treatments is not different from 
the controls but is higher at Day 6 after addition of between 1.88µM and 15µM. 
 
 
† † † † 
† 
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4.4.8.4.3 Quantity of collagen observed after culture with genistein in dex media. 
 
 
 
 
Fig 4.21 Staining of collagen in dex media cultured BMSC monolayers after 2, 4 and 6 
days treatment with genistein. N=8, error bars indicate SD, * is significant from control, † 
denotes significant increase from Day 2 to Day 6. P<0.05 
 
 
 
In dex containing medium (fig 4.21) the controls do increase collagen production over 
time in culture, from Day 2 to Day 6. After genistein treatment collagen is the same at 
Day 2 and 4. At Day 6 there is an increase in deposition, highest at 30 and 300µM 
genistein which are also significantly compared with controls. 
 
† † † 
† 
†  
* 
†  
* 
† 
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4.4.8.4.4 Quantity of collagen observed after culture with genistein in osteogenic 
media. 
 
 
 
Fig 4.22 Staining of collagen found in osteogenic media cultured BMSC monolayers 
after 2, 4 and 6 days treatment with genistein. N=8, error bars indicate SD, * is significant 
from control, † denotes significant increase from Day 2 to Day 6. P<0.05 
 
 
 
After growth of BMSC in osteogenic medium (fig 4.22) there is no change in the 
controls. In osteogenic media with genistein supplemented there is increased collagen 
production with increase in genistein and time. 
 
†  
* 
†  
* 
†  
* 
†  
* 
* 
†  
* *  * * * 
†  
* *  * * 
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4.4.8.5 Alizarin Red staining for the quantification of mineralisation. 
Alizarin red collates with calcium ions and is therefore more selective than Von Kossa 
stain which stains phosphates. The method used here has been developed for quantitative 
analysis of staining, a full description can be found at 2.2.10.1. 
 
4.4.8.5.1 Alizarin red staining observed after culture with genistein in growth media 
 
 
Fig 4.23 Alizarin red staining of mineralisation in growth media cultured BMSC 
monolayers after 2, 4 and 6 days treatment with genistein. N=2, error bars indicate SD, * 
is significant from control P<0.05 
 
In growth medium controls (fig 4.23) alizarin red staining of the mineralised ECM was 
the same, there was a slight increasing trend in mineralisation with time.  
In the gen treatments at Day 2 levels of mineralisation were higher than controls but 
comparable to each other. Mineralisation increased step wise at the next two time points 
in 1.88–7.5µM. Day 6 mineralisation was comparable to earlier time points at 
concentrations higher than 15µm. 
* 
* * * 
* 
* 
* 
* 
* 
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4.4.8.5.2 Alizarin red staining observed after culture with genistein in ß-
glycerophosphate media  
 
 
 
Fig 4.24 Alizarin red staining of mineralisation in beta media cultured BMSC monolayers 
after 2, 4 and 6 days treatment with genistein. N=2, error bars indicate SD, * is significant 
from control P<0.05 
 
 
In beta medium the control mineralisation (fig 4.24) of the monolayers remained similar 
throughout the experiment. In the genistein treatments a trend of increasing 
mineralisation at each time point was observed. 
*  *  *        *  *  *       *  *  *       *  *  *           *  * 
*  *  * 
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4.4.8.5.3 Alizarin red staining observed after culture with genistein in dex media  
 
 
 
Fig 4.25 Alizarin red staining of mineralisation found in dex media cultured BMSC 
monolayers after 2, 4 and 6 Days treatment with Genistein. N=2, error bars indicate SD, 
all experimental conditions are significant from controls P<0.05 
 
 
In dex medium controls (fig 4.25) levels of mineralisation were similar throughout. In the 
genistein treated cells mineralisation accumulated at each time point in all the 
concentrations studied. 
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4.4.8.5.4 Alizarin red staining observed after culture with genistein in osteogenic 
media  
 
 
 
Fig 4.26 Alizarin red staining of mineralisation in osteogenic media cultured BMSC 
monolayers after 2, 4 and 6 days treatment with genistein. N=2, error bars indicate SD, * 
is significant from control P<0.05 
 
 
In osteogenic medium controls (fig 4.26) there was a small increase in mineralisation at 
each time point. In the genistein treated cells there was a significant increase above 
controls, but no change with concentration of genistein at Day 2 and 4. By Day 6 a trend 
of increasing mineralisation with increasing genistein was apparent, ≥15µM is 
significantly higher than the control. 
*  * 
*  * 
*  * 
*  *  * 
*  * *  * 
* 
* 
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4.5. Discussion  
4.5.1 Characterisation. 
Cells were isolated for use in this chapter from bone marrow by a combination of 
methods based on the original publications of Friedenstein and Caplan, mononuclear cells 
were ficoll hypaque density gradient separated from human bone marrow and plated at 
clonal densities. This technique does not separate the cell population into categories of 
phenotypic expression, as described by the ISCT, but CFU-F selection is classically 
recognised as producing a BMSC culture (Friedenstein et al 1970, Colter et al 2001).  
Further characterisation of the cell population is important no matter the epitope 
phenotype because differentiation potential is heavily related to culturing conditions and 
population age (Kuznetsov et al. 2009). Much research in the literature uses a known 
antibody panel to define the studied population and even if the antibodies used overlap 
there are some difficulties comparing work, it may even be found subsequently that 
populations have distinct properties (Buhring et al. 2007 & 2009, Arufe et al. 2010). 
Characterisation of cells for epitope presentation may only become important once the in 
vivo niche is known and direct selection is required (Deschaseaux et al. 2003, Seeberger 
et al. 2008). 
In this study we have used only two of the most significant antibodies to characterise the 
cells, they have been previously shown to select for the whole BMSC population (STRO-
1) and extremely selectively for embryonic stem cells and recently BMSCs (SSEA-4) 
followed by self renewal of single cell clones and differentiation to three commonly used 
phenotypes (Simmons and Torok-Storb 1991, Gang et al 2007). Because of cost 
implications and the possibility of change over time in the cell population no in vivo 
testing was undertaken, this is compatible with most of the recent published literature 
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which do not undertake this step either (da Silva Meirelles et al. 2006, Roobrouck et al. 
2011). 
Therefore as well as screening the cultures for expression of the surface markers STRO-1 
and SSEA-4 two differentiation studies were under taken to improve the characterisation 
of the culture. The isolate was split at each experimental passage and differentiation to 
chondrocytes, adipocytes and osteoblasts was undertaken concurrent with further 
culturing, this characterisation of the BMSC culture is undertaken by almost all literature 
concerning “MSCs” to prove culture potential (Aicher et al 2010). It was undertaken in 
this chapter to allow analysis of culture potential at the beginning of any experimental 
methodology and therefore provides proper controls. Secondly single cell cloning was 
undertaken as an extension of this analysis of potential; single cell cloning in combination 
with analysis of differentiation potential eliminates the possibility that some of the many 
cell types that mimic BMSC in vitro are providing the culture with multipotentiality 
(Bianco et al. 2008). 
Single cell cloning was achieved using a limiting dilution technique which has long 
standing in cell biology, having first been used for the cloning of irradiated HeLa cells; 
but has not been carefully used for analysis of human BMSCs until Sarugaser et al. in 
2009; in the Sarugaser paper a comparison is made between techniques that pick single 
cell colonies (Puck et al. 1955, Sarugaser et al. 2009). For many authors the modern 
technique of cell sorting using a FACs machine is regarded as the best method to select 
single cells into individual wells; however single cell cloning by limiting dilution is more 
easily assessable (Salem and Thiemermann 2010). 
Sarugaser reports that single cell cloning at low frequency is more reliable than FACS 
cloning, using MoFlo FACS they attributed a return of nil colonies from 768 sorted cells. 
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Whereas use of a limiting dilution of 0.5 cell per well returned 17.5% viable and 8.75% 
tri-potent. However the confidence that a single cell clone is returned is only 75% when 
0.5 cells are seeded. These authors continued, seeding 0.2 cells per well resulted in 7.14% 
viable clones, and 2.92% tri-potent. The confidence that these clones are derived from a 
single cell is greater than 99.9%.  
In the work in this chapter the cells were accurately seeded at a dilution of 0.3 cells per 
well, the confidence that there will be a single cell seeded into the well at this dilution 
will be 95.54% according to Poisson distribution (Morley et al. 1983). The return of 
viable clones (Table 4.2) was 11.9%±2.7 SD and tri-potent single cell clones were found 
at a frequency of 5.3%±0.91 SD which favourably compares with the Saragaser data.  
The single cell clones (SCC) from the cultures studied here were cloned from the bulk 
culture at approximately 15 population doublings from isolation. In total testing of the 
clones required an estimated 15 population doublings, from a single cell to 3.5x10
4
. The 
total cumulative population doublings of the SCCs was analogous to the longevity of the 
bulk cultures. Unfortunately after cloning, self renewal analysis and testing pluripotency 
there is little proliferation capacity with concurrent multipotentiality left for 
experimenting and the original bulk culture must be used. 
There are many practical technical issues with the cloning of BMSCs that have much to 
do with the relatively small in vitro longevity and pluripotency that most authors report, 
Sarugaser et al. overcame this in part by using cord blood isolates (Bruder et al 1997, 
Muraglia et al 2000, Baxter et al 2004). The findings of this chapter are consistent with 
the longevity of others cultures, in that differentiation and cell growth seems dependant 
on the isolate (Table 4.1). These findings agree with other authors; this may well indicate 
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that each culture comprises of a homogeneous population of cells that is at various stages 
of age and differentiation (DiGirolamo et al. 1999). 
Clonal isolation of the BMSC population is key; clonal isolation selects those 
mononucleocytes whose growth is not contact inhibited, it is likely that any stem cell 
residing in the bone marrow stroma would be isolated by this technique (Bianco et al 
2008). A fraction of cells isolated by this technique are multipotent in vivo and 
clonogenic cells can be increased by selection with STRO-1 and MCAM (Sacchetti et al 
2007). Because only a tiny fraction of cells in these differently isolated populations are 
capable of in vivo multipotency it currently makes no difference how you select for them; 
as long as proof is provided that the culture contains single cells capable of differentiation 
to multiple phenotypes. However classical methods as described by Bianco are more 
efficient and select a larger CFU-F proportion (Bianco et al 2008). 
Because cultures of BMSC have heterogeneous capacity for self renewal and lose their 
multipotentiality over time in culture it is important to use them experimentally before the 
loss occurs. Therefore, concurrent with the single cell cloning assay and pluripotency 
testing the original heterogeneous populations were grown in large numbers, tested for 
pluripotency and ultimately used in the experiments outlined here before their usefulness 
expires. 
Therefore we know the multipotent cells used to generate the data in this chapter were 
clonally isolated from human bone marrow. These bulk cultures were themselves capable 
of pluripotent differentiation for several passages, however contained within them was a 
cell population that was capable of in vitro self renewal and differentiation to multiple 
phenotypes at a frequency of around 5% of the heterogeneous population.  
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4.5.2 Genistein mediated differentiation 
After testing the BMSC pluripotency and self renewal capability some preliminary 
genistein testing was undertaken. Conditions were replicated from Chapter 3 in order to 
observe any differences in the effects of genistein on MG63s compared with primary 
human BMSCs in this confluent model. Results from this chapter can be compared to the 
graph (fig 4.1) which shows the change in markers of osteoblast differentiation when 
BMSCs are cultured in osteogenic media.  
Overall the observations in this chapter show collagen expression does not change; while 
in media with dex at Day 4 and without dex at Day 6 ALP increases considerably. With 
genistein mineralisation is above controls and increases at all time points, indicating that 
treatment with genistein in this model compresses the differentiation process compared 
with control cultures. This effect can be seen in growth media but more significantly in a 
combination of osteogenic media and supplementation with ≤15µM genistein, indicating 
a combination effect. 
After addition of 30µM and 300µM of genistein in all media types there is a large amount 
of cell death, however there is also a high level of ALP activity and mineralisation. As 
postulated by Morris et al. (2006) this effect may be due to pathogenic mineralisation. As 
the effect of 30µM and 300µM on expression of ALP and mineralisation is similar to the 
effect of 15µM of genistein; which does not cause increased cell death when compared 
with controls, it is unlikely that pathogenic mineralisation accounts for the observations at 
that concentration. 
Heim et al (2004) isolated mononucleocytes from human bone marrow aspirates and 
cultured them in high glucose DMEM. After demonstrating bulk culture multipotency 
they experimentally cultured the BMSCs sub-confluently in osteogenic media with 
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genistein at 1µM and 10nM (Frank et al 2002, Heim et al 2004). The Heim data suggests 
that during osteogenic differentiation 1µM of genistein induces an increase in ALP 
activity 3.5 fold relative with controls, increases Cbfa-1 expression 3 fold and increases 
mineralisation at Day 15. During adipocyte differentiation 1µM genistein increases TGFb 
expression and decreases markers of adipogenesis; these observations were removed by 
addition of 5µM of Fulvestrant, ICI 182780 (Frank et al 2002, Heim et al 2004). 
Heim did not offer any selection criteria other than non-clonal adherence to tissue culture 
plastic in high glucose medium followed by characterisation of bulk differentiation 
potential. As expounded upon at length in the chapter introduction it is uncertain what 
populations of cells may adhere in this manner and culture as if BMSC. Although it 
cannot be said that the culture in the Heim paper contains similar cells the data is quite 
strikingly similar to the data presented in this chapter. Genistein at 1µM in the Heim 
paper and 1.88µM in this chapter is effective at accelerating osteogenic differentiation 
when applied in osteogenic medium.  
Liao et al (2007) report that a culture of non-clonally isolated mouse bone marrow cells 
in osteogenic medium with genistein added at 1µmol/litre increased expression of ALP 
and deposition of mineralisation compared with controls. Reported increases are lower 
than the increases reported here and controls activate in a more rapid manner than human 
BMSC. These differences could be due to the difference in initial isolation of non-
clonogenic populations or are animal specific. 
Pan et al (2005) also report applying genistein at 10nM to 10µM in osteogenic medium to 
non-clonally derived mouse marrow stromal cells resulting in a dose dependant increase 
in proliferation, ALP, Cbfa1 and mineralisation. This data compares favourably with the 
data presented in this chapter, Pan et al. report 1µM genistein application in osteogenic 
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medium at 24 hours increases proliferation by 1.8 fold, the data presented here shows 
proliferation increased by 3.33 fold at 1.88 µM genistein and 2 days. Pan reports that the 
differentiation effect can be removed using Fulvestrant at 100nM.  
Kim et al. report isolation of MSC from the Wharton's jelly (WJ-MSC) of the umbilical 
cord; they isolated an un-reported number of cells at an unknown initial seeding density. 
These cells, when cultured for 2 passages, express some commonly used markers of 
BMSCs; i.e. CD44, CD105, SH2, SH3, CD29 and CD51, whilst they do not express 
CD34, CD45, and can be differentiated into chondrocytes, osteocytes, adipocytes and 
cardiomyocytes (Kim et al. 2010).  
Using these cells Shieh et al, applied genistein at 40µM and 200µM retarding 
proliferation of the WJ-MSCs without reducing cell number at 72 hours (Shieh et al. 
2010). Both concentrations induced accumulation of cells at the G0/G1 phase together 
with a reduction in S phase cells by 48 hours. Although cell number in control cells 
appeared to increase over the time of the experiment protein levels remained constant. 
The authors attribute the effect of genistein on the reduction of intracellular Ca
+2
 they 
also provide evidence for inhibition of β-catenin signalling and postulate mediation of 
actin filament reordering that has been shown to occur in differentiating cells (Andl and 
Rustgi 2005, Lilien and Balsamo 2005).  
Although the data presented in this chapter should be based on comparable cell types the 
effect of the reported concentrations is completely different. Here 30µM is sufficient to 
induce a reduction in cell number at Day 2, whereas Shieh et al. only report cessation of 
proliferation between Day 2 and 3 with 40µM and no proliferation with 200µM. The 
reported differences in expression, proliferation and cell death could be because the cells 
used by Shieh et al are from a post-natal source; however as the isolation procedure is 
 134 
 
unknown the cells are not comparable with any other literature. The Sarugaser data 
suggested that post-natal cells have a much larger capacity for in vitro growth; this 
increased capacity may indicate why WJ-MSCs are not affected by genistein in the same 
manner as adult BMSCs (Sarugaser et al 2009).  
When compared to the MG63 data it is clear that the effect of genistein is different in the 
two models, MG63’s show a completely different proliferation response. ALP is up 
regulated at earlier time points, but to a lower degree, while the difference between media 
types is not as apparent. Collagen production is linked to genistein dose in MG63s, but 
not BMSCs, finally MG63 mineralisation is not as significant as BMSCs and occurs 
faster in the controls.  
As described, after treatment with genistein BMSCs have been observed to differentiate 
similarly to the data presented here. The MG63’s, although providing a large cell number 
to fine tune methods and characterise the confluent model, do not react to genistein in the 
same way as BMSCs. 
The bone marrow isolates characterised here are similar to much of the data available in 
the literature concerning the use of clonally derived BMSCs. Growth potential, CFU-F 
capacity, surface marker expression, single cell cloning and pluripotency are reported at 
levels that are within range of what is widely reported in the literature.  
The use of BMSCs to characterise the effect of genistein on the differentiation of a 
confluent cell model to an osteoblast phenotype is novel. At 1.88µM of genistein in 
osteogenic medium, proliferation, ALP, collagen and mineralisation increased over the 
experimental time period. This shortening of the duration of osteogenesis is not in the 
literature instead authors report that genistein arrests growth when greater than 40µM or 
reduces adipogenesis at 1µM (Frank et al 2002, Heim et al 2004).     
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It has been shown here that genistein can increase osteogenic differentiation when added 
to growth media, however when dex is also added to the media there is an additional, 
complementary effect on osteogenesis.  
The use of an antibody panel for isolation of pluripotent cells has been used by many 
authors that study BMSCs. To provide complete data analysis with large numbers of 
cells, BMSCs from Cambrex were purchased to provide a reliable cell source that has 
been clonally derived, cultured and characterised for differentiation and antibody markers 
that are well studied in the literature. A commercially available population of BMSCs 
was considered in addition to the clonally derived population because of the lack of 
surface epitope marker characterisation and the low number of repetitions in the data. 
4.6 Conclusions  
The application of <15µM genistein proved the hypothesis that genistein accelerates the 
differentiation of primary human BMSCs true; whilst >15µM was sufficient to reduce 
cell number. The observed effects of genistein in growth media were cumulative when 
combined with osteogenic media. 
Classical isolation of BMSCs produces cultures which have sub-populations that are 
pluripotent at the single cell level, the use of BMSC in a confluent differentiating model 
of osteogenesis is possible. 
Although MG63’s and primary human BMSCs both differentiate when exposed to 
genistein MG63’s react to a smaller degree with regards to cell death and activation of 
ALP.   
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CHAPTER 5 
THE USE OF CULTURED CBMSCS IN A CHARACTERISED 
CONFLUENT DIFFERENTIATING MODEL OF OSTEOGENESIS TO 
DETERMINE THE IN VITRO EFFECT OF GENISTEIN IN SEVERAL 
MEDIA. 
5.1 Introduction 
In previous chapters the effect of genistein was studied on the MG63 osteosarcoma cell 
line and classically isolated primary human multipotent BMSCs. However in the 
literature many authors use antibodies for the selection and concurrent characterisation of 
primary human bone marrow cells. In order to provide comparable and reproducible data 
a commercial BMSC source was purchased so that observations could be made using 
cells isolated by identical methods and available to all researchers. The effect of genistein 
was compared between the initial data from classically isolated and characterised primary 
human BMSC and antibody characterised BMSCs to find any differences between the 
two isolates and to increase repetition and confidence in the data.  
Commercial BMSCs (cBMSC) were purchased from Lonza. Lonza sell cBMSCs under 
licence from, and produced by Osiris Therapeutics, the production of cBMSCs is covered 
by several US Patents (US 5,486,359). Each cell isolate is taken from healthy individuals 
between 18 and 30 years of age and is extensively screened and tested using FDA 
approved tests. Prior to harvest, donors are screened for transmittable diseases, the 
medical and social history of each donor is obtained to find any signs, symptoms or 
behaviours that are consistent with a high risk of disease. The health of the donor is then 
monitored for up to five years after donation to further ensure his/her health status.  
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Because of this donor analysis the ethical, health and practical concerns that hamper the 
development of other stem cell treatments are avoided (Hanson 2001). This also provides 
researchers with a bone marrow derived cell product that is as normal as possible, without 
a transmittable disease phenotype or harvesting bias.  
Currently Osiris Therapeutics has Phase 3 clinical trials underway using BMSCs under 
the trademark “Prochymal”. The trials are evaluating cBMSCs use for the treatment of 
several diseases including acute graft versus host disease (GvHD) and Crohn's disease. 
Each donation of bone marrow provides 10,000 cryovials each containing 7.5x10
5
 cells, 
this equates to 7.5x10
9
 cells in total. This large cell number from each donor can only be 
explained if the cells undergo a selection and culture period prior to sale. 
In the past several important BMSC researchers have worked at Osiris Therapeutics, 
including, Jaiswal, Pittenger and Bruder, co-authors on several seminal papers with 
Haynesworth and Caplan, founders of Osiris Therapeutics. Caplan is often quoted as the 
originator of the term Mesenchymal Stem Cell (Kuznetsov et al. 2009). Osiris 
Therapeutics state in patents and FDA licences that the technique that they use to isolate 
the cBMSC is based on the 1999 Pittenger paper (Pittenger et al. 1999).  
The Pittenger paper used density gradient mononuclear cell selection criteria followed by 
initial seeding at a density of 2x10
5
 cells cm
-2
 and culturing in DMEM with 10% FCS for 
several passages. Flow cytometry was used after several passages to analyse the cells, 
which were also capable of differentiation to chondrocytes, adipocytes and osteoblasts. 
Over 50 available antibodies were used in the characterisation of the cells after some 
culture time, a selection panel was developed and the cultures were quality controlled 
based on this phenotype (Pittenger et al. 1999).  
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Pittenger reports no spontaneous differentiation, but it is not clear from this statement if 
they include a spontaneous loss of differentiation potential. Such a loss would only occur 
by differentiation, although not to a defined terminal lineage. To test for individual cell 
potential Pittenger et al used a colony forming cloning assay from isolation and colony 
picking to select single cell clones. Clonal isolation of BMSCs is still the gold standard 
isolation technique. However the colony picking method has since been disproved as a 
single cell selection method because the mobility in culture of BMSC is large and multi-
cell clones have been demonstrated from colonies picked in the manner described by 
Pittenger (Kobayashi et al. 2005).  
The colony picking method is still in use in most of the literature. They do report that 
single cell clones picked in this manner have exactly the same antibody phenotype as the 
bulk culture, but that not all are capable of tri-lineage differentiation. Therefore cBMSCs 
have the same in vitro challenges that are apparent of cells in the literature and the 
isolates from chapter 4.  
In Chapter 4 the terminology used in the literature was outlined in depth, the term 
mesenchymal stem cell utilised by Caplan and Osiris therapeutics is now an outdated 
descriptor. Pluripotent cells from the bone marrow have not yet been proved to be 
capable of in vivo differentiation to all tissues of the mesenchyme, therefore use of 
mesenchymal is not valid. Although there might be a small population of single cells 
within the bone marrow that demonstrate in vitro/in vivo pluripotency the whole 
population cannot be described as stem cells.  
Therefore the use of the term MSC to describe this whole population is wrong. Since the 
isolated cells are from the bone marrow stroma the use of the term bone marrow stromal 
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cell (BMSC) is more descriptive and maintains the MSC acronym. So although the cells 
are sold as mesenchymal stem cells, here they are re-named cBMSC. 
For an example of why the use of this nomenclature is important we can say that some of 
the mononucleocytes from the bone marrow can be isolated clonally (BMSC), from these 
BMSC cultures a small population (~5-10%) can be observed to clonally tri-lineage 
differentiate in vitro (multipotent BMSCs). A small number (~10%) of the clonally 
isolated BMSCs are also capable of in vivo differentiation to multiple lineages (stem 
cells). Both the multipotent BMSC sub-population and the stem cell sub-population 
overlap, however not all multipotent BMSCs are stem cells (Pittenger et al 1999, Bianco 
et al 2006 & 2007).  
The often quoted clonal frequency of 1-50 in 10
5
 bone marrow mononucleocytes which 
are capable of forming a BMSC culture is not the fraction of the culture which is true 
stem cells. Very few studies of properly cloned multipotent BMSC cultures have been 
placed into in vivo models to determine the overlap between single cell clones and in vivo 
tri-potent clones (Bianco et al 2006, Sarugaser et al. 2009). Although the nomenclature is 
correct in the outline above, the proportions of the cultures that are in vitro and in vivo 
multipotent may fluctuate according the methodologies used and the individual isolates.  
To confirm observations of the effect of genistein on human primary BMSCs commercial 
cells were obtained that are available to all researchers, isolated in a standardised manner, 
characterised in a way that predominates in the literature and is approved by the ISCT, 
are disease free and have no harvesting bias. These cells were used to confirm the 
osteogenic effects of genistein in a manner that is achievable by all researchers. 
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5.2. Hypothesis 
The previously observed effects of genistein are the same with more replicates and 
therefore greater statistically certainty in a disease and harvesting bias free BMSC model.  
5.2.1 Aim 
Further to the previous chapters there was a need to investigate the multiple effects of 
genistein on a primary human BMSC strain with more statistical certainty. The cBMSC 
strain was purchased in order to improve the statistical certainty of the data and to 
compare this characterisation method with the classical method. The osteogenic effect of 
genistein on the proliferation, differentiation and mortality of cMBSCs will be observed.  
5.3 Experimental procedure 
The experimental methods for determination of effects of genistein are described in full at 
2.2.13. In brief; the BMSCs were seeded at confluent density and left to attach. The 
medium was replaced with experimental media containing genistein, harvesting occurred 
after Days 2, 4 and 6 of culturing. Methods are described in full at 2.2.10.  
5.4 Results 
5.4.1 T0 samples and confirmation of cell attachment. 
Light microscopy confirmed that the cells were attached and confluent before the 
attachment medium was exchanged for experimental media. At this time point (T0) 
samples were also taken which was essential to quantify some of the results and to ensure 
that the cells remain in a non-differentiated state at the start of the experiment. 
5.4.2 LDH measurement of cell number. 
An LDH standard curve was produced from known cell numbers and used to attribute the 
activity of the cellular LDH to cell number. Unknown samples were lysed and the LDH 
activity was used as a measure of the total cell number present in the lysis suspension.
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5.4.2.1 LDH derived cell number after culture in growth media.  
 
 
Fig 5.1 The cell number present in the total monolayer, derived from the LDH content 
after 0, 2, 4 and 6 days culture with genistein in growth medium. n=6, error bars are SD. 
* indicates the value is significant when compared with the control P<0.05. 
 
 
cBMSC were cultured at confluent density in growth media (fig 5.1) for 6 days, in the 
control cultures the cell number increased from Day 0 to Day 2 and fell afterwards. A 
significant increase in cell number occurred at Day 2 after culture with genistein at 1.88 
and 3.75µM when compared with controls. At Day 4 cell number reduced in all 
treatments but were significantly higher than controls in 1.88 and 7.5µM, at 300µM cell 
number was significantly lower than controls. All genistein treatments were significant at 
Day 6, 1.88-15µM higher than the control and 30-300µM lower.
* * *        *     *           * *              *              *        * * * 
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5.4.2.2 LDH derived cell number after culture in beta-glycerophosphate media. 
 
 
Fig 5.2 The cell number present in the total monolayer, derived from the LDH content 
after 0, 2, 4 and 6 days culture with genistein in beta medium. n=6, error bars are SD. * 
indicates the value is significant when compared with the control (P<0.05). 
 
 
After culture in beta medium (fig 5.2) control cBMSCs increased in number from Day 0 
to Day 2, after Day 2 LDH derived cell number reduced. At Day 2 in the genistein 
treatment media cell number increased from 1.88 to 15µM, significantly at 7.5 and 
15µM, while decreasing significantly at 30 and 300µM. 
On Day 4 cell number was significantly greater at lower genistein <15µM and lower at 
30 and 300µM. By Day 6 only 30 and 300µM were significantly different from controls. 
    *              * *   *           *    *         * * * 
*  
*  
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5.4.2.3 LDH derived cell number after culture in dex media. 
 
 
Fig 5.3 The cell number present in the total monolayer, derived from the LDH content 
after 0, 2, 4 and 6 days culture with genistein in dex medium. n=6, error bars are SD. * 
indicates the value is significant when compared with the control (P<0.05). 
 
 
After control cBMSCs were treated with dex medium (fig 5.3) LDH derived cell number 
did not significantly differ. When genistein was added to dex media at concentrations 
between 1.88 and 30µM LDH derived cell number was significantly greater at Days 2 
and 4. After addition of 300µM cell number was reduced compared with controls over 
the same period. At Day 6 cell number was not different from the controls. 
*  *  
 * *           * *          * *           * * 
* *  
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5.4.2.4 LDH derived cell number after culture in osteogenic media. 
 
Fig 5.4 The cell number present in the total monolayer, derived from the LDH content 
after 0, 2, 4 and 6 days culture with genistein in osteogenic medium. n=6, error bars are 
SD. * indicates the value is significant when compared with the control (P<0.05). 
Control cultures in osteogenic medium (fig 5.4) were not significantly different. When 
genistein was added to osteogenic media between 1.88 and 30µM cell number was 
significantly greater at Days 2 and 4. After addition of 300µM a reduction was apparent 
when compared with controls. 
5.4.2.5 LDH derived cell number summary. 
General trends across all media types are apparent; in control cultures there is some 
proliferation of the cultures, increasing on average 3x10
3
 (±8.35x10
2
) from seeded. The 
increased cell number is not maintained, by Day 6 cell number returns to the seeded 
density. After genistein treatments from 1.88–15µM, cell number is largely increased in 
dex and osteogenic media, in growth and beta media cell number increases but the 
proliferation is not as large. Cell number is reduced after culture with genistein at 30 and 
300µM in all media.
*  *          * *         *  *         *  * 
*  *  
*  *  
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5.4.3 Summary of cell counts and live/dead measurements.  
The method used to determine the live dead proportion was described at 2.1.11.6. In 
order to measure the total number of cells at each time point as well as differentiate 
between living and dead a HPI live/dead cell count was used. 
 
Fig 5.5 Average Hoechst stained cell counts of the monolayer after genistein treatment in 
media at Day 6. N=6. Error bars equate to SD. * indicates significant when compared 
with relevant control, † indicates significant difference when compared with growth 
media (P<0.05). 
 
 
Total cell numbers and live/dead HPI stains enhance our understanding of the balance 
between toxicity and proliferation as well as providing confirmation of the LDH data. 
The graph of direct live cell counts (fig 5.5) confirms the LDH data. When genistein is 
added to dex and osteogenic media cell number increases significantly at <15µM and 
decreases significantly at 30 and 300µM. This data is in concurrence with the information 
from the LDH assay. 
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5.4.4 Summary of Brd-U Incorporation into replicating DNA. 
Using the method described in 2.2.10.5.2 the incorporation of BrdU into replicating DNA 
was measured.  
 
 
Fig 5.6 Incorporation of BrdU into cBMSCs after treatment with genistein for 6 days. 
The error bars represent the standard deviation, n=24. * indicates significant when 
compared with relevant control P<0.05. 
 
 
The representative data measured by BrdU incorporation (Fig 5.6) into cBMSCs at Day 6 
after culture in the four media shows no significant difference between controls. After 
treatment with genistein from 1.88µM to 15µM there was a significant increase relative 
to the controls while 300µM was observed to have significantly less proliferation. After 
treatment with 1.88 and 3.75µM genistein dex and osteogenic media proliferated 
significantly more than GM and beta, while after 15µM GM was greater than dex and 
osteo, at 30 and 300µM both GM and beta were  significant when compared with dex and 
osteo (P<0.05).
*    * * 
    *             * 
* 
* 
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5.4.5 LDH in the supernatant as a measurement of cell death. 
The method used were as described by the manufacturer and can be found in full at 
2.2.10.5.1. The amount of LDH available in the monolayer combined with the 
supernatant LDH was used as a measure of total LDH. The LDH available in the 
supernatant was directly compared with the total LDH. Therefore a relative LDH value 
approaching 100% indicates a small number of monolayer cells combined with a large 
release of LDH into the supernatant. 
5.4.5.1 Supernatant LDH after culture in growth media. 
 
Fig 5.7 Supernatant LDH as a proportion of total LDH after cBMSCs were cultured with 
genistein in growth media for 2, 4 and 6 days. n=24, error bars represent SD. * indicates 
significance compared with control (P<0.05). 
In the growth media controls (fig 5.7) the relative LDH release is not significantly 
different indicating that over the experiment there is low cell death relative to total live 
cells in the monolayer. In the genistein treatments at Day 2 only 1.88 and 3.75µM are not 
significantly greater than controls. At Day 4 and 6 all genistein concentrations induced 
increased LDH release when compared with the control. 
*               *              *              * 
*               *              *              *               * 
*              *              *              *              *           *  * 
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5.4.5.2 Supernatant LDH after culture in beta-glycerophosphate media. 
 
  
Fig 5.8 Supernatant LDH as a proportion of total LDH after cBMSCs were cultured with 
genistein in beta media for 2, 4 and 6 days. n=24, error bars represent SD. * indicates 
significance compared with control. (P<0.05). 
 
 
In beta medium controls (fig 5.8) LDH release is not significantly different from Day 2 to 
4 but drops at Day 6. After culture for 2 days in beta media containing genistein from 
1.88µM to 15µM cell death was not different from controls, at 30µM and 300µM cell 
death was significantly higher than controls. At Day 4 and 6 cell death was significantly 
greater than controls in all the treatments. There was a trend of increasing cell death with 
time and concentration.  
 
 
*               *              *              *                
*              *               *              *              *          * 
* 
*          *  * 
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5.4.5.3 Supernatant LDH after culture in dex media. 
 
  
Fig 5.9 Supernatant LDH as a proportion of total LDH after cBMSCs were cultured with 
genistein in dex media for 2, 4 and 6 days. n=24, error bars represent SD. * indicates 
significance compared with control (P<0.05). 
 
 
After culture with dex medium (fig 5.9) controls were similar to growth and beta-
glycerophosphate media at Day 2, at Day 4 and 6 relative LDH release was significantly 
lower. At Day 2 culture in dex media supplemented with genistein concentrations 1.88–
30µM were significantly lower than controls. At Day 4 30 and 300µM were significantly 
higher than controls. By Day 6 all concentrations of gen cause increased relative LDH 
release. The observable trend was that at early time points relative LDH release was 
reduced when genistein was added, however LDH release increases with both time in 
culture and concentration of genistein. 
 
*              *              *              *              *            
     *          * 
*              *              *              *                       
* 
* 
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5.4.5.4 Supernatant LDH after culture in osteogenic media. 
 
Fig 5.10 Supernatant LDH as a proportion of total LDH after cBMSCs were cultured with 
genistein in osteogenic media for 2, 4 and 6 days. n=24, error bars represent SD. * 
indicates significance compared with control (P<0.05). 
Osteogenic medium controls (fig 5.10) do not release large quantities of LDH when 
compared to the other medium types, over time in culture the controls do not change 
significantly. After culture in osteogenic media supplemented with genistein a trend of 
increasing relative LDH release with time and increasing concentration of genistein was 
observable. At Day 2 all treatments have significantly more relative release than controls, 
by Day 4 concentrations greater than 3.75µM are significantly higher than controls. At 
Day 6 all treatments are significantly higher than controls.  
5.4.5.5 Summary of relative LDH release. 
Control LDH release was lower in the dex containing media. Generally across all media 
the relative release of LDH was lower at ≤15µM. By Day 6 all treatments were 
significantly greater than the controls and increased with time in culture.
* 
*              *               *  *          *  * 
*  * 
*              *              *              *              *           *   
* 
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5.4.6 Measurements of ATP availability.  
The method used was as described by the manufacturer and is explained at 2.2.10.6. The 
availability of ATP is indicative of the metabolic state of the cell, it is well established 
that the level of intracellular ATP determines cell fate; ATP depletion is a manifestation 
of type III programmed cell death (Tsujimoto 1997, Nicotera and Leist 1997, Orrenius et 
al 1997). It is possible to see very early effects of a compound on cells by analysis of the 
levels of ATP (Talha and Harel 1985, Jeong and Seol 2008). 
5.4.6.1 ATP after culture with genistein in growth media  
 
Fig 5.11. ATP available after cBMSCs were cultured with genistein in growth media for 
2 and 72 hours. Control n=24/48 and experimental n=14, error bars represent SD. * 
indicates significance compared with control. † indicates significantly larger than the 
alternative time point (P<0.05). 
In growth media supplemented with genistein (fig 5.11) up to 7.5µM there was a 
significant increase after 2 hours in the availability of ATP compared with controls. After 
culture with 15µM to 300µM genistein there is significantly less ATP available compared 
with the controls. After 72 hours incubation with ATP the controls are significantly lower 
than 2 hours although the means are the same, this effect is due to the larger value of n at 
*              *              * 
†              †              † 
*   * 
†  
† 
*   * 
†  
*   * 
†  
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72 hours (48 vs 24). There are no differences between the control and 1.88µM to 7.5µM; 
from 15µM to 300µM ATP is significantly lower than the control.  
5.4.6.2 ATP after culture with genistein in beta-glycerophosphate media. 
 
Fig 5.12. ATP available after cBMSCs were cultured with genistein in beta media for 2 
and 72 hours. Control n=24/48 and experimental n=14, error bars represent SD. * 
indicates significance compared with control. † indicates significantly larger than the 
alternative time point (P<0.05). 
 
In beta media (fig 5.12) containing genistein after 2 hours there are clear similarities to 
growth media, significantly higher ATP is found at concentrations from 1.88µM to 
7.5µM, whereas higher concentrations are significantly lower than controls. Although 
there is lower available ATP in controls after 72 hours in treatments there is a dose 
response similar to 2 hours; after treatment with 15µM to 300µM ATP is significantly 
lower. After 72 hours culture with 300µM ATP cannot be differentiated from the blanks 
and is therefore depleted.  
*               *              * 
†               †              † 
†  *   * 
†  
*   * 
†  
*   * 
†  
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5.4.6.3 ATP after culture with genistein in dex media 
 
  
Fig 5.13. ATP available after cBMSCs were cultured with genistein in dex media for 2 
and 72 hours. Control n=24/48 and experimental n=14, error bars represent SD. * 
indicates significance compared with control. † indicates significantly larger than the 
alternative time point. (P<0.05). 
 
 
cBMSCs cultured in dex medium (fig 5.13) showed a decrease in the control levels of 
ATP from 2 hours to 72 hours. Compared to growth media there was an increase in the 
level of ATP in cBMSCs when grown in dex media.  
Similar to the two previous treatment regimen (fig 5.11 and 5.12) there was a decrease in 
the level of ATP at ≥15µm, 300µM was significantly lower than the next lowest. By 72 
hours treatments contained less ATP overall but the dose response curve was very similar 
to observations at 2 hours, no significant differences were observed between 1.88 and 
7.5µM and the control. After 72 hours culture with 300µM genistein ATP levels were 
indistinguishable from background. 
 
*   * 
†  *   * 
†  
*   * 
†  
*               *              * 
†               †              † 
†  
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5.4.6.4 ATP after culture with genistein in osteogenic media.  
 
 
Fig 5.14. ATP available after cBMSCs were cultured with genistein in osteogenic media 
for 2 and 72 hours. Control n=24/48 and experimental n=14, error bars represent SD. * 
indicates significance compared with control. † indicates significantly larger than the 
alternative time point (P<0.05). 
After 2 hours culturing in osteogenic media (fig 5.14) ATP levels in the control were 
greater than in growth media alone. Similarly the combination of osteogenic media and 
genistein has a cumulative effect on ATP levels at 2 hours. After culture with 1.88µM to 
7.5µM genistein ATP is significantly greater than the control, 30µM and 300µM are 
significantly lower. After 72 hours the application of 30 and 300µM significantly reduced 
ATP when compared with controls. In osteogenic media application of 300µM genistein 
results in near depletion of ATP at 72 hours.  
5.4.6.5 Summary of ATP availability in all media.  
In all tested media 1.88µM-7.5µM of genistein significantly increases ATP at 2 hours and 
is the same as the controls at 72 hours. Concentrations greater than 15µM significantly 
reduce ATP in all tests, after culture with 300µM ATP is either depleted or near depletion 
at 72 hours.
*              *              * 
†               †              † 
*   * 
†  
*   * 
†  
† 
† 
 155 
 
5.4.7 ALP activity as an early measurement of differentiation 
Alkaline phosphatase (ALP) is an early marker of osteoblast differentiation; 
measurements were made using the methods described at 2.2.10.2 
 
5.4.7.1 ALP activity after genistein treatment in growth media 
 
Fig 5.15. ALP activity after cBMSCs were cultured with genistein in growth media for 2, 
4 and 6 days. n=6, error bars represent SD. Θ indicates not significant compared with 
control, all other data is significant when compared with the relevant control. † indicates 
significance compared with the previous time point. (P<0.05). 
 
 
After culture in growth medium (fig 5.15) controls show increased expression of ALP 
from Day 2 to 4 and no significant change thereafter. All the genistein supplemented 
media at Day 2 and 4 induced a significant increase in the activity of ALP. At Day 6 all 
concentrations except 300µM were significantly greater than the control. 
Peak ALP was observed in the mid range (3.75-15µM) of the concentrations tested. 
 
Θ 
† † 
† 
† 
†   † 
† † 
†   † 
† 
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5.4.7.2 ALP activity after genistein treatment in beta-glycerophosphate media 
 
 
Fig 5.16. ALP activity after cBMSCs were cultured with genistein in beta media for 2, 4 
and 6 days. n=6, error bars represent SD. all experimental data is significant. † indicates 
significance compared with the previous time point. (P<0.05). 
 
In beta medium controls (fig 5.16) ALP activity increased significantly over time from 
Day 2 to 4 and was not significantly different from Day 4 to 6. After supplementing beta-
glycerophosphate medium with genistein there was a significant increase in activity of 
ALP at all concentrations and time points. 
At Day 2 and 4 ALP activity was very similar at all genistein concentrations. By Day 6 
3.75µM was most highly activated, generally activity reduced with increase in genistein 
>3.75µM. 
† 
†    † 
† 
† 
† 
† 
† 
† 
† † 
† 
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5.4.7.3 ALP activity after genistein treatment in dex media 
 
 
Fig 5.17. ALP activity after cBMSCs were cultured with genistein in dex media for 2, 4 
and 6 days. n=6, error bars represent SD. Θ indicates not significant compared with 
control, all other data is significant. † indicates significance compared with the previous 
time point (P<0.05). 
 
 
After culture in dex medium the controls (fig 5.17) show an increase in ALP activity over 
time; dex media alone increases the activity of ALP over time when compared to growth 
media. When dex media is supplemented with genistein only 300µM at Day 6 is not 
significant when compared with the controls. There is a stepwise increase with time in 
culture after addition of genistein from 1.88 to 30µM.  
 
Θ
† 
 
†   † 
† 
† 
† 
† 
† 
† 
† 
† 
† 
† 
† 
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5.4.7.4 ALP activity after genistein treatment in osteogenic media 
 
 
 
Fig 5.18. ALP activity after cBMSCs were cultured with genistein in osteogenic media 
for 2, 4 and 6 days. n=6, error bars represent SD. Θ indicates not significant compared 
with control, all other data is significant. † indicates significance compared with the 
previous time point. (P<0.05). 
 
 
In osteogenic medium controls (fig 5.18) there is increasing ALP with time in culture, 
significant increases occur at each time point.  
When compared with the controls ALP is significantly increased at all time points after 
culture with genistein concentrations between 1.88µM and 30µM. The addition of 
1.88µM initiates peak activation of ALP, reducing with increasing concentration, while 
concurrently increasing with time.  
300µM of genistein increases ALP significantly at Day 2, however at Day 4 there is no 
difference from the control, at Day 6 there is a significant reduction in activation when 
compared to the control. 
Θ 
 † 
 
† 
† 
† 
† 
† 
† 
† 
† 
† 
† 
† † 
 159 
 
5.4.7.5 Summary of ALP activity after genistein treatment. 
Genistein at concentrations 1.88–30µM induce an increase in ALP activity at all time 
points and in all media. Activation of ALP by genistein in growth and beta media is about 
halved from the dex containing media.  
5.4.8 Collagen production after culture with genistein containing media. 
Collagen deposition is a marker of osteogenesis. An increase in production of collagen is 
directly attributable to an increase in osteogenic phenotype when studied in conjunction 
with differentiation markers and mineralisation data. The method to determine collagen 
production is described in full at 2.2.10.4. 
5.4.8.1 Collagen production after culture with genistein in growth media. 
 
Fig 5.19. collagen deposition after cBMSCs were cultured with genistein in growth media 
for 2, 4 and 6 days. n=24, error bars represent SD. * indicates significance compared with 
control (P<0.05). 
In growth media collagen controls (fig 5.19) increase from Day 4 to Day 6. In the 
genistein treatments at Day 2 1.88-30µM are significantly lower than controls. At Day 4 
all are significantly greater than controls. At Day 6 cultures 3.75 to 30µM are 
significantly lower than the control. 
*   *               *   *  *           *  *   *          *   *   *          *  *  *          *   *   * 
 160 
 
5.4.8.2 Collagen after culture with genistein in beta-glycerophosphate media. 
 
 
Fig 5.20. Collagen deposition after cBMSCs were cultured with genistein in beta media 
for 2, 4 and 6 days. n=24, error bars represent SD. * indicates significance compared with 
control (P<0.05). 
 
 
After culture with beta medium (fig 5.20) there is an increase in collagen production over 
the experiment, significant from Day 2 to 4 and from 4 to 6. Compared with controls after 
2 days culture with the addition of genistein at concentrations of 1.88 and 7.5-30µM there 
is a significant reduction in collagen. At Day 4 only 30-300µM induced a significant 
increase in collagen. On Day 6 none of the genistein concentrations were different from 
the control. 
*      *              *      *              *               *     * 
* 
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5.4.8.3 Collagen production after culture with genistein in dex media. 
 
Fig 5.21. collagen deposition after cBMSCs were cultured with genistein in dex media for 
2, 4 and 6 days. n=24, error bars represent SD. * indicates significance compared with 
control (P<0.05). 
 
 
After culture with dex medium (fig 5.21) there is a significant increase in collagen 
production over the experiment, from Day 2 to Day 6. After 2 days culture with the 
addition of genistein at 3.75µM there is a significant reduction in collagen, while and 
300µM induces a significant increase. At Day 4 all genistein induced a significant 
increase in collagen. On Day 6 only 3.75 and 7.5µM were not greater than the controls.
  * *       *  *              *              *  *          *  *       *  *  * 
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5.4.8.4 Collagen production after culture with genistein in osteogenic media. 
 
Fig 5.22. collagen deposition after cBMSCs were cultured with genistein in osteogenic 
media for 2, 4 and 6 days. n=24, error bars represent SD. * indicates significance 
compared with control. (P<0.05). 
 
The osteogenic medium control cultures (fig 5.22) significantly increased collagen 
production at each time point of the experiment. At Day 2 after culture in osteogenic 
media with 1.88µM and 3.75µM genistein a significant reduction in collagen was 
observed when compared with the control. At Day 4 all concentrations of genistein 
induced collagen production that was significantly higher than the control. At Day 6 all 
treatments induced a further increase in collagen, only 30µM was not significantly higher 
than the control.  
 
5.4.8.5 Summary of collagen production after culture with genistein. 
General observations of all media indicate that genistein induces an increase in collagen 
over time. In dex containing media supplemented with genistein collagen was deposited 
in greater quantities than the controls.   
* 
*        *  *              *               *  *          *  *        * *  * 
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5.4.9 Quantitative alizarin red staining of mineralisation. 
Mineralisation of the ECM was determined using the method described at 2.2.10.1  
5.4.9.1 ARS after culture with genistein in growth media. 
 
Fig 5.23. Alizarin red staining of calcium after cBMSCs were cultured with genistein in 
growth media for 0, 2, 4 and 6 days. n=6, error bars represent SD. * indicates no 
significance compared with control, all other points are significantly lower than controls. 
(P<0.05). 
 
 
In growth medium control cultures (Fig 5.23) increase stained monolayer calcium over 
time in culture. In genistein supplemented media almost all treatments and time points 
were significantly less than the controls, only 15µM at Day 6 was not different from the 
control mineralisation. 
* 
 164 
 
5.4.9.2 ARS after culture with genistein in beta-glycerophosphate media 
 
 
Fig 5.24. Alizarin red staining of calcium after cBMSCs were cultured with genistein in 
beta media for 0, 2, 4 and 6 days. n=6, error bars represent SD. * indicates significance 
compared with control (P<0.05). 
 
 
In beta medium control cultures (Fig 5.24) mineralisation accumulated over time in 
culture. When genistein is added to the media there is no difference from controls at Day 
2. After culture with genistein at 30 and 300µM at Day 4 mineralisation is significantly 
lower than controls. 
At Day 6 after treatment with 1.88, 7.5 and 15µM of genistein mineralisation is lower 
than the control. 30 and 300µM induce significantly increased mineralisation at Day 6 
when compared with the control. 
*                             *              *           *  *         * 
* 
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5.4.9.3 ARS after culture with genistein in dex media 
 
 
Fig 5.25. Alizarin red staining of calcium after cBMSCs were cultured with genistein in 
dex media for 0, 2, 4 and 6 days. n=6, error bars represent SD. * indicates significance 
compared with control (P<0.05). 
 
 
In dex medium control cultures (fig 5.25) there is an accumulation of mineralisation over 
time in culture. When genistein is added to dex media at Day 2 there is significantly more 
mineralisation from 7.5-30µM. At Day 4 only 15µM is significant. By Day 6 all 
concentrations of genistein induce increased mineralisation compared with controls. 
  *                        *               *             *     * 
*               *           * *                              * 
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5.4.9.4 ARS after culture with genistein in osteogenic media 
 
 
Fig 5.26. Alizarin red staining of calcium after cBMSCs were cultured with genistein in 
osteogenic media for 0, 2, 4 and 6 days. n=6, error bars represent SD. * indicates 
significance compared with control. (P<0.05). 
 
In osteogenic medium control cultures (fig 5.26) there is a relatively small amount of 
mineralisation, increasing over time in culture. In the genistein treated cultures 
mineralisation is significantly greater than controls at 30µM at all time points, at Day 2 
and 4 all other genistein is not significantly different from controls  
At Day 6 genistein from 3.75-300µM induces a significant increase in mineralisation. 
 
5.4.9.5. ARS summary. 
After treatment with genistein, at Day 2 and 4, mineralisation was mostly either lower or 
the same as controls. At Day 6 in all media other than growth medium there was a 
significant increase in mineralisation, largest at 30 and 300µM of genistein.  
 * * 
*               *              *  
* 
* 
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5.5 Discussion 
Previous chapters have shown that genistein is able to stimulate the differentiation of an 
osteoblast phenotype in both immortalised cell lines and primary cultures of human 
BMSC. This chapter more fully investigates the proliferative, toxicity and differentiation 
effects on primary BMSC when genistein is supplemented into both osteogenic and non-
osteogenic media.  
For this section of the work cBMSC were purchased from Cambrex for several reasons; 
firstly the cells we all derived from healthy donors and were therefore free of disease 
phenotypes. The primary cells used in previous chapters were from donated tissues 
remaining from surgical procedures, which have an unknown status for disease 
phenotype and an inherent harvesting bias; as they were discarded from elective surgical 
procedures. 
Secondly, a purchased cell source has no limitations of supply and work was not halted 
because of lack of cells. Thirdly, the cells were characterised for standardised surface 
epitopes and therefore the cells used in these studies are directly comparable to the work 
of other groups who also use cells purchased from this supplier or whose cells are 
similarly screened for these markers.  
Compliance with these points can also be obtained by the use of cell lines such as SAOS2 
and MG63's, however as shown in previous chapters these cell lines do not have a 
primary phenotype or produce a response contemporaneous with primary cells.  
5.5.1 Proliferation and cell death 
As the effect of genistein on cell toxicity was an aim of this chapter the immediate effect 
of genistein on the cell was considered, it is known that the level of available ATP in a 
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cell is an indicator of whether a cell initiates cell death and is used extensively as a 
measurement of cellular activity and vitality (Tsujimoto 1997, Mueller et al 2004). It is 
possible to directly measure the change in levels of available ATP very quickly after 
addition of the isoflavone, attributing the addition of genistein with a measurable and 
persistent outcome independent of metabolites (Talha and Harel 1985, Mueller et al. 
2004). An ATP assay differs from many other commonly used cytotoxicity assays as 
ATP is used by the cell rapidly and requires functional mitochondria to maintain 
(Orrenius et al. 1997, Nicotera and Leist 1997). For example, the MTT assay is based on 
the production of NADH by the mitochondrial enzyme succinate dehydrogenase and can 
show viable cells even after mitochondrial activity is poisoned (Loveland et al. 1992). 
The LDH assay uses the same chemistry for an indirect measurement of NADH 
production by lactate dehydrogenase (Mueller et al 2004).  
A clear relationship between dose and ATP availability can been seen in the figures at 
5.4.6 indicating that there is an immediate effect of application of isoflavone on the 
availability of ATP, at low doses there is an increase in the level of available ATP 
dropping below control levels at high doses. At the longest time point and the highest 
dose there is very little detectable ATP, a correlation between low ATP and cell death is 
apparent in the literature where authors report that apoptotic and necrotic cell death 
maybe in part regulated by ATP availability (Stefanelli et al 1997, Tsujimoto 1997, Jeong 
and Seol 2008).  
Genistein induced apoptosis has been often reported in the literature as a cellular response 
to treatment with the isoflavone (Li 1999). Many of the papers published that examine the 
apoptotic or enzyme inhibition effects of genistein do so at non-physiological levels 
which are thought to achieve 10µM at the very most. It is also debatable that these 
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experiments always use the correct cytotoxicity testing to quantify cell death, 
komissarova (2005) suggests that ending experiments after a short interval (less than 48 
hours) can lead to an underestimation of cell death and utilises a long term clonal cell 
proliferation assay to better quantify the level of toxicity (Komissarova et al 2005).  
In order to better observe the cell death and proliferation occurring during our 
experiments further measurements were made by both imaging the cells in vitro and 
quantifying the amount of cell death by total cell counts. The results in figs 5.1-5.10 show 
that low concentrations of genistein stimulate proliferation of BMSCs even when they are 
confluent, only high concentration of genistein result in a net loss of cells when compared 
to controls. 
When we studied the total cell counts and phase micrographs alongside the HPI data it 
establishes that there is a net cell increase at low genistein (<15µM) and decrease at high 
doses (>30µM) of genistein. Viewing the monolayers it is apparent that there are 
morphological differences between the control cells and the treated cells. Control cells 
appear contact inhibited, spindle shaped and fibroblastic. In growth media the phenotype 
in the genistein treated cBMSCs changes to stacking at confluence rather than the contact 
inhibited growth seen in the controls. In osteogenic media the treated cell morphology 
becomes square and osteoblast like by Day 4. 
The use of the HPI stain provides us with cell numbers from the initial seeding and final 
time points, live and dead counts of the monolayer together with the remaining cell 
number. Therefore this membrane integrity test is often used as an indication of cell 
viability. However cells often have leaky membranes and are still able to produce 
progeny therefore the data should not be taken on its own to indicate viability (Belloc et 
al 1994).  
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Therefore an assessment of proliferation was undertaken by analysis of the incorporation 
of BrdU into copying DNA. Fig 5.6 shows that the rate of proliferation in the lower 
concentrations of genistein was significantly higher than controls, only at 300µm of 
genistein was proliferation significantly lower than the control. 
In the literature there is discussion about the effect of genistein on the proliferation and 
cell fate of many cell types, much of this discussion is centred on tumour cell types, due 
to the SERM nature of phytoestrogens. There is evidence to suggest that in breast tumour 
cell lines expressing the marker Brac1 the application of 15µM genistein is sufficient to 
cause significant cell death after 7 days of exposure this was attributed to the 
accumulation of polyploidy cells (Tominaga et al 2007).  
In NIH 3T3 cells a decrease in cell number was observed after 24 hours at a 
concentration of 7.5µM genistein by HPI staining and MTT assay with no significant 
differences at lower concentrations (Rucinska et al 2008). In BMSCs previous studies 
have investigated the effect of genistein on differentiation and found it to increase 
osteoblast differentiation and decrease adipocyte differentiation, with morphological 
phenotype apparent days after treatment (Frank et al 2002, Heim et al. 2004). 
As a further indication of cell death and proliferation of the course of the experiments cell 
turnover was measured using the total release of LDH into the media. The LDH method 
allows enumeration of the number of cells lost during the experiment and also takes into 
account the amount of proliferation that has occurred, therefore this data should be 
complementary to the proliferation data that was already collected.  
As noted previously assays for the level of cell metabolism and ATP availability are often 
reported as being utilised in an inefficient manner. LDH, MTT and MTS assays are often 
used in periods of time up to 48 hours, but very rarely at time points above this (Klein & 
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King 2007). Essentially, long term survivability is best monitored over long time points. 
The data presented here shows the changes in LDH availability over longer time points 
and also accounts for the variation in media types. 
The LDH data shows the accumulating enzyme in the culture conditions, the more LDH 
in the supernatant the greater the amount of release from the cells from which we infer an 
increase in cell death. In the non-treated control cultures the amount of LDH released into 
the media remains at a level much lower than 100%, indicating that the control cells 
released less LDH than is available in the cell monolayer i.e fewer cells died than are left 
in the monolayer. Because we have cell counts from day 0 to day 6 that are not 
significantly different it is possible to infer that the control cells were confluent and 
contact inhibited, and only undertook light proliferation to replace cells. 
In the growth media experiment genistein treatment gives us an indication of the effect on 
the cells that is attributable to just the effect of genistein. In the treatments that are lower 
than 15µM there is no significant change in supernatant LDH until Day 6 when there is 
significant release into the supernatant indicating a significant spike in cell death. 
However when we look at the number of cells in the monolayer there is no significant 
change in cell number between these time points, this indicates that there is also 
significant proliferation during this time to maintain cell numbers. 
LDH data from the treatment with greater than 30µM of genistein produces a trend of 
increasing LDH release into the supernatant when compared to monolayer LDH, this 
trend provides evidence of increasing cell death and proliferation. At 300µM there is 
significant increase of LDH accumulation over time.  
The combination of these data sets indicates that genistein induces proliferation at 
concentrations from 1.88µm to 15µM, has no net effect on cells at 30µM and that cell 
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death occurs in this system at the 300µM. These findings are consistent with the findings 
of others, that physiological concentrations (<7.5µM) of genistein are not toxic (Branca 
2003, Frank et al. 2002, Heim et al. 2004). 
5.5.2 Differentiation 
In our model the genistein acts to significantly increase the abundance of osteogenic 
markers; the marker ALP increased by Day 4 even at the lowest concentration of 
1.88µM. When supplemented in the concentration range 3.75µM to 15µM the up 
regulation in activity of ALP is not significantly different from observations of 
osteogenic media controls.  
In this model we observed accelerated differentiation with detectable levels of ALP well 
before the previously reported 7 day limit, the markers in growth medium control cultures 
did not significantly increase from T0, and osteogenic differentiation medium controls 
differentiated in a normal manner (Heim et al. 2004).  
The literature shows that genistein supplementation of osteogenic medium is significant 
at lower levels than those tested here; we do show that there is a reduction in ALP 
activity from the lowest concentration of genistein to the highest in osteogenic media at 
Day 4 and 6. When genistein is added to osteogenic media there is a double activation 
effect indicating separate mechanisms are responsible for the action of the media 
components, an effect not tested for by anyone else.  
The media component responsible for initiating the increase in ALP activity in osteogenic 
media is the dex. Beta media has similar ALP activity after genistein treatment to growth 
media. Dex is a steroid and activates ALP by the steroid response element, akin to the 
oestrogen response element but activating a different pathway (Shur et al. 2005). Dual 
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activation by stimulating both the steroid and oestrogen response elements has produced 
nearly double the effect of each acting solely. To further test the hypothesis that this dual 
activation is due to the double effect of the action of the steroid and the isoflavone the 
addition of a pure anti-oestrogen would act as an inhibitor, blocking the effect of 
genistein and reducing the activity of ALP in a competitive manner. 
Collagen production is another frequently used marker of differentiation, because bone 
formation requires that type I collagen be used extensively in the extracellular matrices 
prior to the formation of mineralisation nodules. In all of the experiments used for the 
evaluation of collagen production it is apparent that there is a general trend of increased 
collagen production with increasing genistein concentration and that the production of 
collagen continues over time, increasing the total available collagen in the monolayer that 
has the potential to be mineralised.  
In 2004 Heim et al published one of very few studies investigating the effects of genistein 
on human BMSCs, their findings were that genistein increases the level of early markers 
of osteogenesis such as ALP and has no effect on late markers. The findings from this 
chapter clearly show that genistein concentrations tested here are efficacious at increasing 
the production of ALP and in a more timely fashion than Heim, this is probably due to 
the culture conditions utilised by us. Since we cultured our cells at a confluent level we 
effectively shortened the proliferation step from the first 7 days of differentiation, 
resulting in our finding significant increases in ALP by Day 4 rather than Day 18 as 
shown by Heim. We also observed an increase in mineralisation, a late marker of 
osteogenesis (Frank et al. 2002, Heim et al. 2004). 
In the model presented here a relationship between dose, differentiation, cell death and 
mineralisation is evident. At non-toxic concentrations of genistein, <15µM, there is an 
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increase in proliferation, in ALP activity and in mineralisation over the controls. This 
effect is lower or neutral towards 30µM of genistein. At 300µM genistein there is lower 
cell numbers, cell death and relatively lower ALP activity however there is also a small 
trend towards increased collagen and a large and significant increase in mineralisation. 
5.6 Conclusions. 
The hypothesis that the osteogenic effect of genistein can be shown with greater 
statistical certainty in a disease and harvesting bias free BMSC population is true; 
genistein is demonstrably effective at increasing proliferation, cell number and 
osteogenesis in the cBMSCs confluent culture model.  
The effect of the application of genistein is observable after 2 hours and persists for at 
least 6 days. 
Addition of an oestrogen receptor inhibitor would demonstrate the effect is due to the 
phytoestrogen interaction with an oestrogen receptor. 
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CHAPTER 6 
THE OSTEOGENIC EFFECT OF SOY EXTRACT ON THE CBMSC 
MODEL. 
6.1 Introduction. 
Soy is a quality protein source, therefore soy extracts are used extensively in the food 
industry (Heiser and Trentelman 1989). The year on year increase in soy crop and its 
relative cheapness has encouraged the large scale usage of soy in a variety of food 
applications including as gelation agents and emulsifiers (Genovese et al. 2007). 
Industrially soy is sold as hexane defatted white flake; this technology exists and has 
been in use since the 1930’s (Heiser and Trentleman 1989, Horan 1974).  
There is longstanding use of soy as a food stuff, more recently evidence suggests that 
there are positive effects on peri-menopausal symptoms and the “western diseases” 
including osteoporosis (Adlercreutz and Mazur 1997, Sayegh and Stubblefield 2002, 
Lethaby et al. 2007, Kwack et al 2009, Kim et al 2009, Barnes 2010). This evidence has 
led to soy being used as a “wellbeing” product, with the intent to reduce the incidence of 
the western diseases and increase quality and longevity of life (Setchell and Cassidy 
1999, Pandey and Rizvi 2009, Blake et al 2011).  
Due to these many perceived benefits of soy isoflavones they have been studied 
intensively as pharmacologically active dietary supplements (Adlercreutz et al 2004, 
Hedelin et al 2008). However, in order to reach pharmacologically relevant doses large 
quantities of soy or isoflavone extracts often have to be consumed (Adlercreutz et al 
2004, Joshi et al 2007, Marini et al 2007). The Asian diet contains up to 50mg of 
isoflavone per day, soy beans contain approximately 1mg isoflavone per gram (Reinli and 
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Block 1996). There is some evidence that the western diseases can occur in this group 
when the diet is changed to contain a low phytoestrogen content (Barnes 1998). 
A method to extract soy isoflavones from raw soy flour was published in 2003 when Choi 
and Koo used ethanol extraction, in a similar manner to the method used in this chapter. 
After addition of the extract to mouse MC3T3-E1 cells for 48 hours they observed an 
increase in proliferation, ALP and reduced TNF-α production. Although this report is 
based on the analysis of mouse osteoblastic cells it is the only literature reference 
describing the treatment of osteoblasts with soy extract prepared in a similar manner to 
the extract described here. Other reports include McCall et al. (2010) who derived a 
genistein and polysaccharide combination (GCP) from soy extract which induced several 
human lymphoma cell lines to inhibit proliferation and increase apoptosis.  
Soy extracts and pure soy isoflavones have been observed to have different properties. In 
2006 Fuchs et al used pure genistein at 25µM and soy extract, adjusted to a genistein 
content of 25µM, to alter the expression levels of different and defined groups of genes 
known to inhibit apoptosis in human endothelial cells. Therefore, according to Fuchs et 
al, extract containing 25µM of genistein should inhibit apoptosis and increase 
proliferation. There are currently no published in vitro studies of the effect of an extracted 
soy product with increased concentrations of isoflavones on human BMSCs. The only 
available reference which has studied soy extract on osteoblastic cells is the Choi paper 
the majority of work undertaken in this field is in vivo (Choi and Koo 2003).  
An in vivo study analysing the effect of clover isoflavone extract on ovariectomised rats 
was undertaken by Kawakita et al in 2009. They observed that clover extract reduced 
bone resorption compared to controls and mild alkalinisation. This study follows on from 
some of the first isoflavone studies from the 1940’s, Bennetts et al (1946), showed that 
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sheep infertility was directly related to the presence of equol in the blood of sheep 
grazing on clover. Later research indicated that the equol was primarily metabolised from 
methoxy-daidzein (Davies and Hill 1989).  
In an interesting Rat study by Cho et al (2009) soy saponins were identified as a potential 
compound that may cause the observed in vivo differences between purified soy 
isoflavones and soy extracts. The water and ethanol extracted soy used by Cho et al was 
94% saponins and 6% isoflavones. Soy saponins have been shown to stimulate antibody 
production and show antigenotoxic and antitumor activity (Rao and Sung 1995, Berhow 
et al 2000, Rowlands et al. 2002, Oda et al. 2003). Cho et al identified the lowest 
observed adverse effect level (loael) in F344 rats as 725mg/kg. Although they did not 
attempt to separate the effects of the soy isoflavones from soy saponins in the soy extract 
used, previous studies have identified the loael of orally administered synthetic genistein 
in Wistar rats to be 500mg/kg (McClain et al. 2005 & 2007).  
Further long term rat studies have been undertaken; Hagiwara et al. (2010) found no 
adverse effect after feeding F344 rats hot water soy extract for 28 days at “3,618 mg/kg 
bw/day for males and 4,066 mg/kg bw/day for females” indicating that extraction 
methodology may have an effect on efficacy. Brolling et al. (2009) also observed that 
solvent processing can effect the presence of phenols and the efficacy of the resulting 
solution for antioxidant scouring.  
These in vivo studies demonstrate that soy extracts can be very different dependent on 
extraction methods and animal model. The relevance of the outlined animal models to 
this work can also be questioned for several other reasons. For example, some isoflavones 
will be metabolised in the gut before entering the blood stream, absorption and 
pharmacological doses are different between animal models, and as shown in previous 
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chapters the difference of human cell culture systems compared with the rat and mouse 
calls into question that these models metabolise the active ingredients in soy in the same 
manner as human cells do (Adegunloye et al. 2003, Soucy et al. 2006, Tamura et al. 
2011). In cell culture several human cell types have been shown to metabolise the 
conversion of flavonoid glycosides to active aglycones including, epithelial, intestinal 
and hepatic (Murota et al. 2002, Nemeth et al. 2003, Walle et al. 2005, Chen et al. 2011).  
As well as the well studied isoflavones genistein and daidzein and their conjugates, the 
extract also contains other phytoestrogens that are less well studied including saponins. 
Discoveries of novel soy phytoestrogens are still reported in the literature, daidzein 
derivatives glycinol and glyceollin have been reported recently (Bolling et al. 2009). 
Since the soy extract is not concentrated or purified in any way it is likely that it contains 
unknown components including phytoestrogens with unknown oestrogen receptor 
binding efficiencies and unknown transcription effects of the ER-ligand.  
In an attempt to provide evidence that the observed effects are due to the phytoestrogen 
component of the soy extract the pure oestrogen receptor antagonist Fulvestant was added 
to the cell culture. Fulvestant competitively forms ligands with oestrogen receptors; 
however the formed ligand is inactive. The removal of observed effects after application 
of Fulvestant is an indicator that binding to oestrogen receptors is responsible for the 
observations (Chen and Anderson 2001). 
6.2 Hypothesis 
Soy extracts have an osteogenic effect on the primary human cBMSC differentiating cell 
model characterised in the preceding chapters and the use of an oestrogen receptor 
inhibitor will competitively inhibit any observations.  
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6.3 Methods 
The experimental method was undertaken as described in 2.2.13.3 
6.4 Results 
6.4.1 HPLC quantification of soy extract isoflavone content. 
Soy extract was prepared as per the instructions in the methods described at 2.2.11 and 
the HPLC was undertaken as described at 2.2.11.2 
 
Six batches of soy extract were quantified in triplicate using HPLC and observed to have 
140 mg (±2.34 mg) genistein per gram of dried extract.   
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Fig.6.1 A representative HPLC trace of extracted soy protein over time (minutes), the 
isoflavones are labelled: 1, daidzin; 2, genistin; 3, acetlyglucosides and 
malonylglucosides; 4, daidzein; 5, genistein; 6, formononetin (internal standard). The 
marked peaks provide quantitative data for the determination of soy isoflavone content 
by the area beneath the peak relative to the knowns. 
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6.4.2 Direct cell counts. 
Cell number was counted from HPI stained cell cultures, examples of the monolayer 
cultures and photographs of the HPI stains used to create the following graphs can be 
found at 6.4.3 
 
6.4.2.1 Live cell counts of cBMSCs cultured in growth media and soy extract. 
 
Fig 6.2 Direct live cell counts (HPI) of 9 fields of view per experimental conditions after 
cBMSCs were cultured with growth media and soy extract. N=24, error bars indicate SD. 
* Indicates not significant when compared with the control (P<0.05). 
 
After culture in growth media control (fig 6.2) cBMSCs increased in number, but not to a 
significant degree.  
After treatment with soy extract at 8.45 mg/ml cell number increased at each time point 
over the course of the experiment. After culture in media with 16.89 and 33.79 mg/ml 
there was an initial large increase in cell number followed by a reduction over time. The 
addition of soy extract at 67.57 and 135.14 mg/ml caused a reduction in cell number.  
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6.4.2.2 Live cell counts of cBMSCs cultured in growth media with inhibitor and soy 
extract. 
 
 
Fig 6.3 Direct live cell counts (HPI) of 9 fields of view per experiment after cBMSCs 
were cultured with growth media with inhibitor and soy extract. N=24, error bars indicate 
SD. All points are significant when compared with the controls P<0.05. 
 
Addition of the inhibitor Fulvestrant to growth medium reduced the proliferation of the 
control cultures (fig 6.3) when compared with controls without inhibitor (fig 6.2).  
The effect of soy extract on cell number observed in media without inhibitor (fig 6.2) was 
attenuated by the addition of inhibitor (fig 6.3); both peak proliferation and cell death was 
lower and higher respectively. Although the difference between cell proliferation and 
death was reduced with the addition of inhibitor otherwise observations matched those 
found in growth media without inhibitor. 
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6.4.2.3 Live cell counts of cBMSCs cultured in osteogenic media and soy extract. 
 
 
Fig 6.4 Direct live cell counts (HPI) of 9 fields of view per experimental conditions after 
cBMSCs were cultured with osteogenic media and soy extract. N=24, error bars indicate 
SD. * Indicates not significant when compared with the control P<0.05. 
 
When control osteogenic medium was applied to cultures cell number increased at each 
time point (fig 6.4). 
Addition of soy extract between 8.45 and 33.79 mg/ml increased cell number between 
Day 2 and 6 where it remained until the end of the experiment; 67.57 mg/ml induced 
initial proliferation followed by cell death. After culture with 135.14 mg/ml cell number 
was higher than controls at Day 2, the same as controls at Day 6, and cell death occurred 
at all subsequent time points. 
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6.4.2.4 Live cell counts of cBMSCs cultured in osteogenic media with inhibitor and 
soy extract. 
 
 
Fig 6.5 Direct live cell counts (HPI) of 9 fields of view per experiment after cBMSCs 
were cultured with osteogenic media with inhibitor and soy extract. N=24, error bars 
indicate SD. * Indicates not significant when compared with the control P<0.05. 
 
The addition of inhibitor to osteogenic media significantly reduced proliferation in the 
control cultures, although controls did increase in cell number at each time point. (fig 6.5) 
After addition of soy extract cell number increased when compared to controls. Cell 
number did not increase to the level found in media without inhibitor, cell number 
increases were more apparent at larger doses of soy extract.  
 
6.4.2.5 Summary of soy extract and inhibitor effect on cell number. 
Cell number was increased by the addition of soy extract at between 8.45 and 33.79 
mg/ml and reduced at larger quantities. This effect can be either reduced or attenuated by 
the addition of an ER inhibitor, indicating oestrogens are potentially responsible for the 
observations.  
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6.4.3 Inverted photomicroscopy of cBMSC cultures. 
6.4.3.1 Control cBMSC cultures. 
 
   
 
Fig 6.6 Images of confluent controls, cultured in A) growth medium and B) osteogenic 
medium for 10 days (x10). 
6.4.3.2 HPI stained cBMSCs after culture in osteogenic media and soy extract. 
 
Fig 6.7, Black field Inverted phase micrographs of cBMSCs after 10 days culture with 
soy extract in osteogenic media, A) control, B) 8.45mg/ml, C) 16.89 mg/ml, D) 33.79 
mg/ml, E) 67.57 mg/ml, F) 135.14 mg/ml (x10). 
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6.4.4 Quantification of the activity of ALP. 
ALP was measured as per the method described in 2.2.10.2 and protein by the Bradford 
method as described in 2.2.10.3 
 
6.4.4.1 ALP activity after culture in growth media and soy extract. 
 
 
Fig 6.8 The activity of ALP measured after culturing cBMSCs with soy extract in growth 
media for 2, 6, 8 and 10 days. N=4 and the error bars indicate SD. * indicate significance 
when compared to the control P<0.05. 
 
After culture in growth medium the control cultures (fig 6.8) increased expression of 
ALP over time in culture. After culture with media containing soy extract ALP increased 
from Day 0 to Day 8 at 8.45 and 16.89 mg/ml. At concentrations 33.78-135.14 mg/ml 
activation of ALP occurred at Day 6 and reduced at subsequent time points. 
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6.4.4.2 ALP activity after culture in growth media with inhibitor and soy extract. 
 
 
Fig 6.9 The activity of ALP measured after culturing cBMSCs with soy extract in growth 
media and Fulvestrant (ICI 182780) for 2, 6, 8 and 10 days. N=4 and the error bars 
indicate SD. * indicate significance when compared to the control P<0.05. 
 
 
After addition of inhibitor to growth media (fig 6.9) ALP activity did not change. 
When growth media was supplemented with inhibitor and soy extract the peak activity 
was reduced. ALP activation was greater than control at Day 2 and 6 after addition of all 
soy extracts. After addition of soy extracts between 8.45 and 16.89 mg/ml soy extract 
induced a significant increase when compared to the control. 
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6.4.4.3 ALP activity after culture in beta media and soy extract. 
 
 
  
Fig 6.10 The activity of ALP measured after culturing cBMSCs with soy extract in beta 
media for 2, 6, 8 and 10 days. N=4 and the error bars indicate SD. * indicate significance 
when compared to the control P<0.05. 
 
 
 
In beta control medium (fig 6.10) ALP activity was relatively similar over the period of 
the experiment.  
After addition of soy extract there is a large activation of ALP at early time points at all 
concentrations, this effect is reduced at later time points, but is still significant compared 
to controls.  
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6.4.4.4 ALP activity after culture in beta media with inhibitor and soy extract. 
 
 
 
Fig 6.11 The activity of ALP measured after culturing cBMSCs with soy extract in beta 
media and Fulvestrant (ICI 182780) for 2, 6, 8 and 10 days. N=4 and the error bars 
indicate SD. * indicate significance when compared to the control P<0.05. 
 
 
Addition of inhibitor to the beta medium control cultures (fig 6.11) did not significantly 
influence ALP expression.  
Addition of the inhibitor to beta media with soy extract reduced the peak activation of 
ALP; the activation profile was similar at all soy extract concentrations, reducing from 
Day 6 to Day 10.  
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6.4.4.5 ALP activity after culture in osteogenic media and soy extract. 
 
 
 
Fig 6.12 The activity of ALP measured after culturing cBMSCs with soy extract in 
osteogenic media for 2, 6, 8 and 10 days. N=4 and the error bars indicate SD. * indicate 
significance when compared to the control P<0.05. 
 
 
Osteogenic media controls (fig 6.12) were observed to increase production of ALP over 
the period of the experiment. 
After addition of soy extract to osteogenic media ALP activity increased at all 
concentrations by Day 6; significantly at less than 67.57 mg/ml and falling at later time 
points. At 67.57 and 135.14 mg/ml activity was significantly less than controls at Day 8 
and 10. 
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6.4.4.6 ALP activity after culture in osteogenic media with inhibitor and soy extract. 
 
Fig 6.13 The activity of ALP measured after culturing cBMSCs with soy extract in 
osteogenic media and Fulvestrant (ICI 182780) for 2, 6, 8 and 10 days. N=4 and the error 
bars indicate SD. * indicate not significant when compared with control P<0.05. 
 
Addition of the inhibitor to osteogenic medium (fig 6.13) results in a reduction ALP 
when compared to medium without inhibitor (Fig 6.12). After addition of soy extract to 
the media ALP activity is not upregulated to the same degree as osteogenic media alone. 
Peak activation is delayed until Day 8 at 8.45 and 16.89 mg/ml. 
 
6.4.4.7 Summary of ALP activity after addition of soy extract.  
In all media soy extract induced an increase in ALP activity, this increase was reduced 
after addition of inhibitor. 
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6.4.5 Analysis of terminal differentiation by cbfa-1 expression. 
Expression of the osteoblast differentiation marker cbfa-1 was semi-quantitatively 
analysed using RT-PCR according to the method described at 2.2.10.7.  
 
6.4.5.1 The effect of soy extract on the expression of cbfa-1 in cBMSCs cultured in 
growth media and growth media with inhibitor. 
 
 
Fig 6.14 The observed relative fold change in expression of cbfa-1 mRNA after treatment 
of cBMSCs with soy extract for 10 days in growth media and growth media with 
inhibitor. The change in expression is plotted relative to the control, which is arbitrarily 
set at 0 and is therefore a plot of the ΔΔCt. N=3, error bars are the SD of the ΔCt. * 
indicates significance when the ΔCt is compared with the control P<0.05 
 
Expression of cbfa-1 is increased in soy extract supplemented media when compared to 
growth media controls (Fig 6.14). The peak increase of 2.3 fold was observed after 
addition of 16.89 mg/ml of soy extract. The increase in expression fell with increasing 
concentration of soy extract up to 135 mg/ml where there is a significant decrease in 
expression of cbfa-1. The addition of the inhibitor reduced the effect.  
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6.4.5.2 The effect of soy extract on the expression of cbfa-1 in cBMSCs cultured in 
osteogenic media and osteogenic media with inhibitor 
 
Fig 6.15 The observed relative fold change in expression of cbfa-1 mRNA after treatment 
of cBMSCs with soy extract for 10 days in osteogenic media and osteogenic media with 
inhibitor. The change in expression is plotted relative to the control, which is arbitrarily 
set at 0 and is therefore a plot of the ΔΔCt. N=3, error bars are the SD of the ΔCt. * 
indicates significance when the ΔCt is compared with the control P<0.05. 
 
After culturing with soy extract in osteogenic media there was a 5.3 fold increase in cbfa-
1 expression after addition of 16.89 mg/ml. expression was lower than controls after 
addition of 135.14 mg/ml.  
The addition of inhibitor to the experiment led to an observed overall decrease in the 
expression of the cbfa-1 marker, although the dose response was maintained. The peak 
expression up-regulation occurred at 16.89 mg/ml and was a 1.4 fold increase.  
 
6.4.5.3 Summary of the effect of soy extract on cbfa-1 expression. 
Cbfa-1 expression was increased after addition of 8.48 and 33.79 mg/ml and reduced at 
higher concentrations; the increase was reduced after addition of inhibitor.  
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6.4.6 Alizarin red staining (ARS) of mineralised ECM  
6.4.6.1 ARS of monolayers after culture with soy extract in growth media. 
 
 
Fig 6.16 The mineralisation measured by alizarin red staining after culturing cBMSCs 
with soy extract in growth media for 6 and 10 days. N=10 and the error bars indicate SD. 
All experiments are significant when compared to the control P<0.05. 
 
 
Culture in growth medium induced the controls (fig 6.16) to increase mineralisation 
between Day 6 and 10. After addition of soy extract to the media mineralisation was 
increased at all time points and for all concentrations. A similar dose effect could be 
observed at both time points.   
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6.4.6.2 ARS of monolayers after culture with soy extract in growth media and 
inhibitor. 
 
 
Fig 6.17 The mineralisation measured by alizarin red staining after culturing cBMSCs 
with soy extract in growth media and the inhibitor Fulvestrant (ICI 182780) for 6 and 10 
days. N=10 and the error bars indicate SD. * indicates significance when compared to the 
control P<0.05. 
 
 
After addition of inhibitor to growth media mineralisation of the control cultures did not 
increase. Addition of extract and inhibitor to the culture media reduces the increase in 
mineralisation. 33.79 mg/ml and 135.14 mg/ml are the only concentrations that are 
significantly higher than controls at both time points. 
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6.4.6.3 ARS of monolayers after culture with soy extract in osteogenic media. 
 
 
 
Fig 6.18 The mineralisation measured by alizarin red staining after culturing cBMSCs 
with soy extract in osteogenic media for 6 and 10 days. N=10 and the error bars indicate 
SD. * indicates significance when compared to the control P<0.05. 
 
 
In osteogenic media the control cultures (fig 6.18) slightly increased mineralisation over 
the course of the experiment. After addition of soy extract to the media there was a 
similar dose response to the observations of growth media. Addition of 135.14 mg/ml 
was the only extract combination that caused a significant increase in mineralisation at 
both time points. 
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6.4.6.4 ARS of monolayers after culture with soy extract in osteogenic media and 
inhibitor. 
 
Fig 6.19 The mineralisation measured by alizarin red staining after culturing cBMSCs 
with soy extract in osteogenic media and Fulvestrant (ICI 182780) for 6 and 10 days. 
N=10 and the error bars indicate SD. * indicates significance when compared to the 
control P<0.05. 
 
Addition of inhibitor to the osteogenic medium controls (fig 6.19) had little effect on the 
mineralisation of the culture. After addition of inhibitor and soy extract to the media the 
effects observed in media without inhibitor was removed. 
 
6.4.6.5 Summary of the effect of soy extract on mineralisation.  
Soy extract increased mineralisation of cultures, an effect that was removed with the 
addition of inhibitor.  
 
6.4.7 Summary of results. 
Addition of soy extract increases cell number, ALP, cbfa-1 expression and 
mineralisation. These observations can be removed or reduced with the addition of an 
inhibitor.  
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6.5 Discussion 
6.5.1 Comparison with literature. 
The osteogenic effect of soy extract when added to cultured human cBMSCs has not been 
reported in the literature. However the addition of soy extract to immortalised mouse 
osteoblasts was reported by Choi and Koo in 2001 & 2003. Choi and Koo (2003) studied 
the effect of soy extract on proliferation, apoptosis and ALP expression on confluent 
MC3T3-E1 cells after culture in growth media with 0.05 g/l (50µg ml
-1
) of soy extract for 
48 hours. In their report they observed that the addition of the ethyl acetate fraction of soy 
extract increases the proliferation and differentiation of mouse osteoblasts. The observed 
induction in differentiation occurs to a greater degree than with soy extract alone, 
therefore they suggest that less polar (hydrophobic) compounds are responsible for the 
increased osteogenic efficacy of the extract. Although they do not test the extracts for 
isoflavone content genistein and genistin are considered moderately polar compounds 
(Zhang et al. 2010).  
The HPLC trace at fig 6.1 is run in a manner that increases acetonitrile in the solvent as 
time increases. Therefore high polarity (hydrophilic) compounds are removed from the 
column initially, followed at some length by the most polar (hydrophobic) compounds. 
Therefore according to the data presented at fig 6.1 we would postulate that the 
compounds extracted and concentrated in Choi and Koo’ paper were the soy aglycones. 
The concentrating of available isoflavones in this fraction of the isolate would account for 
the authors observed increase in osteogenic effects. This chapter goes further than Choi 
and Koo, in that the observed effects of the soy extract can be blocked by the addition of 
an oestrogen receptor inhibitor, therefore the osteogenic effect of soy extract is directly 
attributed to the presence of phytoestrogens. 
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When Choi and Koo studied cell death in their model they found that addition of soy 
extract reduced apoptosis and expression of TNF-α. Therefore the authors suggest that 
soy extract protects against nitrite induced apoptosis, which can be a product of electron 
chain blockage in mitochondria. The data presented here in growth media at Day 2 
contains soy extract at 1000 fold more concentrated, at this concentration and time point 
there is increased cell number and ALP activity; data which fits with the Choi and Koo 
data. Because Choi and Koo do not characterise their extract for phytoestrogen content it 
is difficult to pick apart the reasons for this discrepancy, it could be a difference between 
immortalised mouse cells and primary human or simply that they extraction performed by 
Choi and Koo did not concentrate the isoflavones to the same degree as reported in this 
chapter.  
The data presented here also shows that the choice of media is important for measuring 
the effects of soy extract; there is a significant difference between growth media and 
osteogenic media. The similarity to previous chapters and the significant reduction in 
efficacy of the soy extract when used in conjunction with the inhibitor suggests that the 
majority of the osteogenic effect of the soy extract is due to the presence of soy 
phytoestrogens. Perhaps due to the use of a combination of flavones the effect of soy 
extract in this chapter is significantly greater than the effect of pure soy isoflavones in the 
previous chapters.  
Other studies have suggested that soy extract is more potent than pure soy isoflavones, 
for example in Kim et al (2008) published an in vivo study observing that human breast 
cancer cells injected into athymic nude mice proliferated when treated with pure genistein 
but were significantly reduced with soy extracts. Similarly Gallo et al (2008) found that a 
soy extract double selected for isoflavones is effective at delaying the progression of lung 
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cancer in the same mouse model. The observed increased potency of soy extract is 
potentially due to the combination of phytoestrogens or perhaps processing has reduced 
conjugated isoflavones into active aglycones (de Lima Toccafondo Vieira et al. 2008). 
6.5.2 Comparison with previous chapters 
The results presented in this chapter have on the whole no comparable published studies, 
although studies do exist for pure isoflavones or combinations thereof there are few 
human in vitro studies using soy extract and no observations of osteogenesis. As can be 
seen from the table at 2.2.13.5 the soy extract added to the media was adjusted for 
genistein content, therefore the data presented here can be directly compared with 
previous chapters. When we compare this chapter with the previous chapters we find 
ongoing trends; there is a dose response from the soy extract that indicates osteogenic 
effects at the lowest concentration studied 8.45 mg/ml, because this effect can be 
removed by the application of inhibitor we can deduce that the effective components of 
the extract are phytoestrogens.  
The cumulative effects observed when we supplement genistein to osteogenic media are 
also maintained when soy extract is added to the osteogenic media, although this effect is 
only apparent at concentrations ≤33.78 mg/ml (Fig 6.13). In this chapter we use the 
combination of ALP and cbfa1 expression to monitor the differentiation state of 
cBMSCs. The osteoblast marker cbfa-1 has been often used as an indicator of phenotype 
in differentiating cBMSC systems as its expression is obligatory during osteogenesis and 
it is known to regulate the production of osteocalcin (Guillot et al 2008, Maromet al 
2005). Treatment with soy extract at 16.89 mg/ml in growth media is shown here to be 
sufficient to increase ALP activation by more than 1 fold and cbfa1 expression by more 
than 2 fold. When supplemented to osteogenic media 16.89 mg/ml soy extract increases 
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the activity of ALP by 4.5 fold and cbfa1 expression by 5.3 fold. Adding inhibitor to 
these experiments causes a reduction in the effectiveness of the isoflavones by about 
50%, as is expected from a competitive inhibitor (Heim et al 2004). Overall these 
observations indicate that the most effective method to differentiate cBMSCs to 
osteoblasts is to supplement osteogenic media with 16.89 mg/ml of soy extract, 
containing 1.88 µM of genistein.  
6.6 Conclusions. 
The hypothesis that soy extract is more efficacious at differentiating BMSCs than 
purified genistein alone and that the osteogenic effect of the soy extract can be removed 
with the addition of an oestrogen receptor inhibitor is proved.  
The removal of effect with the addition of inhibitor indicates that the observations are due 
to the phytoestrogen content of the soy extracts. 
Cell death is less pronounced after culture with soy extract than with pure genistein.  
Soy extract is significantly osteogenic in both growth media and osteogenic media; this 
indicates there is a cumulative effect in addition to the osteogenesis mediated by the 
dexamethasone and β-glycerophosphate in the osteogenic media.  
Cbfa-1 can be used as a marker of osteogenesis in this model as it is upregulated along 
with ALP.  
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CHAPTER 7 
DIFFERENTIATION OF CBMSCS ON CALCIUM PHOSPHATE 
CEMENTS. 
7.1 Introduction. 
Calcium phosphate (CaP) ceramics have been used to fill small bone defects since 1920 
(Albee 1920). Since the 1980’s research has concentrated on biphasic calcium phosphate 
(BiCaP) which is a combination of two ceramics, hydroxyapatite (HA) and β-tricalcium 
phosphate (β-TCP) (Jarcho 1981). The ratio of HA to TCP was optimised during the late 
1980’s and early 1990’s by Daculsi et al (reviewed Daculsi et al 2003). Both block and 
granule forms of BiCaP ceramics have been used to fill bone defects (Eggli et al. 1988, 
Gauthier et al. 2005).  
Block and granular BiCaP are useful because they can be carved or compressed into bone 
defects. In addition to block or granular BiCaP, a self setting cement was introduced that 
can be injected and moulded to fit defects perfectly, the setting of the cement used the 
work by Daculsi to optimise the reaction for the production of calcium deficient 
hydroxyapatite (CDHA) (Chow and Takagi 2001). However all forms have problems 
with mechanical stability during normal body stresses (Habibovic et al. 2006, 
Schumacher et al. 2010). Therefore these materials are mostly used where adequate 
mechanical stability and host bone tissue is already present, foremost in craniofacial 
surgery.  
Materials made from BiCaP are bioactive and osteoconductive; they form a direct 
interconnection with the surrounding tissue and encourage cell penetration and 
remodelling (Levengood et al. 2010). It is known that the success or failure of these 
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materials is due to the porosity and solubility of the construct, resorption and remodelling 
of the CaP cement into bone is a critical clinical property (LeGeros et al. 2003, 
Kobayashi et al. 2009). 
Because the porosity of the cement is critical to the speed of tissue remodelling an 
injectable CaP foam was investigated by Ginebra et al. (2006) as a mechanism of 
introducing macroporosity. Previously reports had followed either subtractive logic to 
introduce porosity; they were partially comprised of sugars or polylactose fibres that 
wash out of the set cement (Markovic et al 2000, Xu and Quinn 2002). Alternatively 
porosity can be generated within the cement during setting by breakdown of bicarbonate 
or similar (del Real et al 2002, Hesaraki et al 2007). Ginebra introduced the use of a 
biological surfactant to stably foam the cement prior to injection without introducing 
toxic or incompatible reagents (Ginebra et al 2006).  
Further work has shown that the introduction of gelatine as a foaming agent decreases the 
setting time and increases the strength and pore size of the composite when compared 
with the cement alone (Montufar et al 2010). In good agreement with the literature 
(Fujishiro et al 2001, Bigi et al. 2004). Happily the authors also report that the use of 
gelatine increases the injectability of the cement paste without compromising the 
formation of CDHA (Montufar et al. 2010). Other reports in the literature indicate that 
addition of gelatine to CaP cements was detrimental to the setting time but agreed that 
compressive strength increased significantly (Shie et al. 2008).  
Because CaP cements set at low temperature it is possible to introduce bioactive 
molecules into the cement prior to use to increase performance and for drug delivery. If 
the cement is intended for use in a patient with a history of infection then the use of a 
slow release antibiotic in combination with the cement could allow the control of 
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bacterial load while integration with the host tissue occurs (Jiang et al. 2010). The 
addition of an osteogenic component like bone morphogenic protein (BMP) to a CaP 
cement can induce osteogenesis, actively recruiting and committing progenitor cells to an 
osteogenic lineage (Polak et al. 2011, Wang et al. 2011). These osteoinductive BiCaP 
cements are the next generation of bone regenerative templates. Since isoflavones are 
oestrogenic their incorporation in a cement should also increase osteogenesis; and when 
cultured with SAOS-2 cells soy cements did increase osteogenesis (Perut et al. 2011).  
Soy products have a long standing use as engineering materials; famously Henry Ford 
used soy based bioplastics in the 1940’s to construct car parts (Murray 2007). More 
recently soy has been incorporated into composite plastics to enhance biodegradation 
(Reddy and Yang 2011). Because soy based plastics have enhanced biodegradability they 
have also been developed to replace aliphatic polyester biomaterials (Vaz et al. 2003). 
Soy has also been added to biomaterials in order to enhance the strength and pore size of 
the structure (Luo et al. 2008). Therefore soy has properties that make it ideal for use in a 
bone regenerative material; it contains phytoestrogens, allows modulation of porosity and 
can enhance degradation.  
The formulation of a soy based osteogenic CaP cement has allowed the localised delivery 
of pharmaceutically relevant concentrations of soy extract that have the potential to 
initiate osteogenesis in cell lines (Santin et al. 2008). 
Combining osteoconductive cement with a pharmaceutical concentration of an active and 
eluted ingredient allows optimisation of the material for regeneration and integration into 
bone (Heliotis et al. 2006, Luvizuto et al. 2011). The use of soy extract as an initiator of 
osteogenic differentiation was proven in the previous chapters with the intent that the 
extract would be combined with a CaP cement that would have an intrinsically greater 
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osteogenic effect than the original formulation alone. The addition of human 
osteoprogenitors may accelerate the engraftment process (McGonagle et al 2007). The 
use of human bone marrow stem cells is already recommended in clinic for treatment of 
host vs graft disease; alternative clinical uses for BMSCs may be easier to licence once 
efficacy and safety has been proven over the mid to long term (Sato et al. 2010). 
Human BMSCs are at the forefront of bone research, therefore there is literature available 
describing the effect of cements on differentiation as well as BMSC growth on cements. 
A comparative study of BMSC loaded grafts using either biphasic CaP or natural bovine 
bone mineral (bio-oss) was undertaken in dogs by Jafarian et al (2008), finding no 
significant difference in efficacy. Also in 2008 Mankani et al demonstrated that HA/TCP 
and human BMSC can be directly injected into the dorsal subcutaneous space of mice 
resulting in de novo bone formation without the necessity of open surgery. More recently 
Li et al. (2011) cultured human adipose-derived stem cells on BiCaP ceramic discs 
resulting in osteogenic differentiation and increased mineralisation of the scaffolds.  
Human clinical trials have described the use of autologous human BMSCs in bespoke 
manufactured macroporous HA constructs, finding that healing was accelerated by about 
6 months in two patients (Quarto et al. 2001). Bone was also successfully regenerated in 
clinic by Schimming and Schmelzeisen (2004) who were successful in transplanting 18 
patients with a construct comprising of autologous periosteum derived osteoblasts on a 
resorbable Ethisorb matrix, although the scaffold was not CaP based this study showed 
stem cell derived de novo bone production is possible in multiple patients. Also in 2004, 
Kitoh et al. used autologous BMSC and platelet-rich plasma to form an injectable fast 
setting gel in patients undergoing leg lengthening and observed an acceleration in healing 
times.  
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BMSC have been analysed after culture on CDHA cements which were used as a 
substrate to culture rabbit BMSCs (isolated at unknown density) after pre-treatment in 
osteogenic medium for one week. After addition to CDHA and hydroxyapatite (HA) 
control substrates and continued culture in osteogenic medium there was an increase in 
ALP activity and proliferation. When these scaffold and cell constructs were implanted 
into rabbit mandibles for 8 weeks no differences were observed between normal bone and 
the remodelled scaffold (Gou et al 2009).  
Human BMSC isolated at clonal density were cultured on CDHA cements by Park et al 
(2011), who observed increased proliferation, collagen, ALP, and osteopontin production 
after 6 weeks culture. The effect of a soy extract calcium phosphate cement on human 
BMSC differentiation is unknown. 
7.2 Hypothesis 
As outlined in the introduction injectable foamed cements for the replacement of bone 
tissue have been reported in the literature previously. We postulated that the addition of 
soy extract containing the phytoestrogens described in the previous chapters would be of 
benefit, that increased differentiation could be achieved in vitro compared with gelatine 
control cements. Therefore we hypothesise that a soy cement biomaterial will increase the 
proliferation and osteogenic differentiation of a primary human cBMSC culture.  
7.3 Methods 
Cements were produced by the method described at 2.2.12, outlined briefly here. Gelatine 
was warmed to 50°C; soy extract was added for soy cements, for the control it was left 
out. The warmed gelatine solution was then foamed and combined with the CaP, mixed, 
and then injected into moulds. The cements were immersed in saline for 12 days prior to 
cell culture. cBMSCs were added to the cements using the protocol at 2.2.14; 4.5x10
4
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cells were seeded to set cements in growth medium and cultured for up to 24 days prior to 
analysis of the cultures for cell number and differentiation by the methods described at 
2.2.10. Cements were imaged by SEM, method at 2.2.15, in brief; fixed and freeze dried 
materials were sputter coated with Palladium and visualised under high vac in an SEM. 
7.4 Results 
7.4.1 Visual comparison of cements. 
Soy and gelatine mixtures foamed more easily than gelatine alone, the amount of foaming 
was more consistent and durable. Injection of the mixed cements to moulds was more 
easily accomplished in the soy containing cements.  
7.4.1.1 Photographs of set cements. 
In the finished soy/gelatine (SG) cements (fig 7.1B) there was a reduction in the friable 
nature of the gelatine (G) cement, the surface was more robust. The bubbles in both 
foams resulted in a visible pore structure but pores were more numerous in SG cements. 
SG cements were better able to fill the moulds without introducing voids or requiring 
subsequent packing. 
 
Fig 7.1, photographs for comparison of A) gelatine control B) soy/gelatine cement.  
A B 
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7.4.1.2. SEM of set cements. 
SEM at relatively low magnification confirmed that SG cements had increased porosity 
compared with G cements. At higher magnification (fig 7.2) there is increased pore size 
and frequency in SG cements, while in the G control hydroxyapatite crystals appear more 
numerous, smaller and densely packed.  
 
 
 
Fig 7.2, SEM of cement biomaterials A) gelatine B) soy/gelatine.   
A 
B 
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7.4.1 Proliferation of cBMSCs on cements. 
 
 
 
Figure 7.3, LDH derived cell number after cBMSCs were cultured on materials for 0, 12 
and 24 days. Error bars indicate SD. n=6. Cell number increases significantly on both 
materials at each time point. * indicates a significantly greater cell number when cements 
are compared at each time point P<0.05. 
 
 
 
The proliferation of cBMSCs on cements was quantified using LDH content (fig 7.3). 
Cells were seeded at 4.5x10
4
 cells per biomaterial, at Day 12 there is no difference in cell 
number between the two biomaterial types. By Day 24 there was a statistically greater 
number of cells on the SG cements when compared with the G cements.  
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7.4.2 Expression of cbfa-1 after culture of cBMSCs on cements. 
 
 
 
Fig 7.4. Semi-quantified expression of the osteogenic marker cbfa-1 in cBMSCs cultured 
on biomaterials for 0, 12 and 24 days. The data is expressed as the ΔΔCt, where 
expression of cbfa-1 is adjusted for loading error to the expression of gapdh (the ΔCt) a 
comparison is then made of the ΔCt‘s from cBMSCs cultured on G cements relative to 
SG cements (ΔΔCt). n=5 and error bars indicate SD. * indicate significantly greater ΔCt 
when cultured on SG cements than G cements. 
 
 
Analysis of the expression of cbfa-1 in cBMSCs on SG cements compared to G cements 
(Fig 7.4) shows that although there is no comparative increase in cell number after 12 
days incubation there is a significant 1 fold (100%) increase in cbfa-1 RNA production. 
At 24 days there is a 5.3 fold increase in cbfa-1 expression in SG cultured cBMSCs 
relative to the G cement. 
 
  
0
1
2
3
4
5
6
7
0 12 24
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 o
f 
c
b
fa
-1
 i
n
 C
B
M
S
C
s
 
c
u
lt
u
re
d
 o
n
 S
G
 c
e
m
e
n
ts
 w
h
e
n
 c
o
m
p
a
re
d
 t
o
 G
 
c
e
m
e
n
t 
c
o
n
tr
o
ls
.
Time (Days)
* 
* 
 210 
 
7.4.3 SEM of cements with CMBSCs. 
After culture of cBMSC with the biomaterials for 24 days the cements were harvested 
and the surface was observed by SEM. Cell sheets covering the surface of the cements 
are visible (fig 7.5B), it is apparent that there is deposition on the surfaces of both 
cements. The surface of the SG cements appears more homogenous and consists of cells 
and a surface coating. The G cement appears to have less incorporation of the cells into 
the modification of the surface. 
 
Figure 7.5, SEM of cements after 24 days culture with CMBSCs. A) G, B) SG. ECM 
covering the surface of the cements is visible in both images; however the cells cultured 
on the SG cement appear completely covered when compared with the G cement.  
B 
A 
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7.4.2 Soy/gelatine cement remodelling. 
Concurrent with cells differentiating on the SG cement there was also a remodelling 
effect on the cement surface. SEM shows that after cBMSCs have been cultured on the 
surface of the SG cement the plate shaped crystals are replaced with a smaller scale 
amorphous surface (fig 7.6).  
 
Figure 7.6, SEM of SG cement before (A) and after (B) the growth of cBMSC on the 
surface for 24 days.  
A 
B 
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7.4.3 Gelatine cements after culture with cBMSCs 
The fine structure of the surface of the G cements under the SEM (fig 7.7) appears coated 
and is partially concealed. The modifications observed in SG cements are not apparent.    
 
Fig 7.7, Gelatine cements A) before and B) after culture with cBMSC for 24 days. 
  
A 
B 
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7.5 Discussion. 
The gelatine and soy/gelatine cements used in this chapter have previously been 
described in the literature. Foamed CaP cements were described by Ginebra et al (2006) 
using albumen as a natural foaming agent to impart additional porosity, this also lowered 
compressive strength. Addition of albumen did not prevent the formation of calcium 
deficient hydroxyapatite (CDHA), which is the mechanism by which the cement is set. 
The use of albumen foam as a porogen decreased the microporosity by 10% and 
increased macroporosity by up to 56%, increasing total porosity as much as 77% overall.  
The foaming technique was developed in the subsequent report, Montufar et al (2010a), 
using polysorbate-80 as a foaming reagent the porosity was found to be controlled by the 
ratio of polysorbate used in the liquid phase of the cement. Use of low concentrations of 
polysorbate (<5%) had no effect on the setting reaction, but increased both injectability 
and porosity. The tailored use of this porogen allowed optimisation of the cement for the 
growth of the human osteosarcoma SAOS-2 cell line, with a concurrent increase in 
expression of osteoblastic markers without addition of osteogenic medium. 
Gelatine foamed cements were also described by Montufar et al. (2010b) with 
improvements in injectability, setting time, porosity and compressive strength. While 
addition of gelatine maintained the microporosity of the cement it also increased the 
macroporosity, total porosity reached as much as 74%. The authors did not culture cells 
on or with the cements.  
The foamed soy extract and gelatine combined calcium phosphate cement was described 
in 2011 by Perut et al. The 20S5G cements described in the paper by Perut et al are 
identical to the SG cements presented in this chapter. The liquid to powder (L/P) used in 
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this chapter was the adjusted value of 0.55 ml g
-1
 as described in the paper, this ratio was 
used to ensure cohesion and injectability, and to provide comparability between the work.  
This SG cement has a wide range of pore sizes, attributed to a combination of the foam 
and the innate porosity of the CaP cement. The most common pore size was 20µm, this 
was attributed to the narrowest interconnectivity between pores as at the surface pores 
were larger than 20µm. X-ray diffraction analysis of the setting reaction products 
indicated that addition of soy extract increased the setting time in the early period. After 8 
hours the SG cements were 15% CDHA, compared with 40% in the G cements. During 
this setting period all the cement formulations demonstrated an increase in surface area, 
this increase is related to the formation of plate like HA crystals (fig 7.2) which in soy 
cements were larger and had better separation than gelatine cements (fig 7.6A).  
The SG cements increased surface area to a greater degree than is accountable for by just 
cement precipitation, the increased porosity and pore interconnectivity compaired with G 
cements may account for this observation. It is an interesting observation that this 
increase in surface area and porosity develops over the period of setting time. At 168 
hours the SG cement is 85% set and has the same surface area as the already set non-
foamed control cement. When the SG cement is completely set the surface area has 
increased significantly indicating that either there is a very large increase in nucleation of 
HA crystals as the last αTCP dissolves and precipitates or there is a washing out of soy 
extract, freeing more nucleation sites.  
The authors use the human osteosarcoma cell line SAOS-2 to culture cells both directly 
and indirectly in contact with the cements. When cultured indirectly with SG cements the 
proliferation and collagen deposition of SAOS-2 cells were not different from the control 
cements, however ALP was observed to increase significantly. When SAOS-2 cells were 
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cultured directly on the SG cements an increase in Alamar blue reduction was observed, 
this reduction was attributed to proliferation on the cement. This observation was 
confirmed by direct visualisation of the Hoechst stained cells on the cement surface. 
Relative to control cements culture of SAOS-2 cells directly on SG cements did not 
induce an increase in ALP; however, when compared to indirect culture all cements 
induced an increase in ALP.  
Increased differentiation of cells on many CaP cements has been described in the 
literature previously and has been attributed to the localised increase of Ca
+2
 ions in 
solution, surface topology and the type of HA deposited (Pi et al. 2005, Guo et al. 2009, 
Park et al. 2011, Ewald et al. 2011). The effect of the active soy isoflavones present in the 
cement, which was significant when cultured indirectly, would be expected to increase 
differentiation markers more than controls in direct contact, even in non-osteogenic 
medium. As demonstrated in Chapters 4-6 human osteosarcoma cell lines do not respond 
in the same manner as primary multipotent BMSCs when cultured with isoflavones.  
Soy biomaterials have also been used in a pre-clinical rabbit model Giavaresi et al (2010). 
The material comprised of 320 mg of soy extract, prepared as described at 2.2.11.1, 
which was formed into a hydrogel by the addition of CaCl2 solution. This hydrogel was 
mixed 50/50 with thermoset soy curd granules and was implanted into critical sized 
defects in the distal femur of New Zealand rabbits. In the control treatments the defects 
were non-healing at 24 weeks. When the granules in the soy material were not packed 
densely increased trabecular growth was observed at 8 and 24 weeks compared with 
commercially available Fisiograft. Compaction of the packing commonly occurs when 
HA granules are used in clinic; some reports indicate almost no resorption several years 
after the surgery (Mendelson et al. 2010).   
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The aim of combining the cement with the soy extract was to create a product that was 
superior to the cement alone. When primary human cBMSCs were cultured directly on 
the surface of the SG cement cell numbers increased and osteogenic markers were up 
regulated. In this chapter ALP, collagen and mineralisation were not considered as 
markers. This was because ALP extraction would co-extract protein from the soy extract 
and gelatine present in the cements, skewing the results when they were presented 
adjusted for protein. Collagen has been measured by absorption of picrosirius red in 
previous chapters, which also stains gelatine; this signal drowns the very small 
differences that have been observed in previous chapters. Measuring increased 
mineralisation on CaP cements is similarly not possible.  
Therefore semi quantitative RT-PCR was used to measure the relative expression of 
cbfa1, which is upregulated during osteogenesis and regulates the production of 
osteopontin and other mineralisation genes (chapter 6). The data in this chapter indicates 
that the oestrogenic effect observed when extract was directly applied to cBMSCs was 
delayed.  
Further work by the group suggests that after setting there is a 4 day isoflavone release 
spike followed by sustained release for a further 10 days, further time points were not 
taken (appendix 2). This slow release of isoflavones from the SG cements may account 
for the slower osteogenesis on cements compared with direct application of extract. 
7.6 Conclusions. 
The hypothesis that the addition of soy extract to CaP cements will increase in vitro 
proliferation and osteogenic differentiation of primary human multipotent BMSCs was 
proven to be true. Soy CaP cements are likely to have a beneficial osteogenic effect in 
vivo. 
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CHAPTER 8 
CONCLUSIONS AND FUTURE WORK 
8.1 Scientific background of the work 
Bone regenerative biomaterials are in demand as adjuncts and replacements to autograft 
(Brandoff et al. 2008). Current synthetic materials are often not resorbed or integrated 
into the patient tissue (Stellingsma et al. 2004). The addition of pharmaceuticals to 
biomaterials can accelerate, modulate or prevent host responses to the implant and 
therefore the selection of materials tailored to a desired patient outcome becomes relevant 
(Brydone et al. 2010). 
Calcium phosphate cements are considered to be low strength osteoconductive materials 
that can be loaded with growth factors to increase the differentiation of in situ progenitors 
to osteoblasts (Brydone et al. 2010). Some authors have added osteoprogenitors to 
cements, thereby creating a true osteogenic material (Park et al. 2011). 
The use of growth factors in vivo is problematic, recombinant BMP is expensive and 
therefore only indicated in the most severe cases (Garrison et al. 2010). However calcium 
phosphate cements are only indicated for use in non-load bearing craniofacial surgery, 
with mechanical stabilisation (Ambard and Mueninghoff 2006). It is unlikely that the 
outcomes with BMP enhanced cements would be so significant that its use would be 
endorsed by NICE (Garrison et al. 2007). 
An additional cement that is osteoinductive without the added cost of growth factor 
treatment is therefore desirable. Soy has potential as an enhancer of osteoinduction 
because; isoflavones are oestrogenic and have been shown to improve outcomes in 
osteoporotic menopausal women, soy protein is a commonly used emulsifier and is a 
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natural amphiphilic surfactant and soy is very cheap and abundant (Barnes 2010, Bolanos 
and Francia 2010). Therefore soy was incorporated into a CaP cement with the intention 
of improving outcomes compared to cement without osteoinduction and without the 
associated cost of recombinant human growth factors (Perut et al. 2011).  
The osteogenic capabilities of the soy extract and the soy cement on the primary 
differentiating cells that are present in bone was unknown.   
8.2 The hypothesis of this work 
We hypothesised in section 1.12 that the addition of soy extract to calcium phosphate 
cements would prove to be osteogenic when primary human BMSCs were cultured in 
direct contact. This hypothesis has proven to be correct.  
This study has contributed to our understanding of some of the gaps in the literature. 
Previous reports of MG63 cultures with genistein failed to report any increase in markers 
of osteogenesis (Morris et al 2006). It was reasoned that the culture of MG63s in a 
confluent model would accelerate differentiation as well as limiting proliferation; 
therefore any osteogenic effect attributable to genistein would be highlighted using the 
model described here. The confluent model shows that genistein has an osteogenic effect 
on MG63s, in agreement with the hypothesis.  
The osteogenic effect on BMSCs of supplementary isoflavone in more than one medium 
has also not been previously reported, most authors use osteogenic media supplemented 
with isoflavones. It was hypothesised that isoflavones are sufficiently osteogenic alone 
and that other components of the medium are not required for differentiation, this proved 
to be the case.  
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The osteogenic effect of complex soy extracts on human BMSCs was previously 
unknown, as was the combination in a calcium phosphate cement. Therefore it was 
hypothesised that soy extract containing a complex mixture of phytoestrogens would 
have a greater osteogenic effect than single isoflavones, both alone and in combination 
with known osteogenic agents. This was shown to be correct. 
It has previously been shown that pure soy isoflavones are osteogenic in primary human 
cell culture and cell line culture. This osteogenic effect can be modulated by the addition 
of an oestrogen receptor inhibitor; therefore the observed effects are attributable to 
isoflavones (Heim et al. 2004, Morris 2006). We utilised this research to hypothesise that 
the addition of an ER inhibitor would modulate the osteogenic effect of soy extracts 
demonstrating that the active components of the extract is phytoestrogens. The results 
presented here clearly show that this hypothesis is correct. 
8.3 Findings of the work. 
8.3.1 MG63 cell line observations 
The confluent MG63 osteosarcoma cell line model described here was useful to observe 
the action of genistein on markers of differentiation alone and in combination with 
components of osteogenic medium after short culture periods. A previous report has 
shown addition of genistein at the concentrations used in this study reduced proliferation 
and early markers of osteogenesis, while increasing mineralisation (Morris 2006). Our 
findings in this model are that genistein significantly increases osteogenic markers and 
shortens differentiation time in osteogenic medium.   
8.3.2 Primary human BMSCs 
In primary human BMSC pure genistein induces a greater response than in the MG63 
cells, again a larger effect in osteogenic media, but genistein is osteogenic alone. The 
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addition of genistein up regulates the relevant osteogenic markers and there is an 
immediate and persistent metabolic response after only 2 hours incubation. These results 
agree with the literature, genistein increases osteogenic markers when added to 
osteogenic medium (Heim et al. 2004). We also observed that genistein increased 
osteogenesis in culture media without further supplementation, which has not previously 
been reported.   
In the same human BMSCs strain soy extract is more osteogenic than pure genistein. The 
osteogenic effect of the soy extract can be decreased with the addition of a competitive 
inhibitor, indicating that the isoflavones within the extract are responsible for the 
osteogenesis. This osteogenic effect occurs in culture medium, but is greater in 
osteogenic media. 
When cultured on the surface of calcium phosphate cements containing either soy and 
gelatine or gelatine alone, BMSCs significantly increased markers of osteogenesis on the 
soy extract cements when compared with the gelatine cements, the surface of the cement 
was also remodelled more after culture with the soy extract. 
8.4 Novel contribution 
This thesis has shown that genistein is osteogenic when cultured with MG63s; it is 
inherently osteogenic but also acts sympathetically with osteogenic media to increase 
markers of osteogenesis. The model and culture methods outlined in chapter 3 were also 
shown to be effective when observing the differentiation of primary human BMSCs. 
Observations of human BMSCs after addition of soy extract allowed the conclusion that 
the extract induces the osteogenic differentiation; alone or as a supplement to osteogenic 
medium. The osteogenesis was proven to be due to the presence of isoflavones in the soy 
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extract because the addition of an estrogen receptor binding competitive inhibitor reduced 
the observed markers of osteogenesis. 
The addition of soy extract to calcium phosphate cements significantly increased the 
osteogenic differentiation of human BMSCs that were cultured on the surface. This 
finding encourages the development of osteogenic soy cements that are efficacious and 
economical in use. 
8.5 Future work 
The co-injection of autologous BMSCs and cements is the next logical step in the 
production of a bone filler to replace autograft. In order for this to be a feasible 
proposition the cells would need to be protected from the cement in some manner; this 
could conceivably be done by the formation of micro gelatine beads containing cells. It 
has already been reported in the literature that encapsulation in alginate is effective at 
protecting human BMSCs from the calcium phosphate setting reaction (Zhao et al. 2011). 
An adaptation of this method for the proposed soy/gelatine cement should be achievable.  
Further tailoring of the soy cement should be considered; this study has provided data 
showing the effect of a wide range of concentrations on the osteogenic differentiation of 
BMSCs. The data provided could be the basis for further work to perfectly balance the 
isoflavone content and release from the cement. To achieve this goal experiments should 
include a combination of in vitro cement culture as described in Chapter 7 and in vivo 
experimentation of optimised cement and cement with BMSCs should be undertaken. 
In addition to the incorporation of autologous cells in CaP cements there is also a great 
deal of work still to be undertaken in order to further our understanding of the 
mechanisms of isoflavone action. Proteomic studies of different effects of oestrogen 
receptor ligands may help design or isolate the most potent isoflavone. There are tissue 
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specific effects of the activated oestrogen receptor isoflavone ligand, therefore the 
proteomic studies should be carried out in a differentiating human primary cell strain 
capable of osteogenesis. BMSCs are a prime candidate for such studies. 
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Appendix A.           Statistics. 
Chapter 3 
3.4.1 Cell number. P values 
Day/media GM Beta Dex Osteo 
0 0.950 0.691 0.963 0.963 
2 0.003 0.410 0.998 0.014 
4 0.889 0.956 0.271 0.271 
6 0.000 0.006 0.129, Dunnett’s 0.044 
3.4.2 Cell death. P values 
Day/media GM Beta Dex Osteo 
2 0.000 0.001 0.000 0.000 
4 0.000 0.823 0.080 0.834 
6 0.000 0.080 0.001 0.002 
3.4.3. ALP. P values 
Day/media GM Beta Dex Osteo 
2 0.001 0.000 0.000 0.000 
4 0.000 0.001 0.000 0.000 
6 0.000 0.000 0.000 0.000 
3.4.4 Collagen. P values 
Day/media GM Beta Dex Osteo 
2 0.000 0.000 0.000 0.000 
4 0.000 0.000 0.005 0.000 
6 0.000 0.000 0.000 0.000 
3.4.5 ARS. P values 
Day/media GM Beta Dex Osteo 
2 0.000 0.000 0.000 0.000 
4 0.000 0.000 0.005 0.000 
6 0.000 0.000 0.000 0.000 
Chapter 4 
4.4.8.1 Cell number. P values 
Day/media GM Beta Dex Osteo 
2 0.000 0.000 0.000 0.000 
4 0.030 0.002 0.000 0.000 
6 0.002 0.001 0.001 0.000 
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4.4.8.2 LDH release. P values 
Day/media GM Beta Dex Osteo 
2 0.000 0.000 0.000 0.000 
4 0.000 0.000 0.000 0.000 
6 0.000 0.000 0.002 0.000 
4.4.8.3 ALP. P values 
Day/media GM Beta Dex Osteo 
2 0.016 0.944 0.124, Dunnett’s 0.037 
4 0.707 0.035 0.352 0.000 
6 0.000 0.000 0.000 0.000 
4.4.8.4 Collagen. P values 
Day/media GM Beta Dex Osteo 
2 0.000 0.000 0.000 0.000 
4 0.039 0.001 0.000 0.000 
6 0.033 0.000 0.000 0.000 
Comparison of days between concentrations  
Media/µM 0 1.88 3.75 7.5 15 30 300 
GM 0.804 0.000 0.000 0.000 0.042 0.014 0.116 
Beta 0.035 0.004 0.005 0.001 0.002 0.049 0.215 
Dex 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Osteo 0.234 0.000 0.000 0.002 0.015 0.006 0.073 
Comparison of 1 concentration between days  
4.4.8.5 ARS. P values 
Day/media GM Beta Dex Osteo 
2 0.099 0.021 0.000 0.000 
4 0.000 0.008 0.001 0.001 
6 0.054, Dunnett’s 0.002 0.000 0.028 
Comparison of days between concentrations  
Media/µM 0 1.88 3.75 7.5 15 30 300 
GM 0.261 0.078 0.134 0.117 0.292 0.370 0.828 
Beta 0.241 0.365 0.264 0.626 0.922 0.336 0.576 
Dex 0.156 0.972 0.143 0.137 0.087 0.076 0.077 
Osteo 0.177 0.136 0.093 0.071 0.065 0.054 0.066 
Comparison of 1 concentration between days  
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Chapter 5 
5.4.2. Cell number P values 
Day/media GM Beta Dex Osteo 
0 0.809 0.709 0.851 0.462 
2 0.000 0.000 0.000 0.000 
4 0.000 0.000 0.000 0.000 
6 0.000 0.000 0.018 0.111 
5.4.3 cell number HPI counts P values 
Media/µM 0 1.88 3.75 7.5 15 30 300 
All media 0.000 0.000 0.000 0.000 0.000 0.000 0.001 
5.4.4 Brd-U incorporation P values 
Media/µM 0 1.88 3.75 7.5 15 30 300 
All media 0.153 0.000 0.000 0.008 0.003 0.000 0.001 
5.4.5. Cell death by LDH P values 
Day/media GM Beta Dex Osteo 
2 0.000 0.000 0.000 0.000 
4 0.000 0.000 0.000 0.000 
6 0.000 0.000 0.000 0.000 
5.4.6 ATP P values 
hour/media GM Beta Dex Osteo 
2 0.000 0.000 0.000 0.000 
72 0.000 0.000 0.000 0.000 
5.4.7 ALP P values 
Day/media GM Beta Dex Osteo 
2 0.000 0.000 0.000 0.000 
4 0.000 0.000 0.000 0.000 
6 0.000 0.000 0.000 0.000 
Comparison of days between concentrations  
Media/µM 0 1.88 3.75 7.5 15 30 300 
GM 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Beta 0.001 0.000 0.000 0.000 0.000 0.000 0.001 
Dex 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Osteo 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Comparison of concentrations between days 
5.4.8 Collagen P values 
Day/media GM Beta Dex Osteo 
2 0.000 0.000 0.000 0.000 
4 0.000 0.016 0.000 0.000 
6 0.000 0.029 0.000 0.000 
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5.4.9 ARS P values 
Day/media GM Beta Dex Osteo 
2 0.000 0.598 0.000 0.000 
4 0.000 0.000 0.000 0.000 
6 0.000 0.000 0.000 0.000 
Chapter 6 
6.4.2 Cell counts P values 
Day/media GM GM+I Osteo Osteo+I 
2 0.000 0.000 0.000 0.000 
6 0.000 0.000 0.000 0.000 
8 0.000 0.000 0.000 0.000 
10 0.000 0.000 0.000 0.000 
6.4.4 ALP P values 
Day/media GM GM+I Beta Beta+I Osteo Osteo+I 
2 0.000 0.016 0.000 0.000 0.217 0.000 
6 0.000 0.000 0.000 0.000 0.000 0.000 
8 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.000 0.000 0.000 0.001 0.000 0.000 
6.4.5 Cbfa-1 P values 
Day/media GM GM+I Osteo Osteo+I 
10 0.000 0.000 0.000 0.002 
6.4.6 ARS P values 
Day/media GM GM+I Beta Beta+I Osteo Osteo+I 
6 0.000 0.000 0.000 0.000 0.000 0.000 
10 0.000 0.003 0.000 0.000 0.000 0.000 
Chapter 7 
7.4.1 Proliferation P values   
Day Cements   Cement All days 
0 0.004   Gelatine 0.000 
12 0.142   Soy 0.000 
24 0.000   
Comparison between time points       Comparison between cements 
7.4.2 Cbfa1 expression P values 
Day Cements 
0 0.004 
12 0.018 
24 0.000 
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Appendix B 
 
 
Isoflavone  
Days in  
Saline solution 
Daidzin  Genistin  Daidzein  Genistein  
2 Days 134.026  54.336  2.293  0.870  
4 Days 94.936  58.886  1.473  0.665  
7 Days 15.189  7.919  0.271  0.165  
8 Days  13.139  4.656  0.095  0.092  
10 Days 15.437  5.713  0.108  0.089  
12 Days  19.464  8.557  0.093  0.094  
Table showing the release of isoflavones from a soy extract and gelatine foamed cement 
 
